0001564590-21-025570.txt : 20210507 0001564590-21-025570.hdr.sgml : 20210507 20210507161704 ACCESSION NUMBER: 0001564590-21-025570 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210507 DATE AS OF CHANGE: 20210507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL HEALTH REALTY INCOME TRUST CENTRAL INDEX KEY: 0000798783 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 236858580 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09321 FILM NUMBER: 21902907 BUSINESS ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH RD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: 610-265-0688 MAIL ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH ROAD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 10-Q 1 uht-10q_20210331.htm 10-Q uht-10q_20210331.htm
false Q1 0000798783 --12-31 3 1 2 us-gaap:ManagementServiceMember us-gaap:ManagementServiceMember 0.0050 0.0050 1 1 1 3 1 2 0.0050 0.0050 1 1 1 P5Y P10Y P10Y 2021-02 125000000 0.60 0.30 0.60 0.0150 0000798783 2021-01-01 2021-03-31 xbrli:shares 0000798783 2021-04-30 iso4217:USD 0000798783 uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember 2020-01-01 2020-03-31 0000798783 uht:NonRelatedPartyMember 2021-01-01 2021-03-31 0000798783 uht:NonRelatedPartyMember 2020-01-01 2020-03-31 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-03-31 0000798783 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-03-31 0000798783 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-03-31 0000798783 2020-01-01 2020-03-31 0000798783 us-gaap:ManagementServiceMember 2021-01-01 2021-03-31 0000798783 us-gaap:ManagementServiceMember 2020-01-01 2020-03-31 iso4217:USD xbrli:shares 0000798783 uht:UniversalHealthServicesHospitalIncMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesHospitalIncMember 2020-01-01 2020-03-31 0000798783 2021-03-31 0000798783 2020-12-31 0000798783 us-gaap:CommonStockMember 2020-12-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000798783 us-gaap:RetainedEarningsMember 2020-12-31 0000798783 uht:CumulativeDividendsMember 2020-12-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000798783 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000798783 uht:CumulativeDividendsMember 2021-01-01 2021-03-31 0000798783 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000798783 us-gaap:CommonStockMember 2021-03-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000798783 us-gaap:RetainedEarningsMember 2021-03-31 0000798783 uht:CumulativeDividendsMember 2021-03-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000798783 us-gaap:CommonStockMember 2019-12-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000798783 us-gaap:RetainedEarningsMember 2019-12-31 0000798783 uht:CumulativeDividendsMember 2019-12-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000798783 2019-12-31 0000798783 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000798783 uht:CumulativeDividendsMember 2020-01-01 2020-03-31 0000798783 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000798783 us-gaap:CommonStockMember 2020-03-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000798783 us-gaap:RetainedEarningsMember 2020-03-31 0000798783 uht:CumulativeDividendsMember 2020-03-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000798783 2020-03-31 xbrli:pure 0000798783 srt:MinimumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2021-03-31 0000798783 srt:MaximumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2021-03-31 uht:Property 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember srt:MinimumMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember srt:MaximumMember 2021-01-01 2021-03-31 uht:Time 0000798783 uht:UniversalHealthServicesIncMember 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember us-gaap:AssetsLeasedToOthersMember 2021-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2021-01-01 2021-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2020-01-01 2020-03-31 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-03-31 0000798783 uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-03-31 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-03-31 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 uht:RenewalOption 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember srt:MinimumMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember srt:MaximumMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember 2020-01-01 2020-12-31 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:BaseRentsMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:BaseRentsMember 2020-01-01 2020-12-31 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:BonusRentsMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:BonusRentsMember 2020-01-01 2020-12-31 0000798783 uht:GraysonPropertiesTwoLPMember uht:DenisonTexasMember 2019-09-30 0000798783 uht:UniversalHealthServicesIncMember 2019-09-01 2019-09-30 0000798783 uht:UniversalHealthServicesIncAndCatholicHealthInitiativesMember 2019-07-01 2019-07-31 0000798783 uht:UniversalHealthServicesIncAndCatholicHealthInitiativesMember 2019-07-31 uht:Lease 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2020-01-01 2020-03-31 0000798783 uht:UniversalHealthServicesIncMember 2020-12-31 0000798783 uht:AtMarketATMProgramsMember 2020-06-30 0000798783 uht:AtMarketATMProgramsMember 2021-01-01 2021-03-31 0000798783 uht:AtMarketATMProgramsMember 2020-04-01 2020-06-30 0000798783 uht:AtMarketATMProgramsMember us-gaap:OtherExpenseMember 2021-01-01 2021-03-31 uht:Acquisition uht:Disposition 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember uht:MedicalOfficeBuildingsMember 2021-03-31 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 uht:BrunswickAssociatesMember 2021-03-31 0000798783 uht:GraysonPropertiesMember 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember srt:MaximumMember 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember 2021-01-01 2021-03-31 0000798783 uht:GraysonPropertiesTwoLPMember srt:MaximumMember uht:DenisonTexasMember 2021-03-31 0000798783 uht:GraysonPropertiesTwoLPMember 2021-03-31 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-01-01 2021-03-31 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-03-31 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-03-31 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-12-31 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2020-12-31 0000798783 uht:FTXMobPhaseTwoLPMember 2021-01-01 2021-03-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FTXMobPhaseTwoMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:BrunswickAssociatesMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesTwoLPMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FTXMobPhaseTwoMember 2021-01-01 2021-03-31 0000798783 srt:MinimumMember 2021-01-01 2021-03-31 0000798783 srt:MaximumMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember uht:BaseRentsMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember uht:BaseRentsMember 2020-01-01 2020-03-31 0000798783 uht:UniversalHealthServicesIncMember uht:BonusRentsMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember uht:BonusRentsMember 2020-01-01 2020-03-31 0000798783 uht:UniversalHealthServicesIncMember uht:TenantReimbursementsMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember uht:TenantReimbursementsMember 2020-01-01 2020-03-31 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2021-01-01 2021-03-31 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2020-01-01 2020-03-31 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2021-01-01 2021-03-31 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2020-01-01 2020-03-31 uht:Bed 0000798783 uht:KindredChicagoCentralHospitalCentralChicagoIllinoisMember 2021-01-01 2021-03-31 0000798783 uht:KindredChicagoCentralHospitalCentralChicagoIllinoisMember 2020-01-01 2020-12-31 0000798783 uht:EvansvilleRehabilitationHospitalEvansvilleIndianaMember 2021-01-01 2021-03-31 0000798783 uht:CorpusChristiCorpusChristiTexasMember 2021-01-01 2021-03-31 uht:Land 0000798783 us-gaap:RevolvingCreditFacilityMember 2021-03-31 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LetterOfCreditMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:ShortTermDebtMember 2018-03-27 0000798783 uht:RevolvingBFacilityMember 2020-01-01 2020-06-30 0000798783 uht:RevolvingBFacilityMember 2020-06-30 0000798783 uht:RevolvingAFacilityMember 2021-01-01 2021-03-31 0000798783 uht:RevolvingAFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember us-gaap:BaseRateMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember us-gaap:BaseRateMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember uht:FederalFundsEffectiveRateMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-03-31 0000798783 uht:RevolvingAFacilityMember us-gaap:BaseRateMember 2021-01-01 2021-03-31 uht:Option 0000798783 uht:RevolvingBFacilityMember 2021-01-01 2021-03-31 0000798783 uht:RevolvingBFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember us-gaap:BaseRateMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember us-gaap:BaseRateMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember uht:FederalFundsEffectiveRateMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-03-31 0000798783 uht:RevolvingBFacilityMember us-gaap:BaseRateMember 2021-01-01 2021-03-31 0000798783 srt:MaximumMember 2021-03-31 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:BRBMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:DesertValleyMedicalCenterFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:BRBMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:DesertValleyMedicalCenterFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 us-gaap:FairValueInputsLevel2Member 2021-03-31 0000798783 us-gaap:FairValueInputsLevel2Member 2020-12-31 uht:Derivative 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-01 2020-03-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-01-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-09-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-07-01 2019-09-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0000798783 us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-03-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-03-31 uht:Segment

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2021

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                      

Commission file number 1-9321

 

UNIVERSAL HEALTH REALTY INCOME TRUST

(Exact name of registrant as specified in its charter)

 

 

Maryland

 

23-6858580

(State or other jurisdiction of

incorporation or organization)

 

(I. R. S. Employer

Identification No.)

 

 

 

UNIVERSAL CORPORATE CENTER

367 SOUTH GULPH ROAD

KING OF PRUSSIA, Pennsylvania

 

19406

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code (610265-0688

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

 

Trading Symbol(s)

 

Name of each exchange on which registered

Shares of beneficial interest, $0.01 par value

 

UHT

 

New York Stock Exchange

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated Filer

 

 

 

 

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Number of common shares of beneficial interest outstanding at April 30, 2021—13,772,112.

 

 

 

 

 


 

 

UNIVERSAL HEALTH REALTY INCOME TRUST

INDEX

 

 

 

 

 

PAGE NO.

PART I. FINANCIAL INFORMATION (unaudited)

 

 

Item 1.

 

Financial Statements

 

 

 

 

Condensed Consolidated Statements of Income—Three Months Ended March 31, 2021 and 2020

 

4

 

 

Condensed Consolidated Statements of Comprehensive Income—Three Months Ended March 31, 2021 and 2020

 

5

 

 

Condensed Consolidated Balance Sheets—March 31, 2021 and December 31, 2020

 

6

 

 

Condensed Consolidated Statements of Changes in Equity—Three Months Ended March 31, 2021 and 2020

 

7

 

 

Condensed Consolidated Statements of Cash Flows—Three Months Ended March 31, 2021 and 2020

 

8

 

 

Notes to Condensed Consolidated Financial Statements

 

9 through 19

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

20 through 31

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

31 through 32

Item 4.

 

Controls and Procedures

 

32

PART II. OTHER INFORMATION

 

33

Item 1A. Risk Factors

 

33

Item 6.

 

Exhibits

 

33

 

 

 

 

 

SIGNATURES

 

34

 

 

 

This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2021. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

As disclosed in this Quarterly Report, including in Note 2 to the condensed consolidated financial statements—Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions, a wholly-owned subsidiary of UHS (UHS of Delaware, Inc.) serves as our Advisor pursuant to the terms of an annually renewable Advisory Agreement dated December 24, 1986, and as amended and restated as of January 1, 2019. Our officers are all employees of UHS through its wholly-owned subsidiary, UHS of Delaware, Inc. In addition, three of our hospital facilities are leased to wholly-owned subsidiaries of UHS, one of our hospital facilities is leased to a joint venture between a wholly-owned subsidiary of UHS and a third party, and subsidiaries of UHS are tenants of eighteen medical office buildings or free-standing emergency departments, that are either wholly or jointly-owned by us. Any reference to “UHS” or “UHS facilities” in this report is referring to Universal Health Services, Inc.’s subsidiaries, including UHS of Delaware, Inc.

In this Quarterly Report, the term “revenues” does not include the revenues of the unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%.  As of March 31, 2021, we had investments in five jointly-owned LLCs/LPs. We currently account for our share of the income/loss from these investments by the equity method (see Note 5 to the condensed consolidated financial statements included herein).

 

 

3


 

 

Part I. Financial Information

Item I. Financial Statements

Universal Health Realty Income Trust

Condensed Consolidated Statements of Income

For the Three Months Ended March 31, 2021 and 2020

(amounts in thousands, except per share information)

(unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2021

 

 

2020

 

Revenues:

 

 

 

 

 

 

 

 

  Lease revenue - UHS facilities (a.)

 

$

7,132

 

 

$

5,881

 

  Lease revenue - Non-related parties

 

 

13,092

 

 

 

12,842

 

  Other revenue - UHS facilities

 

 

226

 

 

 

214

 

  Other revenue - Non-related parties

 

 

249

 

 

 

270

 

 

 

 

20,699

 

 

 

19,207

 

Expenses:

 

 

 

 

 

 

 

 

  Depreciation and amortization

 

 

6,787

 

 

 

6,380

 

  Advisory fees to UHS

 

 

1,062

 

 

 

1,016

 

  Other operating expenses

 

 

5,602

 

 

 

5,383

 

 

 

 

13,451

 

 

 

12,779

 

Income before equity in income of unconsolidated limited liability companies ("LLCs"), interest expense and gains on sales

 

 

7,248

 

 

 

6,428

 

  Equity in income of unconsolidated LLCs

 

 

471

 

 

 

435

 

Interest expense, net

 

 

(2,133

)

 

 

(2,309

)

Net income

 

$

5,586

 

 

$

4,554

 

Basic earnings per share

 

$

0.41

 

 

$

0.33

 

Diluted earnings per share

 

$

0.41

 

 

$

0.33

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding - Basic

 

 

13,750

 

 

 

13,736

 

Weighted average number of shares outstanding - Diluted

 

 

13,771

 

 

 

13,758

 

 

 

 

 

 

 

 

 

 

(a.) Includes bonus rental on UHS hospital facilities of $1,695 and $1,380 for the three-month periods ended March 31, 2021 and 2020, respectively.

 

See accompanying notes to these condensed consolidated financial statements.

 

 

4


 

 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Comprehensive Income

For the Three Months Ended March 31, 2021 and 2020

(amounts in thousands)

(unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2021

 

 

2020

 

Net income

 

$

5,586

 

 

$

4,554

 

Other comprehensive gain/(loss):

 

 

 

 

 

 

 

 

Unrealized derivative gains/(losses) on cash flow hedges

 

 

3,348

 

 

 

(4,671

)

Total other comprehensive gain/(loss):

 

 

3,348

 

 

 

(4,671

)

Total comprehensive income/(loss)

 

$

8,934

 

 

$

(117

)

 

See accompanying notes to these condensed consolidated financial statements.

 

 

5


 

 

Universal Health Realty Income Trust

Condensed Consolidated Balance Sheets

(amounts in thousands, except share information)

(unaudited)

 

 

 

March 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Assets:

 

 

 

 

 

 

 

 

Real Estate Investments:

 

 

 

 

 

 

 

 

Buildings and improvements and construction in progress

 

$

608,366

 

 

$

605,292

 

Accumulated depreciation

 

 

(222,521

)

 

 

(216,648

)

 

 

 

385,845

 

 

 

388,644

 

Land

 

 

55,157

 

 

 

55,157

 

               Net Real Estate Investments

 

 

441,002

 

 

 

443,801

 

Investments in limited liability companies ("LLCs")

 

 

9,087

 

 

 

4,278

 

Other Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

6,171

 

 

 

5,742

 

Lease and other receivables from UHS

 

 

3,252

 

 

 

3,199

 

Lease receivable - other

 

 

7,780

 

 

 

7,504

 

Intangible assets (net of accumulated amortization of $19.0 million and

   $19.5 million, respectively)

 

 

11,013

 

 

 

11,742

 

Right-of-use land assets, net

 

 

8,907

 

 

 

8,914

 

Deferred charges and other assets, net

 

 

8,582

 

 

 

8,829

 

               Total Assets

 

$

495,794

 

 

$

494,009

 

Liabilities:

 

 

 

 

 

 

 

 

Line of credit borrowings

 

$

247,650

 

 

$

236,200

 

Mortgage notes payable, non-recourse to us, net

 

 

58,403

 

 

 

58,895

 

Accrued interest

 

 

346

 

 

 

351

 

Accrued expenses and other liabilities

 

 

11,375

 

 

 

19,802

 

Ground lease liabilities, net

 

 

8,907

 

 

 

8,914

 

Tenant reserves, deposits and deferred and prepaid rents

 

 

10,446

 

 

 

10,842

 

               Total Liabilities

 

 

337,127

 

 

 

335,004

 

Equity:

 

 

 

 

 

 

 

 

Preferred shares of beneficial interest,

   $.01 par value; 5,000,000 shares authorized;

   none issued and outstanding

 

 

-

 

 

 

-

 

Common shares, $.01 par value;

   95,000,000 shares authorized; issued and outstanding: 2021 - 13,772,095;

   2020 - 13,771,287

 

 

138

 

 

 

138

 

Capital in excess of par value

 

 

267,667

 

 

 

267,368

 

Cumulative net income

 

 

686,313

 

 

 

680,727

 

Cumulative dividends

 

 

(794,984

)

 

 

(785,413

)

Accumulated other comprehensive (loss)/income

 

 

(467

)

 

 

(3,815

)

     Total Equity

 

 

158,667

 

 

 

159,005

 

               Total Liabilities and Equity

 

$

495,794

 

 

$

494,009

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 


 

6


 

 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Changes in Equity

For the Three Months Ended March 31, 2021

(amounts in thousands)

(unaudited)

 

 

 

Common Shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital in

 

 

 

 

 

 

 

 

 

 

Accumulated other

 

 

 

 

 

 

 

Number

 

 

 

 

 

 

excess of

 

 

Cumulative

 

 

Cumulative

 

 

comprehensive

 

 

Total

 

 

 

of Shares

 

 

Amount

 

 

par value

 

 

net income

 

 

dividends

 

 

income/(loss)

 

 

Equity

 

January 1, 2021

 

 

13,771

 

 

$

138

 

 

$

267,368

 

 

$

680,727

 

 

$

(785,413

)

 

$

(3,815

)

 

$

159,005

 

Shares of Beneficial Interest:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issued

 

 

1

 

 

 

 

 

 

57

 

 

 

 

 

 

 

 

 

 

 

 

57

 

Restricted stock-based compensation expense

 

 

 

 

 

 

 

 

242

 

 

 

 

 

 

 

 

 

 

 

 

242

 

Dividends ($.695/share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,571

)

 

 

 

 

 

(9,571

)

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

 

 

 

5,586

 

 

 

 

 

 

 

 

 

5,586

 

Unrealized net gain on cash flow hedges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,348

 

 

 

3,348

 

Subtotal - comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,586

 

 

 

 

 

 

 

3,348

 

 

 

8,934

 

March 31, 2021

 

 

13,772

 

 

$

138

 

 

$

267,667

 

 

$

686,313

 

 

$

(794,984

)

 

$

(467

)

 

$

158,667

 

 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Changes in Equity

For the Three Months Ended March 31, 2020

(amounts in thousands)

(unaudited)

 

 

 

Common Shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital in

 

 

 

 

 

 

 

 

 

 

Accumulated other

 

 

 

 

 

 

 

Number

 

 

 

 

 

 

excess of

 

 

Cumulative

 

 

Cumulative

 

 

comprehensive

 

 

Total

 

 

 

of Shares

 

 

Amount

 

 

par value

 

 

net income

 

 

dividends

 

 

income/(loss)

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

January 1, 2020

 

 

13,757

 

 

$

138

 

 

$

266,723

 

 

$

661,280

 

 

$

(747,417

)

 

$

1,010

 

 

$

181,734

 

Shares of Beneficial Interest:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issued

 

 

1

 

 

 

 

 

 

50

 

 

 

 

 

 

 

 

 

 

 

 

50

 

Restricted stock-based compensation expense

 

 

 

 

 

 

 

 

197

 

 

 

 

 

 

 

 

 

 

 

 

197

 

Dividends ($.685/share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,424

)

 

 

 

 

 

(9,424

)

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

 

 

 

4,554

 

 

 

 

 

 

 

 

 

4,554

 

Unrealized loss on cash flow hedges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,671

)

 

 

(4,671

)

Subtotal - comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4,554

 

 

 

 

 

 

 

(4,671

)

 

 

(117

)

March 31, 2020

 

 

13,758

 

 

$

138

 

 

$

266,970

 

 

$

665,834

 

 

$

(756,841

)

 

$

(3,661

)

 

$

172,440

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

 

 

 

 

 

 

 

 

7


 

 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Cash Flows

(amounts in thousands)

(unaudited)

 

 

 

Three months ended March 31,

 

 

 

2021

 

 

2020

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income

 

$

5,586

 

 

$

4,554

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

6,787

 

 

 

6,380

 

Amortization related to above/below market leases, net

 

 

(45

)

 

 

(46

)

Amortization of debt premium

 

 

(12

)

 

 

(13

)

Amortization of deferred financing costs

 

 

216

 

 

 

157

 

Stock-based compensation expense

 

 

242

 

 

 

197

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Lease receivable

 

 

(329

)

 

 

181

 

Accrued expenses and other liabilities

 

 

(633

)

 

 

(867

)

Tenant reserves, deposits and deferred and prepaid rents

 

 

(396

)

 

 

65

 

Accrued interest

 

 

(5

)

 

 

(25

)

Leasing costs paid

 

 

(365

)

 

 

(182

)

Other, net

 

 

204

 

 

 

(264

)

Net cash provided by operating activities

 

 

11,250

 

 

 

10,137

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Investments in LLCs

 

 

(1,544

)

 

 

(1,468

)

Advance made to LLC

 

 

(3,500

)

 

 

-

 

Additions to real estate investments, net

 

 

(6,974

)

 

 

(5,521

)

Deposit on real estate assets

 

 

(200

)

 

 

-

 

Net cash used in investing activities

 

 

(12,218

)

 

 

(6,989

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Net borrowings on line of credit

 

 

11,450

 

 

 

6,250

 

Repayments of mortgage notes payable

 

 

(510

)

 

 

(432

)

Financing costs paid

 

 

(35

)

 

 

(35

)

Dividends paid

 

 

(9,564

)

 

 

(9,424

)

Issuance of shares of beneficial interest, net

 

 

56

 

 

 

50

 

Net cash provided by/(used in) financing activities

 

 

1,397

 

 

 

(3,591

)

Increase/(decrease) in cash and cash equivalents

 

 

429

 

 

 

(443

)

Cash and cash equivalents, beginning of period

 

 

5,742

 

 

 

6,110

 

Cash and cash equivalents, end of period

 

$

6,171

 

 

$

5,667

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

 

Interest paid

 

$

1,935

 

 

$

2,190

 

Invoices accrued for construction and improvements

 

$

468

 

 

$

3,151

 

 

See accompanying notes to these condensed consolidated financial statements.

 

8


 

 

UNIVERSAL HEALTH REALTY INCOME TRUST

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2021

(unaudited)

 

(1) General

This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2021. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.  As of March 31, 2021, we had investments in five jointly-owned LLCs/LPs. We currently account for our share of the income/loss from these investments by the equity method (see Note 5). These LLCs are included in our consolidated financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.    

The condensed consolidated financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2020.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.

 

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties from certain subsidiaries of UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and renewal terms for each of the three hospital facilities leased to wholly-owned subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with wholly-owned subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the three acute care hospital facilities leased to wholly-owned subsidiaries of UHS accounted for approximately 22% of our consolidated revenues for each of the three months ended March 31, 2021 and 2020. In addition to these three UHS hospital facilities, one of our hospital facilities is leased to a joint venture between a subsidiary of UHS and a third party, and we have eighteen medical office buildings (“MOBs”) or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us that include tenants which are subsidiaries or joint ventures of UHS. The aggregate revenues generated from UHS-related tenants comprised approximately 36% and 32% of our consolidated revenues during the three-month periods ended March 31, 2021 and 2020, respectively.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of the three acute care hospitals with wholly-owned subsidiaries of UHS, as reflected below, UHS has the option, among other things, to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities from us at their appraised fair market value upon any of the following:  (i) at the end of the lease terms or any renewal terms; (ii) upon one month’s notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the lease in the event that UHS provides notice to us of their intent to offer a substitution property/properties in exchange for one (or more) of the three hospital facilities leased from us, should we be unable to reach an agreement with UHS on the properties to be substituted. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.

9


 

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2026

 

 

5

 

(a.)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b.)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(b.)

 

(a.)

UHS has one 5-year renewal option at the existing lease rate (through 2031).  

(b.)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

 

As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has proposed exchanging potential substitution properties, with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.  The proposed substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of the Board have approved the proposed property substitution subject to satisfactory due diligence and completion of definitive agreements. The effective date of the property substitution is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on the Inland Valley Campus, we earned $1.1 million of lease revenue during the three-month period ended March 31, 2021 ($662,000 in base rental and $454,000 in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).  

In September 2019, we entered into an agreement whereby we own a 95% non-controlling ownership interest in Grayson Properties II L.P., which developed, constructed, owns and operates the Texoma Medical Plaza II, an MOB located in Denison, Texas.  This MOB, which was substantially completed in December 2020, is located on the campus of Texoma Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS.  A 10-year master flex lease was executed with the wholly-owned subsidiary of UHS for over 50% of the rentable square feet of the MOB and commenced in December 2020 upon the issuance of the certificate of occupancy. We account for this LP on an unconsolidated basis pursuant to the equity method since it is not a variable interest entity and we do not have a controlling voting interest.    

In late July 2019, Des Moines Medical Properties, LLC, a wholly-owned subsidiary of ours, entered into an agreement to build and lease a newly constructed UHS-related behavioral health care hospital located in Clive, Iowa.  The lease on this facility, which is triple net and has an initial term of 20 years with five 10-year renewal options, was executed with Clive Behavioral Health, LLC, a joint venture between a wholly-owned subsidiary of UHS and Catholic Health Initiatives - Iowa, Corp (“JV”). Construction of this hospital, for which we engaged a wholly-owned subsidiary of UHS to act as project manager for an aggregate fee of approximately $750,000, was substantially completed in December 2020 and the property received a temporary certificate of occupancy on December 31, 2020.  The hospital lease commenced upon the issuance of the temporary certificate of occupancy.  Pursuant to the lease on this facility, the JV has the option to, among other things, renew the lease at the terms specified in the lease agreement by providing notice to us at least 270 days prior to the termination of the then current term. The JV also has the right to purchase the leased facility from us at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days’ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the JV decline to exercise its purchase right). Additionally, the JV has rights of first offer to purchase the facility prior to any third-party sale.

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the lease revenue currently earned pursuant to these leases.  

 

We are the lessee on twelve ground leases with subsidiaries of UHS (for consolidated and unconsolidated investments). The remaining lease terms on the ground leases with subsidiaries of UHS range from approximately 28 years to approximately 78 years.  The annual aggregate lease payments on these properties are approximately $508,000 for the year ended 2021 and $508,000 for each

10


 

of the years ended 2022, 2023, 2024 and 2025, and an aggregate of $29.0 million thereafter. See Note 7 for further disclosure around our lease accounting.

 

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of March 31, 2021 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

 

Advisory Agreement:   UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an advisory agreement dated December 24, 1986, and as amended and restated as of January 1, 2019 (the “Advisory Agreement”). Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory.

Our advisory fee for the three months ended March 31, 2021 and 2020, was computed at 0.70% of our average invested real estate assets, as derived from our condensed consolidated balance sheets.  Based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the advisory fee computation remained unchanged for 2021, as compared to the last three years. The average real estate assets for advisory fee calculation purposes exclude certain items from our condensed consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, lease receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $1.1 million and $1.0 million for the three months ended March 31, 2021 and 2020, and were based upon average invested real estate assets of $607 million and $581 million, respectively.    

 

Share Ownership: As of March 31, 2021 and December 31, 2020, UHS owned 5.7% of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 36% and 32% of our consolidated revenues during the three-month periods ended March 31, 2021 and 2020, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

(3) Dividends and Equity Issuance Program

Dividends and dividend equivalents:

During the first quarter of 2021, we declared and paid dividends of approximately $9.6 million, or $.695 per share. We declared and paid dividends of approximately $9.4 million, or $.685 per share, during the first quarter of 2020.  Dividend equivalents, which were applicable to shares of unvested restricted stock, were accrued during the first quarter of 2021 and will be paid upon vesting of the restricted stock.

Equity Issuance Program:

During the second quarter of 2020, we commenced an at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of $100 million to or through our agent banks. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective in June 2020.

No shares were issued pursuant to this ATM equity program during the first quarter of 2021.  Pursuant to this ATM program, since the program commenced in the second quarter of 2020, we have issued 2,704 shares at an average price of $101.30 per share, which generated approximately $270,000 of net proceeds (net of approximately $4,000, consisting of compensation to BofA Securities, Inc.). Additionally, as of March 31, 2021, we have paid or incurred approximately $507,000 in various fees and expenses related to the commencement of our ATM program.

11


 

(4) Acquisitions and Dispositions

Three Months Ended March 31, 2021:

Acquisitions:

There were no acquisitions during the first three months of 2021.

Dispositions:

There were no dispositions during the first three months of 2021.

 

Three Months Ended March 31, 2020:    

Acquisitions:

There were no acquisitions during the first three months of 2020.  

Dispositions:    

There were no dispositions during the first three months of 2020.

(5) Summarized Financial Information of Equity Affiliates

In accordance with U.S. GAAP and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

Distributions received from equity method investees in the consolidated statements of cash flows are classified based upon the nature of the distribution. Returns on investments are presented net of equity in income from unconsolidated investments as cash flows from operating activities.  Returns of investments are classified as cash flows from investing activities.

At March 31, 2021, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. We account for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities which we are the primary beneficiary nor do we have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash funding is typically advanced as equity or member loans. These entities maintain property insurance on the properties.

The following property table represents the five LLCs/LPs in which we own a non-controlling interest and were accounted for under the equity method as of March 31, 2021:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)(e.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)(f.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

Grayson Properties II (d.)(f.)

 

 

95

%

 

Texoma Medical Plaza II

 

(a.)

This LLC has a third-party term loan of $9.2 million, which is non-recourse to us, outstanding as of March 31, 2021.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan of $13.3 million, which is non-recourse to us, outstanding as of March 31, 2021.

(c.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.4 million has been funded as of March 31, 2021. During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

12


 

(d.)

Construction on this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, none of which has been funded as of March 31, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $12.4 million as of March 31, 2021.

(e.)

The LLC is the lessee with a third-party lessor under a ground lease for land.

(f.)

These LPs are the lessees with UHS-related parties for the land related to these properties.

Below are the condensed combined statements of income (unaudited) for the four LLCs/LPs accounted for under the equity method at March 31, 2021 and 2020.    

 

 

 

Three Months Ended

March 31,

 

 

 

2021

 

 

2020

 

 

 

(amounts in thousands)

 

Revenues

 

$

2,788

 

 

$

2,516

 

Operating expenses

 

 

1,107

 

 

 

1,028

 

Depreciation and amortization

 

 

521

 

 

 

442

 

Interest, net

 

 

431

 

 

 

318

 

Net income

 

$

729

 

 

$

728

 

Our share of net income

 

$

471

 

 

$

435

 

   

Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs/LPs that were accounted for under the equity method as of March 31, 2021 and December 31, 2020:

 

 

 

March 31,

2021

 

 

December 31,

2020

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

41,822

 

 

$

42,374

 

Other assets (a.)

 

 

8,817

 

 

 

8,818

 

Total assets

 

$

50,639

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Other liabilities (a.)

 

$

8,543

 

 

$

9,402

 

Mortgage notes payable, non-recourse to us

 

 

34,896

 

 

 

39,735

 

Advances payable to us (b.)

 

 

3,500

 

 

 

-

 

Equity

 

 

3,700

 

 

 

2,055

 

Total liabilities and equity

 

$

50,639

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Investments in LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

9,087

 

 

$

4,278

 

   Amounts included in accrued expenses and other liabilities

 

 

(2,700

)

 

 

(3,020

)

Our share of equity in LLCs, net

 

$

6,387

 

 

$

1,258

 

 

 

(a.)

Other assets and other liabilities as of both March 31, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.

 

(b.)

Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.  

13


 

 

As of March 31, 2021, and December 31, 2020, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

3/31/2021

 

 

12/31/2020

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan) (b.)

 

$

-

 

 

$

4,777

 

 

Repaid in Feb., 2021

Grayson Properties (5.034% fixed rate mortgage loan) (c.)

 

 

13,295

 

 

 

13,372

 

 

September, 2021

Brunswick Associates (3.64% fixed rate mortgage loan)

 

 

9,185

 

 

 

9,250

 

 

December, 2024

Grayson Properties II (3.70% fixed rate construction loan) (d.)

 

 

12,416

 

 

 

12,336

 

 

June, 2025

 

 

$

34,896

 

 

$

39,735

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity

 

(b.)

Upon maturity in February, 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

 

(c.)

This loan is scheduled to mature within the next twelve months, at which time the entity intends to refinance pursuant to a new mortgage loan.

 

(d.)

This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.

Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

 

(6) Recent Accounting Pronouncements

 

Accounting for Lease Concessions Granted in Connection with the COVID-19 Pandemic

On April 8, 2020, the Financial Accounting Standards Board ("FASB") held a public meeting and shortly afterwards issued a question-and-answer ("Q&A") document which was intended to provide accounting relief for lease concessions related to the COVID-19 pandemic. The accounting relief permits an entity to choose to forgo the evaluation of the enforceable rights and obligations of a lease contract, which is a requirement of Accounting Standards Codification Topic 842, Leases, which we adopted on January 1, 2019, as long as the total rent payments after the lease concessions are substantially the same, or less than, the total payments previously required by the lease. An entity may account for COVID-19 related lease concessions either (i) as if they were part of the enforceable rights and obligations of the parties under the existing lease contract; or (ii) as a lease modification. To the extent that a rent concession is granted as a deferral of payments, but the total lease payments are substantially the same, lessors are allowed to account for the concession as if no change had been made to the original lease contract.

      

Based on the Q&A, an entity is not required to account for all lease concessions related to the effects of the COVID-19 pandemic under one elected option, however, the entity is required to apply the elected option consistently to leases with similar characteristics and in similar circumstances. The COVID-19 pandemic did not start to adversely impact the economic conditions in the United States until late March 2020 and did not have a material effect on our operations or financial results during the three months ended March 31, 2021 or the year ended December 31, 2020.

Reference Rate Reform

In March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, “Reference Rate Reform.” The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. We will evaluate the impact of the guidance and may apply elections as applicable as additional changes in the market occur.

 

(7) Lease Accounting

 

14


 

 

We adopted the new lease standard on January 1, 2019 and applied it to leases that were in place on the effective date as both a lessor and lessee. We adopted ASC 842 effective January 1, 2019 under the modified retrospective approach and elected the optional transition method to apply the provisions of ASC 842 as of the adoption date, rather than the earliest period presented. We elected to apply certain adoption related practical expedients for all leases that commenced prior to the election date. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.

As Lessor:

We lease our operating properties to customers under agreements that are classified as operating leases. We recognize the total minimum lease payments provided for under the leases on a straight-line basis over the lease term. Generally, under the terms of our leases, the majority of our rental expenses, including common area maintenance, real estate taxes and insurance, are recovered from our customers. We record amounts reimbursed by customers in the period that the applicable expenses are incurred, which is generally ratably throughout the term of the lease.  We have elected the package of practical expedients that allows lessors to not separate lease and non-lease components by class of underlying asset. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.  We assessed these criteria and concluded that the timing and pattern of transfer for rental revenue and the associated tenant reimbursements are the same, and as our leases qualify as operating leases, we accounted for and presented rental revenue and tenant reimbursements as a single component under Lease revenue in our consolidated statements of income for the three months ended March 31, 2021 and 2020.  

The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three month periods ended March 31, 2021 and 2020 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the lease term. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.

 

 

Three Months Ended

 

 

March 31,

 

 

2021

 

 

2020

 

UHS facilities:

 

 

 

 

 

 

 

Base rents

$

5,146

 

 

$

4,244

 

Bonus rents

 

1,695

 

 

 

1,380

 

Tenant reimbursements

 

291

 

 

 

257

 

Lease revenue - UHS facilities

$

7,132

 

 

$

5,881

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-related parties:

 

 

 

 

 

 

 

Base rents

 

10,505

 

 

 

10,378

 

Tenant reimbursements

 

2,587

 

 

 

2,464

 

Lease revenue - Non-related parties

$

13,092

 

 

$

12,842

 

 

Disclosures Related to Certain Hospital Facilities:

Southwest Healthcare System, Inland Valley Campus:

As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has proposed exchanging potential substitution properties, with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.  The proposed substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of the Board have approved the proposed property substitution subject to satisfactory due diligence and completion of definitive agreements. The effective date of the property substitution is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on the Inland Valley Campus, we earned $1.1 million of lease revenue during the three-month period ended March 31, 2021 ($662,000 in base rental and $454,000 in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).

15


 

Kindred Hospital Chicago Central:

The existing lease on Kindred Hospital Chicago Central, a 95-bed specialty hospital located in Chicago, Illinois, is scheduled to expire on December 31, 2021. The tenant of the facility has recently notified us that they do not intend to renew the lease upon its scheduled expiration. We have begun marketing this property to potential new tenants. However, should this property be vacant for an extended period of time, or should we experience a decrease in the lease rate on a future lease as compared to the current lease, or incur substantial renovation costs to make the property suitable for another operator/tenant, our future results of operations could be unfavorably impacted.  Pursuant to the terms of the lease, we earned approximately $390,000 of lease revenue during the three-month period ended March 31, 2021 and $1.6 million of lease revenue during the twelve-month period ended December 31, 2020.  

Vacancies - Evansville, Indiana and Corpus Christi, Texas:

The leases on two hospital facilities, located in Evansville, Indiana, and Corpus Christi, Texas, expired on May 31, 2019 and June 1, 2019, respectively. The former tenant of the hospital located in Evansville, Indiana, entered into a short-term lease with us, which covered the period of June 1, 2019 through September 30, 2019. The hospital located in Evansville, Indiana, has remained vacant since September 30, 2019 and the hospital located in Corpus Christi, Texas, has remained vacant since June 1, 2019.  

We continue to market each property for lease to new tenants. However, should these properties continue to remain owned and vacant for an extended period of time, or should we experience decreased lease rates on future leases, as compared to prior/expired lease rates, or incur substantial renovation costs to make the properties suitable for other operators/tenants, our future results of operations could be materially unfavorably impacted.

 

As Lessee:

We are the lessee with various third parties, including subsidiaries of UHS, in connection with ground leases for land at fourteen of our consolidated properties. Our right-of-use land assets represent our right to use the land for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right-of-use assets and lease liabilities were recognized upon adoption of Topic 842 based on the present value of lease payments over the lease term. We utilized our estimated incremental borrowing rate, which was derived from information available as of January 1, 2019, in determining the present value of lease payments. A right-of-use asset and lease liability are not recognized for leases with an initial term of 12 months or less, as these short-term leases are accounted for similar to previous guidance for operating leases.  We do not currently have any ground leases with an initial term of 12 months or less. As of March 31, 2021, our condensed consolidated balance sheet includes right-of-use land assets of approximately $8.9 million and ground lease liabilities of approximately $8.9 million. There were no newly leased assets for which a right-of-use asset was recorded in exchange for a new lease liability during the three months ended March 31, 2021.

 

 

(8) Debt and Financial Instruments

Debt:

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $350 million revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our ATM equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

In June 2020, we entered into the first amendment (the “First Amendment”) to the revolving credit agreement (“Credit Agreement”), pursuant to which, among other things, an additional tranche of revolving credit commitments in the amount of $50 million, designated as the “Revolving B Facility”, was established thereby increasing the aggregate revolving credit commitment to $350 million from $300 million. The Credit Agreement, as amended, which is scheduled to mature in March 2022, provides for a revolving credit facility in an aggregate principal amount of $350 million, including a $40 million sublimit for letters of credit and a $30 million sublimit for swingline/short-term loans.  Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust’s wholly-owned subsidiaries.  The remainder of the revolving credit commitments provided under the Credit Agreement that were in effect prior to giving effect to the First Amendment, has been designated as the “Revolving A Facility”.  

16


 

Borrowings made pursuant to the Revolving A Facility will bear interest, at our option, at one, two, three, or six-month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines “Base Rate” as the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Revolving A Facility of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At March 31, 2021, the applicable margin over the LIBOR rate was 1.20%, the margin over the Base Rate was 0.20%, and the facility fee was 0.20%. The Credit Agreement also provides for options to extend the maturity date and borrowing availability for two additional six-month periods for the Revolving A Facility.

Borrowings made pursuant to the Revolving B Facility will bear interest, at our option, at one, two, three, or six months LIBOR plus an applicable margin ranging from 1.85% to 2.10% or at the Base Rate plus an applicable margin ranging from 0.85% to 1.10%.  The Credit Agreement defines “Base Rate” as the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%.  The initial applicable margin is 1.95% for LIBOR loans and 0.95% for Base Rate loans.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Revolving B Facility of the Credit Agreement.  The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At March 31, 2021, the applicable margin over the LIBOR rate was 1.95%, the margin over the Base Rate was 0.95% and the facility fee was 0.20%.  

At March 31, 2021, we had $247.7 million of outstanding borrowings and $5.6 million of letters of credit outstanding under our Credit Agreement.  We had $96.7 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2021. There are no compensating balance requirements. At December 31, 2020, we had $236.2 million of outstanding borrowings outstanding against our revolving credit agreement and $108.2 million of available borrowing capacity.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2021 and December 31, 2020. We also believe that we would remain in compliance if, based on the assumption that the majority of the potential new borrowings will be used to fund investments, the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

March 31,

2021

 

December 31,

2020

 

Tangible net worth

 

> =$125,000

 

$

147,654

 

$

147,263

 

Total leverage

 

< 60%

 

 

45.3

%

 

44.8

%

Secured leverage

 

< 30%

 

 

8.5

%

 

8.6

%

Unencumbered leverage

 

< 60%

 

 

43.3

%

 

41.4

%

Fixed charge coverage

 

> 1.50x

 

4.8x

 

4.7x

 

 

 

17


 

 

As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2021 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

$

5,381

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

5,449

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,474

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,538

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

12,984

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

2,789

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

8,656

 

 

 

3.95

%

 

January, 2030

Rosenberg Children's Medical Plaza fixed rate mortgage loan

 

 

12,450

 

 

 

4.42

%

 

September, 2033

Total, excluding net debt premium and net financing fees

 

 

58,721

 

 

 

 

 

 

 

     Less net financing fees

 

 

(447

)

 

 

 

 

 

 

     Plus net debt premium

 

 

129

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

58,403

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. 

The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages outstanding as of March 31, 2021 had a combined fair value of approximately $61.6 million.  At December 31, 2020, we had various mortgages, all of which were non-recourse to us, included in our condensed consolidated balance sheet. The combined outstanding balance of these various mortgages at December 31, 2020 was $59.2 million and had a combined fair value of approximately $62.0 million. The fair value of our debt was computed based upon quotes received from financial institutions.  We consider these to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments.  Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

Financial Instruments:

In March 2020, we entered into an interest rate swap agreement on a total notional amount of $55 million with a fixed interest rate of 0.565% that we designated as a cash flow hedge.  The interest rate swap became effective on March 25, 2020 and is scheduled to mature on March 25, 2027. If the one-month LIBOR is above 0.565%, the counterparty pays us, and if the one-month LIBOR is less than 0.565%, we pay the counterparty, the difference between the fixed rate of 0.565% and one-month LIBOR.

In January 2020, we entered into an interest rate swap agreement on a total notional amount of $35 million with a fixed interest rate of 1.4975% that we designated as a cash flow hedge.  The interest rate swap became effective on January 15, 2020 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.4975%, the counterparty pays us, and if the one-month LIBOR is less than 1.4975%, we pay the counterparty, the difference between the fixed rate of 1.4975% and one-month LIBOR.  

During the third quarter of 2019, we entered into an interest rate swap agreement on a total notional amount of $50 million with a fixed interest rate of 1.144% that we designated as a cash flow hedge. The interest rate swap became effective on September 16, 2019 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.144%, the counterparty pays us, and if the one-month LIBOR is less than 1.144%, we pay the counterparty, the difference between the fixed rate of 1.144% and one-month LIBOR.

We measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from third parties.  We consider those inputs to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. At March 31, 2021, the fair value of our interest rate swaps was a net liability of $467,000 which is included in accrued expenses and other liabilities on the accompanying condensed consolidated balance sheet. During the first quarter of 2021, we paid or accrued approximately $305,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps.  From inception of the swap agreements through March 31, 2021 we paid or accrued approximately $931,000 in net payments made to the counterparty by us pursuant to the terms of the swap (consisting of approximately $199,000 in payments or accruals made to us by the counterparty, offset by approximately $1.1 million of payments due to the counterparty from us).  Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or a liability, with a corresponding amount recorded in accumulated other

18


 

comprehensive income (“AOCI”) within shareholders’ equity.  Amounts are classified from AOCI to the income statement in the period or periods the hedged transaction affects earnings.

 

(9) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  No individual property meets the requirements necessary to be considered its own segment.

 

 

19


 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a real estate investment trust (“REIT”) that commenced operations in 1986. We invest in healthcare and human service related facilities currently including acute care hospitals, behavioral health care hospitals, specialty hospitals, free-standing emergency departments, childcare centers and medical/office buildings. As of April 30, 2021, we have seventy-two real estate investments or commitments located in twenty states consisting of:  

 

seven hospital facilities consisting of three acute care, one behavioral health care, and three specialty hospitals (two of which are currently vacant);

 

four free-standing emergency departments (“FEDs”);

 

fifty-seven medical/office buildings, including five owned by unconsolidated limited liability companies (“LLCs”)/limited liability partnerships (“LPs”), and;

 

four preschool and childcare centers.

Forward Looking Statements and Certain Risk Factors

You should carefully review all of the information contained in this Quarterly Report, and should particularly consider any risk factors that we set forth in this Quarterly Report and in other reports or documents that we file from time to time with the Securities and Exchange Commission (the “SEC”). In this Quarterly Report, we state our beliefs of future events and of our future financial performance. In some cases, you can identify those so-called “forward-looking statements” by words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “appears,” “projects” and similar expressions, as well as statements in future tense. You should be aware that those statements are only our predictions. Actual events or results may differ materially. In evaluating those statements, you should specifically consider various factors, including the risks described elsewhere herein and in our Annual Report on Form 10-K for the year ended December 31, 2020 in Item 1A Risk Factors and in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Forward Looking Statements and in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Forward Looking Statements and Risk Factors, as included herein. Those factors may cause our actual results to differ materially from any of our forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, such performance or results will be achieved. Forward-looking information is based on information available at the time and/or our good faith belief with respect to future events, and is subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Such factors include, among other things, the following:  

 

Future operations and financial results of our tenants, and in turn ours, will likely be materially impacted by numerous factors and future developments related to COVID-19.   Such factors and developments include, but are not limited to, the length of time and severity of the spread of the pandemic; the volume of cancelled or rescheduled elective procedures and the volume of COVID-19 patients treated by the operators of our hospitals and other healthcare facilities; measures our tenants are taking to respond to the COVID-19 pandemic; the impact of government and administrative regulation, including travel bans and restrictions, shelter-in-place or stay-at-home orders, quarantines, the promotion of social distancing, business shutdowns and limitations on business activity; changes in patient volumes at our tenants’ hospitals and other healthcare facilities due to patients’ general concerns related to the risk of contracting COVID-19 from interacting with the healthcare system; the impact of stimulus on the health care industry and our tenants; changes in patient volumes and payer mix caused by deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients as the result of business closings and layoffs); potential disruptions to clinical staffing and shortages and disruptions related to supplies required for our tenants’ employees and patients, including equipment, pharmaceuticals and medical supplies, particularly personal protective equipment, or PPE; potential increases to expenses incurred by our tenants related to staffing, supply chain or other expenditures; the impact of our indebtedness and the ability to refinance such indebtedness on acceptable terms; disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact our ability to access capital or increase associated borrowing costs; and changes in general economic conditions nationally and regionally in the markets our properties are located resulting from the COVID-19 pandemic, including higher sustained rates of unemployment and underemployment levels and reduced consumer spending and confidence.  There may be significant declines in future bonus rental revenue earned on our hospital properties leased to subsidiaries of UHS to the extent that each hospital continues to experience significant decline in patient volumes and revenues. These factors may result in the inability or unwillingness on the part of some of our tenants to make timely payment of their rent to us at current levels or to seek to amend or terminate their leases which, in turn, would have an adverse effect on our occupancy levels and

20


 

 

our revenue and cash flow and the value of our properties, and potentially, our ability to maintain our dividend at current levels.

 

 

Due to COVID-19 restrictions and its impact on the economy, we may experience a decrease in prospective tenants which could unfavorably impact the volume of new leases, as well as the renewal rate of existing leases. The COVID-19 pandemic could also impact our indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financing perspective; and changes in general economic conditions nationally and regionally in the markets our properties are located resulting from the COVID-19 pandemic. We are not able to fully quantify the impact that these factors will have on our financial results during 2021, but developments related to the COVID-19 pandemic are likely to have a material adverse impact on our future financial results.

 

 

Recent legislation, including the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and the Paycheck Protection Program and Health Care Enhancement Act (“PPPHCE Act”), has provided grant funding to hospitals and other healthcare providers to assist them during the COVID-19 pandemic.  There is a high degree of uncertainty surrounding the implementation of the CARES Act and the PPPHCE Act, and the federal government may consider additional stimulus and relief efforts, but we are unable to predict whether additional stimulus measures will be enacted or their impact.  There can be no assurance as to the total amount of financial and other types of assistance our tenants will receive under the CARES Act and the PPPHCE Act, and it is difficult to predict the impact of such legislation on our tenants’ operations or how they will affect operations of our tenants’ competitors.  Moreover, we are unable to assess the extent to which anticipated negative impacts on our tenants (and, in turn, us) arising from the COVID-19 pandemic will be offset by amounts or benefits received or to be received under the CARES Act and the PPPHCE Act.

 

A substantial portion of our revenues are dependent upon one operator, UHS, which comprised approximately 36% and 32% of our consolidated revenues for the three-month periods ended March 31, 2021 and 2020, respectively.  As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has proposed exchanging potential substitution properties, with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.  The proposed substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of the Board have approved the proposed property substitution subject to satisfactory due diligence and completion of definitive agreements. The effective date of the property substitution is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on the Inland Valley Campus, we earned $1.1 million of lease revenue during the three-month period ended March 31, 2021 ($662,000 in base rental and $454,000 in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).     

 

In addition, we cannot assure you that subsidiaries of UHS will renew the leases on our three acute care hospitals (two of which are scheduled to expire in December, 2021 and one of which is scheduled to expire in December, 2026) and two FEDs at existing lease rates or fair market value lease rates. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital facilities and FEDs and do not enter into the substitution arrangement upon expiration of the lease terms or otherwise, our future revenues and results of operations could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to these leases. Please see Note 7 to the condensed consolidated financial statements - Lease Accounting, for additional information related to a potential transaction with a wholly-owned subsidiary of UHS in connection with Southwest Healthcare System, Inland Valley Campus.

 

In certain of our markets, the general real estate market has been unfavorably impacted by increased competition/capacity and decreases in occupancy and rental rates which may adversely impact our operating results and the underlying value of our properties.

 

A number of legislative initiatives have recently been passed into law that may result in major changes in the health care delivery system on a national or state level to the operators of our facilities, including UHS. No assurances can be given that the implementation of these new laws will not have a material adverse effect on the business, financial condition or results of operations of our operators.

 

The potential indirect impact of the Tax Cuts and Jobs Act of 2017, signed into law on December 22, 2017, which makes significant changes to corporate and individual tax rates and calculation of taxes, which could potentially impact our tenants and jurisdictions, both positively and negatively, in which we do business, as well as the overall investment thesis for REITs.

21


 

 

A subsidiary of UHS is our Advisor and our officers are all employees of a wholly-owned subsidiary of UHS, which may create the potential for conflicts of interest.

 

Lost revenues resulting from the exercise of purchase options, lease expirations and renewals and other transactions (see Note 7 to the condensed consolidated financial statements – Lease Accounting for additional disclosure related to lease expirations and subsequent vacancies that occurred during the second and third quarters of 2019 on two hospital facilities and the notice provide by Kindred Healthcare, lessee of one of our other specialty hospitals that they do not intend to renew the lease on its facility which expires on December 31, 2021.

 

Our ability to continue to obtain capital on acceptable terms, including borrowed funds, to fund future growth of our business.

 

The outcome and effects of known and unknown litigation, government investigations, and liabilities and other claims asserted against us, UHS or the other operators of our facilities. UHS and its subsidiaries are subject to legal actions, purported shareholder class actions and shareholder derivative cases, governmental investigations and regulatory actions and the effects of adverse publicity relating to such matters. Since UHS comprised approximately 36% and 32% of our consolidated revenues during the three-month periods ended March 31, 2021 and 2020, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain and review the disclosures contained in the Legal Proceedings section of Universal Health Services, Inc.’s Forms 10-Q and 10-K, as publicly filed with the Securities and Exchange Commission. Those filings are the sole responsibility of UHS and are not incorporated by reference herein.

 

Failure of UHS or the other operators of our hospital facilities to comply with governmental regulations related to the Medicare and Medicaid licensing and certification requirements could have a material adverse impact on our future revenues and the underlying value of the property.

 

The potential unfavorable impact on our business of the deterioration in national, regional and local economic and business conditions, including a further worsening of credit and/or capital market conditions, which may adversely affect our ability to obtain capital which may be required to fund the future growth of our business and refinance existing debt with near term maturities.

 

A continuation in the deterioration in general economic conditions which has resulted in increases in the number of people unemployed and/or insured and likely increase the number of individuals without health insurance; as a result, the operators of our facilities may experience declines in patient volumes which could result in decreased occupancy rates at our medical office buildings.

 

A worsening of the economic and employment conditions in the United States would likely materially affect the business of our operators, including UHS, which would likely unfavorably impact our future bonus rentals (on the UHS hospital facilities) and may potentially have a negative impact on the future lease renewal terms and the underlying value of the hospital properties.

 

Real estate market factors, including without limitation, the supply and demand of office space and market rental rates, changes in interest rates as well as an increase in the development of medical office condominiums in certain markets.

 

The impact of property values and results of operations of severe weather conditions, including the effects of hurricanes.

 

Government regulations, including changes in the reimbursement levels under the Medicare and Medicaid programs.

 

The issues facing the health care industry that affect the operators of our facilities, including UHS, such as: changes in, or the ability to comply with, existing laws and government regulations; unfavorable changes in the levels and terms of reimbursement by third party payors or government programs, including Medicare (including, but not limited to, the potential unfavorable impact of future reductions to Medicare reimbursements resulting from the Budget Control Act of 2011, as discussed in the next bullet point below) and Medicaid (most states have reported significant budget deficits that have, in the past, resulted in the reduction of Medicaid funding to the operators of our facilities, including UHS); demographic changes; the ability to enter into managed care provider agreements on acceptable terms; an increase in uninsured and self-pay patients which unfavorably impacts the collectability of patient accounts; decreasing in-patient admission trends; technological and pharmaceutical improvements that may increase the cost of providing, or reduce the demand for, health care, and; the ability to attract and retain qualified medical personnel, including physicians.

 

Pending limits for most federal agencies and programs aimed at reducing budget deficits by $917 billion between 2012 and 2021, according to a report released by the Congressional Budget Office. Among its other provisions, the law established a bipartisan Congressional committee, known as the Joint Select Committee on Deficit Reduction (the “Joint Committee”), which was tasked with making recommendations aimed at reducing future federal budget deficits by an additional $1.5 trillion over 10 years. The Joint Committee was unable to reach an agreement by the November 23, 2011 deadline and, as a result, across-the-board cuts to discretionary, national defense and Medicare spending were implemented on March 1, 2013

22


 

 

resulting in Medicare payment reductions of up to 2% per fiscal year with a uniform percentage reduction across all Medicare programs. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, continued the 2% reductions to Medicare reimbursement imposed under the Budget Control Act of 2011. Recent legislation has suspended payment reductions through December 31, 2021 in exchange for extended cuts through 2030.  We cannot predict whether Congress will restructure the implemented Medicare payment reductions or what other federal budget deficit reduction initiatives may be proposed by Congress going forward.  We also cannot predict the effect these enactments will have on the operators of our properties (including UHS), and thus, our business.

 

An increasing number of legislative initiatives have been passed into law that may result in major changes in the health care delivery system on a national or state level. Legislation has already been enacted that has eliminated the penalty for failing to maintain health coverage that was part of the original Patient Protection and Affordable Care Act (the “ACA”). President Biden is expected to undertake executive actions that will strengthen the ACA and may reverse the policies of the prior administration.  The Trump Administration had directed the issuance of final rules: (i) enabling the formation of association health plans that would be exempt from certain ACA requirements such as the provision of essential health benefits; (ii) expanding the availability of short-term, limited duration health insurance, (iii) eliminating cost-sharing reduction payments to insurers that would otherwise offset deductibles and other out-of-pocket expenses for health plan enrollees at or below 250 percent of the federal poverty level; (iv) relaxing requirements for state innovation waivers that could reduce enrollment in the individual and small group markets and lead to additional enrollment in short-term, limited duration insurance and association health plans; and (v) incentivizing the use of health reimbursement arrangements by employers to permit employees to purchase health insurance in the individual market.  The uncertainty resulting from these Executive Branch policies had led to reduced Exchange enrollment in 2018, 2019 and 2020, and is expected to further worsen the individual and small group market risk pools in future years.  It is also anticipated that these policies, to the extent that they remain as implemented, may create additional cost and reimbursement pressures on hospitals, including ours. In addition, while attempts to repeal the entirety of the ACA have not been successful to date, a key provision of the ACA was eliminated as part of the Tax Cuts and Jobs Act and on December 14, 2018, a federal U.S. District Court Judge in Texas ruled the entire ACA is unconstitutional. That ruling was appealed and on December 18, 2019, the Fifth Circuit Court of Appeals voted 2-1 to strike down the ACA individual mandate as unconstitutional and sent the case back to the U.S. District Court in Texas to determine which ACA provisions should be stricken with the mandate or whether the entire law is unconstitutional without the individual mandate. On March 2, 2020, the U.S. Supreme Court agreed to hear, during the 2020-2021 term, two consolidated cases, filed by the State of California and the United States House of Representatives, asking the Supreme Court to review the ruling by the Fifth Circuit Court of Appeals. Oral argument was heard on November 10, 2020, and a ruling is expected in 2021. In a February 10, 2021 letter to the Supreme Court, the Department of Justice reversed its earlier position and stated its position that the ACA is constitutional.  The ACA will remain law while the case proceeds through the appeals process; however, the case creates additional uncertainty as to whether any or all of the ACA could be struck down, which creates operational risk for the health care industry. We are unable to predict the final outcome of this matter which has caused greater uncertainty regarding the future status of the ACA. If all or any parts of the ACA are ultimately found to be unconstitutional, it could have a material adverse effect on the business, financial condition and results of operations of the operators of our properties, and, thus, our business. 

 

There can be no assurance that if any of the announced or proposed changes described above are implemented there will not be negative financial impact on the operators of our hospitals, which material effects may include a potential decrease in the market for health care services or a decrease in the ability of the operators of our hospitals to receive reimbursement for health care services provided which could result in a material adverse effect on the financial condition or results of operations of the operators of our properties, and, thus, our business.

 

Competition for properties include, but are not limited to, other REITs, private investors and firms, banks and other companies, including UHS.  In addition, we may face competition from other REITs for our tenants.

 

The operators of our facilities face competition from other health care providers, including physician owned facilities and other competing facilities, including certain facilities operated by UHS but the real property of which is not owned by us. Such competition is experienced in markets including, but not limited to, McAllen, Texas, the site of our McAllen Medical Center, a 370-bed acute care hospital, and Riverside County, California, the site of our Southwest Healthcare System-Inland Valley Campus, a 130-bed acute care hospital.

 

Changes in, or inadvertent violations of, tax laws and regulations and other factors that can affect REITs and our status as a REIT, including possible future changes to federal tax laws that could materially impact our ability to defer gains on divestitures through like-kind property exchanges.

 

 

The individual and collective impact of the changes made by the CARES Act on REITs and their security holders are uncertain and may not become evident for some period of time; it is also possible additional legislation could be enacted in the future as a result of the COVID-19 pandemic which may affect the holders of our securities.

23


 

 

Should we be unable to comply with the strict income distribution requirements applicable to REITs, utilizing only cash generated by operating activities, we would be required to generate cash from other sources which could adversely affect our financial condition.

 

Our ownership interest in five LLCs/LPs in which we hold non-controlling equity interests. In addition, pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

 

Fluctuations in the value of our common stock.

 

Other factors referenced herein or in our other filings with the Securities and Exchange Commission.

Given these uncertainties, risks and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Our actual results and financial condition, including the operating results of our lessees and the facilities leased to subsidiaries of UHS, could differ materially from those expressed in, or implied by, the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. We assume no obligation to publicly update any forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except as may be required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.  

We consider our critical accounting policies to be those that require us to make significant judgments and estimates when we prepare our financial statements, including the following:

Purchase Accounting for Acquisition of Investments in Real Estate:  Purchase accounting is applied to the assets and liabilities related to all real estate investments acquired from third parties. In accordance with current accounting guidance, we account for our property acquisitions as acquisitions of assets, which requires the capitalization of acquisition costs to the underlying assets and prohibits the recognition of goodwill or bargain purchase gains. The fair value of the real estate acquired is allocated to the acquired tangible assets, consisting primarily of land, building and tenant improvements, and identified intangible assets and liabilities, consisting of the value of above-market and below-market leases, and acquired ground leases, based in each case on their fair values. Loan premiums, in the case of above market rate assumed loans, or loan discounts, in the case of below market assumed loans, are recorded based on the fair value of any loans assumed in connection with acquiring the real estate.

 

The fair values of the tangible assets of an acquired property are determined based on comparable land sales for land and replacement costs adjusted for physical and market obsolescence for the improvements. The fair values of the tangible assets of an acquired property are also determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land, building and tenant improvements based on management’s determination of the relative fair values of these assets. Management determines the as-if-vacant fair value of a property based on assumptions that a market participant would use, which is similar to methods used by independent appraisers. In addition, there is intangible value related to having tenants leasing space in the purchased property, which is referred to as in-place lease value. Such value results primarily from the buyer of a leased property avoiding the costs associated with leasing the property and also avoiding rent losses and unreimbursed operating expenses during the hypothetical lease-up period. Factors considered by management in performing these analyses include an estimate of carrying costs during the expected lease-up periods considering current market conditions and costs to execute similar leases. In estimating carrying costs, management includes real estate taxes, insurance and other operating expenses and estimates of lost rental revenue during the expected lease-up periods based on current market demand. Management also estimates costs to execute similar leases including leasing commissions, tenant improvements, legal and other related costs. The value of in-place leases are amortized to expense over the remaining initial terms of the respective leases.

24


 

 

In allocating the fair value of the identified intangible assets and liabilities of an acquired property, above-market and below-market in-place lease values are recorded based on the present value (using an interest rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) estimated fair market lease rates from the perspective of a market participant for the corresponding in-place leases, measured, for above-market leases, over a period equal to the remaining non-cancelable term of the lease and, for below-market leases, over a period equal to the initial term plus any below market fixed rate renewal periods. The capitalized above-market lease values are amortized as a reduction of rental income over the remaining non-cancelable terms of the respective leases. The capitalized below-market lease values, also referred to as acquired lease obligations, are amortized as an increase to rental income over the initial terms of the respective leases.

Asset Impairment:  Purchase accounting is applied to the assets and liabilities related to all real estate investments acquired from third parties. In accordance with current accounting guidance, we account for our property acquisitions as acquisitions of assets, which requires the capitalization of acquisition costs to the underlying assets and prohibits the recognition of goodwill or bargain purchase gains. The fair value of the real estate acquired is allocated to the acquired tangible assets, consisting primarily of land, building and tenant improvements, and identified intangible assets and liabilities, consisting of the value of above-market and below-market leases, and acquired ground leases, based in each case on their fair values. Loan premiums, in the case of above market rate assumed loans, or loan discounts, in the case of below market assumed loans, are recorded based on the fair value of any loans assumed in connection with acquiring the real estate.

 

The fair values of the tangible assets of an acquired property are determined based on comparable land sales for land and replacement costs adjusted for physical and market obsolescence for the improvements. The fair values of the tangible assets of an acquired property are also determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land, building and tenant improvements based on management’s determination of the relative fair values of these assets. Management determines the as-if-vacant fair value of a property based on assumptions that a market participant would use, which is similar to methods used by independent appraisers. In addition, there is intangible value related to having tenants leasing space in the purchased property, which is referred to as in-place lease value. Such value results primarily from the buyer of a leased property avoiding the costs associated with leasing the property and also avoiding rent losses and unreimbursed operating expenses during the hypothetical lease-up period. Factors considered by management in performing these analyses include an estimate of carrying costs during the expected lease-up periods considering current market conditions and costs to execute similar leases. In estimating carrying costs, management includes real estate taxes, insurance and other operating expenses and estimates of lost rental revenue during the expected lease-up periods based on current market demand. Management also estimates costs to execute similar leases including leasing commissions, tenant improvements, legal and other related costs. The value of in-place leases are amortized to expense over the remaining initial terms of the respective leases.

 

In allocating the fair value of the identified intangible assets and liabilities of an acquired property, above-market and below-market in-place lease values are recorded based on the present value (using an interest rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) estimated fair market lease rates from the perspective of a market participant for the corresponding in-place leases, measured, for above-market leases, over a period equal to the remaining non-cancelable term of the lease and, for below-market leases, over a period equal to the initial term plus any below market fixed rate renewal periods. The capitalized above-market lease values are amortized as a reduction of rental income over the remaining non-cancelable terms of the respective leases. The capitalized below-market lease values, also referred to as acquired lease obligations, are amortized as an increase to rental income over the initial terms of the respective leases.

 

Federal Income Taxes:    No provision has been made for federal income tax purposes since we qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986, and intend to continue to remain so qualified.   To qualify as a REIT, we must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of our annual REIT taxable income to shareholders. As a REIT, we generally will not be subject to federal, state or local income tax on income that we distribute as dividends to our shareholders.

We are subject to a federal excise tax computed on a calendar year basis. The excise tax equals 4% of the amount by which 85% of our ordinary income plus 95% of any capital gain income for the calendar year exceeds cash distributions during the calendar year, as defined. No provision for excise tax has been reflected in the financial statements as no tax was due.

Earnings and profits, which determine the taxability of dividends to shareholders, will differ from net income reported for financial reporting purposes due to the differences for federal tax purposes in the cost basis of assets and in the estimated useful lives used to compute depreciation and the recording of provision for investment losses.

25


 

Results of Operations

During the three-month period ended March 31, 2021, net income was $5.6 million, as compared to $4.6 million during the first quarter of 2020.  The $1.0 million increase was attributable to:

 

$315,000 increase in bonus rentals earned on the three hospital facilities leased to subsidiaries of UHS;

 

$176,000 increase resulting from a decrease in interest expense, primarily due to a decrease in our average cost of borrowings under our revolving credit agreement, partially offset by an increase in our average outstanding borrowings, and;

 

$541,000 of other combined net increases including an aggregate net increase in income generated at various properties, including the income recorded in connection with the newly constructed and recently completed Clive Behavioral Health facility.

Total revenues increased $1.5 million, or 7.8% during the three-month period ended March 31, 2021, as compared to the comparable quarter of 2020. The net increase was due primarily to the revenue recorded in connection with the newly constructed Clive Behavioral Health facility located in Clive, Iowa, that was completed in December, 2020, and the $315,000 increase in bonus rental revenues.

Included in our other operating expenses are expenses related to the consolidated medical office buildings and two vacant hospital facilities, which totaled $4.8 million and $4.7 million for the three-month periods ended March 31, 2021 and 2020, respectively. A large portion of the expenses associated with our consolidated medical office buildings is passed on directly to the tenants either directly as tenant reimbursements of common area maintenance expenses or included in base rental amounts. Tenant reimbursements for operating expenses are accrued as revenue in the same period the related expenses are incurred and are included as lease revenue in our condensed consolidated statements of income. Included in our operating expenses for the three months ended March 31, 2021 and 2020, is $164,000 and $196,000, respectively, of aggregate operating expenses related to two vacant hospital facilities located in Corpus Christi, Texas, and Evansville, Indiana.

Funds from operations (“FFO”) is a widely recognized measure of performance for Real Estate Investment Trusts (“REITs”). We believe that FFO and FFO per diluted share, which are non-GAAP financial measures, are helpful to our investors as measures of our operating performance. We compute FFO in accordance with standards established by the National Association of Real Estate Investment Trusts (“NAREIT”), which may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, or that interpret the NAREIT definition differently than we interpret the definition. FFO adjusts for the effects of gains, such as gains on transactions during the periods presented.  To the extent a REIT recognizes a gain or loss with respect to the sale of incidental assets, such as the sale of land peripheral to operating properties, the REIT has the option to exclude or include such gains and losses in the calculation of FFO.  We have opted to exclude gains and losses from sales of incidental assets in our calculation of FFO.  FFO does not represent cash generated from operating activities in accordance with GAAP and should not be considered to be an alternative to net income determined in accordance with GAAP. In addition, FFO should not be used as: (i) an indication of our financial performance determined in accordance with GAAP; (ii) an alternative to cash flow from operating activities determined in accordance with GAAP; (iii) a measure of our liquidity, or; (iv) an indicator of funds available for our cash needs, including our ability to make cash distributions to shareholders.

Below is a reconciliation of our reported net income to FFO for the three-month periods ended March 31, 2021 and 2020 (in thousands):

 

 

Three Months Ended

March 31,

 

 

 

2021

 

 

2020

 

Net income

 

$

5,586

 

 

$

4,554

 

Depreciation and amortization expense on consolidated

   investments

 

 

6,787

 

 

 

6,380

 

Depreciation and amortization expense on unconsolidated

   affiliates

 

 

362

 

 

 

286

 

Funds From Operations

 

$

12,735

 

 

$

11,220

 

Weighted average number of shares outstanding - Diluted

 

 

13,771

 

 

 

13,758

 

Funds From Operations per diluted share

 

$

0.92

 

 

$

0.82

 

Our FFO increased $1.5 million, or $.10 per diluted share, during the first quarter of 2021, as compared to the first quarter of 2020.  The net increase was primarily due to: (i) a favorable impact of $315,000, or $.02 per diluted share, related to an increase in bonus rental earned on the three acute care hospital facilities leased to subsidiaries of UHS; (ii) a favorable impact of $176,000, or $.01 per

26


 

diluted share, resulting from a decrease in interest expense, resulting primarily from a decrease in our average cost of borrowings pursuant to our revolving credit agreement, partially offset by an increase in our average outstanding borrowings, and; (iii) other combined net increases of $1.0 million, or $.07 per diluted share, including a net aggregate increase in income generated at various properties, as discussed above, as well as an increase in depreciation and amortization expense recorded in connection with the newly constructed and recently completed Clive Behavioral Health facility.   

 

Other Operating Results

Interest Expense:

As reflected in the schedule below, interest expense was $2.1 million and $2.3 million during the three-month periods ended March 31, 2021 and 2020, respectively (amounts in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

Three Months

Ended

March 31,

2021

 

 

Three Months

Ended

March 31,

2020

 

 

Revolving credit agreement

 

$

967

 

 

$

1,623

 

 

Mortgage interest

 

 

635

 

 

 

658

 

 

Interest rate swaps expense/(income), net (a.)

 

 

309

 

 

 

(51

)

 

Amortization of financing fees

 

 

216

 

 

 

157

 

 

Amortization of fair value of debt

 

 

(13

)

 

 

(13

)

 

Capitalized interest on major projects

 

 

-

 

 

 

(65

)

 

Other interest

 

 

19

 

 

 

-

 

 

Interest expense, net

 

$

2,133

 

 

$

2,309

 

 

        

 

(a.)

Represents net interest paid by us / (to us) by the counterparties pursuant to three interest rate SWAPs with a combined notional amount of $140 million.

Interest expense decreased by $176,000 during the three-month period ended March 31, 2021, as compared to the comparable period of 2020, due primarily to: (i) a $656,000 decrease in the interest expense on our revolving credit agreement resulting from a decrease in our average cost of borrowings pursuant to our revolving credit agreement (1.3% during the three months ended March 31, 2021 as compared to 2.8% in the comparable quarter of 2020), partially offset by an increase in our average outstanding borrowings ($239.2 million during the three months ended March 31, 2021 as compared to $213.2 million in the comparable 2020 quarter); (ii) a $360,000 net increase in interest rate swap expense during the first quarter of 2021 as compared to the first quarter of 2020; (iii) a $65,000 increase in interest expense due to a decrease in capitalized interest on major projects (both newly constructed facilities were completed in December, 2020), and; (iv) $55,000 of other combined net increases in interest expense.

 

Disclosures Related to Certain Hospital Facilities

Please refer to Note 7 to the condensed consolidated financial statements - Lease Accounting, for additional information regarding certain of our hospital facilities including Southwest Healthcare System, Inland Valley Campus; Evansville, Indiana; Corpus Christi, Texas, and; Kindred Hospital Chicago Central.  

 

Liquidity and Capital Resources    

Net cash provided by operating activities

Net cash provided by operating activities was $11.3 million during the three-month period ended March 31, 2021 as compared to $10.1 million during the comparable period of 2020. The $1.1 million net increase was attributable to:

 

A favorable change of $1.5 million due to an increase in net income plus/minus the adjustments to reconcile net income to net cash provided by operating activities (depreciation and amortization, amortization related to above/below market leases, amortization of debt premium, amortization of deferred financing costs and stock-based compensation), as discussed above;

 

an unfavorable change of $510,000 in lease receivable;

 

a favorable change of $234,000 in accrued expenses;

 

an unfavorable change of $461,000 in tenant reserves, deposits and deferred and prepaid rents, and;

 

other combined net favorable changes of $305,000, resulting primarily from the timing of prepaid expense payments.

27


 

 

Net cash used in investing activities

Net cash used in investing activities was $12.2 million during the first three months of 2021 as compared to $7.0 million during the first three months of 2020.

During the three-month period ended March 31, 2021 we funded: (i) $7.0 million in additions to real estate investments including construction costs related to a newly constructed, 100-bed behavioral health care hospital located in Clive, Iowa, that was substantially completed in late December, 2020 as well as tenant improvements at various MOBs; (ii) $3.5 million in a member loan to an unconsolidated LP; (iii) $200,000 deposit on a potential real estate asset, and; (iv) $1.5 million in equity investments in unconsolidated LLCs.

During the three-month period ended March 31, 2020, we funded: (i) $1.5 million in equity investments in unconsolidated LLCs, primarily related to the construction costs related to Texoma Medical Plaza II that was substantially completed in December, 2020, and; (ii) $5.5 million in additions to real estate investments including $4.1 million of construction costs related to the newly constructed behavioral health care hospital located in Clive, Iowa, that was substantially completed in late December, 2020  and tenant improvements at various MOBs.

Net cash provided by/(used in) financing activities

Net cash provided by financing activities was $1.4 million during the three months ended March 31, 2021, as compared to $3.6 million of cash used in financing activities during the three months ended March 31, 2020.

During the three-month period ended March 31, 2021, we paid: (i) $510,000 on mortgage notes payable that are non-recourse to us; (ii) $35,000 of financing costs related to the revolving credit agreement, and; (iii) $9.6 million of dividends. Additionally, during the three months ended March 31, 2021, we received: (i) $11.5 million of net borrowings on our revolving credit agreement, and; (ii) $56,000 of net cash from the issuance of shares of beneficial interest.

During the three-month period ended March 31, 2020, we paid: (i) $432,000 on mortgage notes payable that are non-recourse to us; (ii) $35,000 of financing costs related to the revolving credit agreement, and; (iii) $9.4 million of dividends.  Additionally, during the three months ended March 31, 2020, we received: (i) $6.3 million of net borrowings on our revolving credit agreement, and; (ii) $50,000 of net cash from the issuance of shares of beneficial interest.

During the second quarter of 2020, we commenced an at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of $100 million to or through our agent banks. No shares were issued pursuant to this ATM equity program during the first quarter of 2021. Since inception pursuant to this ATM equity program, we have issued 2,704 shares at an average price of $101.30 per share which generated approximately $270,000 of net cash proceeds (net of compensation to BofA Securities, Inc. of approximately $4,000).  Additionally, we paid or incurred approximately $507,000 in various fees and expenses related to the commencement of our ATM program.  

Additional cash flow and dividends paid information for the three-month periods ended March 31, 2021 and 2020:

As indicated on our condensed consolidated statement of cash flows, we generated net cash provided by operating activities of $11.3 million and $10.1 million during the three-month periods ended March 31, 2021 and 2020, respectively. As also indicated on our statement of cash flows, non-cash expenses including depreciation and amortization expense, amortization related to above/below market leases, amortization of debt premium, amortization of deferred financing costs and stock-based compensation expense are the primary differences between our net income and net cash provided by operating activities during each period.

We declared and paid dividends of $9.6 million and $9.4 million during the three-month periods ended March 31, 2021 and 2020, respectively. During the first three months of 2021, the $11.3 million of net cash provided by operating activities was approximately $1.7 million greater than the $9.6 million of dividends paid during the first three months of 2021. During the first three months of 2020, the $10.1 million of net cash provided by operating activities was $713,000 greater than the $9.4 million of dividends paid during the first three months of 2020.  

As indicated in the cash flows from investing activities and cash flows from financing activities sections of the statements of cash flows, there were various other sources and uses of cash during the three months ended March 31, 2021 and 2020.  From time to time, various other sources and uses of cash may include items such as investments and advances made to/from LLCs, additions to real estate investments, acquisitions/divestiture of properties, net borrowings/repayments of debt, and proceeds generated from the issuance of equity. Therefore, in any given period, the funding source for our dividend payments is not wholly dependent on the operating cash flow generated by our properties. Rather, our dividends as well as our capital reinvestments into our existing properties, acquisitions of real property and other investments are funded based upon the aggregate net cash inflows or outflows from all sources and uses of cash from the properties we own either in whole or through LLCs, as outlined above.

28


 

In determining and monitoring our dividend level on a quarterly basis, our management and Board of Trustees consider many factors in determining the amount of dividends to be paid each period. These considerations primarily include: (i) the minimum required amount of dividends to be paid in order to maintain our REIT status; (ii) the current and projected operating results of our properties, including those owned in LLCs, and; (iii) our future capital commitments and debt repayments, including those of our LLCs. Based upon the information discussed above, as well as consideration of projections and forecasts of our future operating cash flows, management and the Board of Trustees have determined that our operating cash flows have been sufficient to fund our dividend payments. Future dividend levels will be determined based upon the factors outlined above with consideration given to our projected future results of operations.

We expect to finance all capital expenditures and acquisitions and pay dividends utilizing internally generated and additional funds. Additional funds may be obtained through: (i) borrowings under our existing $350 million revolving credit agreement (which had $96.7 million of available borrowing capacity, net of outstanding borrowings and letters of credit as of March 31, 2021); (ii) borrowings under or refinancing of existing third-party debt pursuant to mortgage loan agreements entered into by our consolidated and unconsolidated LLCs/LPs; (iii) the issuance of equity pursuant to our ATM program, and/or; (iv) the issuance of other long-term debt.

We believe that our operating cash flows, cash and cash equivalents, available borrowing capacity under our revolving credit agreement and access to the capital markets provide us with sufficient capital resources to fund our operating, investing and financing requirements for the next twelve months, including providing sufficient capital to allow us to make distributions necessary to enable us to continue to qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986. In the event we need to access the capital markets or other sources of financing, there can be no assurance that we will be able to obtain financing on acceptable terms or within an acceptable time. Our inability to obtain financing on terms acceptable to us could have a material unfavorable impact on our results of operations, financial condition and liquidity.

Credit facilities and mortgage debt

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $350 million revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our ATM equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

In June 2020, we entered into the first amendment (the “First Amendment”) to the revolving credit agreement (“Credit Agreement”), pursuant to which, among other things, an additional tranche of revolving credit commitments in the amount of $50 million, designated as the “Revolving B Facility”, was established thereby increasing the aggregate revolving credit commitment to $350 million from $300 million. The Credit Agreement, as amended, which is scheduled to mature in March 2022, provides for a revolving credit facility in an aggregate principal amount of $350 million, including a $40 million sublimit for letters of credit and a $30 million sublimit for swingline/short-term loans.  Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust’s wholly-owned subsidiaries.  The remainder of the revolving credit commitments provided under the Credit Agreement that were in effect prior to giving effect to the First Amendment, has been designated as the “Revolving A Facility”.  

Borrowings made pursuant to the Revolving A Facility will bear interest, at our option, at one, two, three, or six-month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines “Base Rate” as the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Revolving A Facility of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At March 31, 2021, the applicable margin over the LIBOR rate was 1.20%, the margin over the Base Rate was 0.20%, and the facility fee was 0.20%. The Credit Agreement also provides for options to extend the maturity date and borrowing availability for two additional six-month periods for the Revolving A Facility.

Borrowings made pursuant to the Revolving B Facility will bear interest, at our option, at one, two, three, or six months LIBOR plus an applicable margin ranging from 1.85% to 2.10% or at the Base Rate plus an applicable margin ranging from 0.85% to 1.10%.  The Credit Agreement defines “Base Rate” as the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%.  The initial applicable margin is 1.95% for LIBOR loans and 0.95% for Base Rate loans.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Revolving B Facility of the Credit Agreement.  

29


 

The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At March 31, 2021, the applicable margin over the LIBOR rate was 1.95%, the margin over the Base Rate was 0.95% and the facility fee was 0.20%.  

At March 31, 2021, we had $247.7 million of outstanding borrowings and $5.6 million of letters of credit outstanding under our Credit Agreement.  We had $96.7 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2021. There are no compensating balance requirements.  At December 31, 2020, we had $236.2 million of outstanding borrowings outstanding against our revolving credit agreement and $108.2 million of available borrowing capacity.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2021 and December 31, 2020. We also believe that we would remain in compliance if, based on the assumption that the majority of the potential new borrowings will be used to fund investments, the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):  

 

 

Covenant

 

March 31,

2021

 

December 31,

2020

 

Tangible net worth

 

> =$125,000

 

$

147,654

 

$

147,263

 

Total leverage

 

< 60%

 

 

45.3

%

 

44.8

%

Secured leverage

 

< 30%

 

 

8.5

%

 

8.6

%

Unencumbered leverage

 

< 60%

 

 

43.3

%

 

41.4

%

Fixed charge coverage

 

> 1.50x

 

4.8x

 

4.7x

 

 

As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2021 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

$

5,381

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

5,449

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,474

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,538

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

12,984

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

2,789

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

8,656

 

 

 

3.95

%

 

January, 2030

Rosenberg Children's Medical Plaza fixed rate mortgage loan

 

 

12,450

 

 

 

4.42

%

 

September, 2033

Total, excluding net debt premium and net financing fees

 

 

58,721

 

 

 

 

 

 

 

     Less net financing fees

 

 

(447

)

 

 

 

 

 

 

     Plus net debt premium

 

 

129

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

58,403

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages outstanding as of March 31, 2021 had a combined fair value of approximately $61.6 million.  At December 31, 2020, we had various mortgages, all of which were non-recourse to us, included in our condensed consolidated balance sheet. The combined outstanding balance of these various mortgages at December 31, 2020 was $59.2 million and had a combined fair value of approximately $62.0 million.

Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

30


 

 

Off Balance Sheet Arrangements

As of March 31, 2021, we are party to certain off balance sheet arrangements consisting of standby letters of credit and equity and debt financing commitments.  Our outstanding letters of credit at March 31, 2021 totaled $5.6 million related to Grayson Properties II.  As of December 31, 2020 we had off balance sheet arrangements consisting of standby letters of credit and equity and debt financing commitments.  Our outstanding letters of credit at December 31, 2020 totaled $5.6 million related to Grayson Properties II.

Acquisition and Divestiture Activity

There were no acquisitions or divestitures during the three-month periods ended March 31, 2021 or 2020.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Reference is made to Item 7A in our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes in the quantitative and qualitative disclosures during the first three months of 2021, except for the additional disclosure below.  

Financial Instruments

In March 2020, we entered into an interest rate swap agreement on a total notional amount of $55 million with a fixed interest rate of 0.565% that we designated as a cash flow hedge.  The interest rate swap became effective on March 25, 2020 and is scheduled to mature on March 25, 2027. If the one-month LIBOR is above 0.565%, the counterparty pays us, and if the one-month LIBOR is less than 0.565%, we pay the counterparty, the difference between the fixed rate of 0.565% and one-month LIBOR.

In January 2020, we entered into an interest rate swap agreement on a total notional amount of $35 million with a fixed interest rate of 1.4975% that we designated as a cash flow hedge.  The interest rate swap became effective on January 15, 2020 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.4975%, the counterparty pays us, and if the one-month LIBOR is less than 1.4975%, we pay the counterparty, the difference between the fixed rate of 1.4975% and one-month LIBOR.  

During the third quarter of 2019, we entered into an interest rate swap agreement on a total notional amount of $50 million with a fixed interest rate of 1.144% that we designated as a cash flow hedge. The interest rate swap became effective on September 16, 2019 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.144%, the counterparty pays us, and if the one-month LIBOR is less than 1.144%, we pay the counterparty, the difference between the fixed rate of 1.144% and one-month LIBOR.

We measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from third parties.  We consider those inputs to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. At March 31, 2021, the fair value of our interest rate swaps was a net liability of $467,000 which is included in accrued expenses and other liabilities on the accompanying condensed consolidated balance sheet. During the first quarter of 2021, we paid or accrued approximately $305,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps.  From inception of the swap agreements through March 31, 2021 we paid or accrued approximately $931,000 in net payments made to the counterparty by us pursuant to the terms of the swap (consisting of approximately $199,000 in payments or accruals made to us by the counterparty, offset by approximately $1.1 million of payments due to the counterparty from us).  Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or a liability, with a corresponding amount recorded in accumulated other comprehensive income (“AOCI”) within shareholders’ equity.  Amounts are classified from AOCI to the income statement in the period or periods the hedged transaction affects earnings.

The sensitivity analysis related to our fixed and variable rate debt assumes current market rates with all other variables held constant. As of March 31, 2021, the fair value and carrying-value of our debt is approximately $309.2 million and $306.4 million, respectively. As of that date, the fair value exceeds the carrying-value by approximately $2.8 million.

31


 

The table below presents information about our financial instruments that are sensitive to changes in interest rates. The interest rate swaps include the $50 million swap agreement entered into during the third quarter of 2019, the $35 million swap agreement entered into in January, 2020 and the $55 million swap agreement entered into in March, 2020. For debt obligations, the amounts of which are as of March 31, 2021, the table presents principal cash flows and related weighted average interest rates by contractual maturity dates.

 

 

 

Maturity Date, Year Ending December 31

 

(Dollars in thousands)

 

2021

 

 

2022

 

 

2023

 

 

2024

 

 

2025

 

 

Thereafter

 

 

Total

 

Long-term debt:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fixed rate:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Debt(a)

 

$

1,571

 

 

$

12,197

 

 

$

11,892

 

 

$

13,550

 

 

$

939

 

 

$

18,572

 

 

$

58,721

 

Average interest rates

 

 

4.3

%

 

 

4.4

%

 

 

4.4

%

 

 

4.4

%

 

 

4.3

%

 

 

4.3

%

 

 

4.3

%

Variable rate:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Debt(b)

 

$

 

 

$

247,650

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

247,650

 

Average interest rates

 

 

 

 

1.3

%

 

 

 

 

 

 

 

 

 

 

1.3

%

Interest rate swaps:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Notional amount(c)

 

$

 

 

$

 

 

$

 

 

$

85,000

 

 

$

 

 

$

55,000

 

 

$

140,000

 

Interest rates

 

 

 

 

 

 

 

 

1.320

%

 

 

 

 

0.565

%

 

 

1.070

%

 

(a)

Consists of non-recourse mortgage notes payable.

 

(b)

Includes $247.7 million of outstanding borrowings under the terms of our $350 million revolving credit agreement.

 

(c)

Includes a $50 million interest rate swap that became effective on September 16, 2019, and a $35 million interest rate swap that became effective on January 15, 2020, both of which are scheduled to mature during 2024. Additionally included is a $55 million interest rate swap that became effective on March 25, 2020, which is scheduled to mature in 2027.

As calculated based upon our variable rate debt outstanding as of March 31, 2021 that is subject to interest rate fluctuations, and giving effect to the above-mentioned interest rate swap, each 1% change in interest rates would impact our net income by approximately $1.1 million.

Item 4. Controls and Procedures

As of March 31, 2021, under the supervision and with the participation of our management, including the Trust’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), we performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “1934 Act”).

Based on this evaluation, the CEO and CFO have concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the 1934 Act and the SEC rules thereunder.

There have been no changes in our internal control over financial reporting or in other factors during the first three months of 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

32


 

 

PART II. OTHER INFORMATION

UNIVERSAL HEALTH REALTY INCOME TRUST

Item 1A. Risk Factors

Our Annual Report on Form 10-K for the year ended December 31, 2020 includes a listing of risk factors to be considered by investors in our securities.  There have been no material changes in our risk factors from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2020.

Item 6. Exhibits

 

(a.)

Exhibits:

 

 

 

 

 

 

  31.1

 

Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  31.2

 

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  32.1

 

Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

  32.2

 

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data file because iXBRL tags are embedded within the Inline XBRL document

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

   104

 

Cover Page Interactive Data file (formatted as Inline XBRL and contained in Exhibit 101)

 

 

33


 

 

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date:  May 7, 2021

 

UNIVERSAL HEALTH REALTY INCOME TRUST

(Registrant)

 

 

 

 

 

/s/ Alan B. Miller 

 

 

Alan B. Miller,

 

 

Chairman of the Board,

President and Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 

/s/ Charles F. Boyle 

 

 

Charles F. Boyle, Vice President and Chief Financial Officer

(Principal Financial Officer)

 

34

EX-31.1 2 uht-ex311_8.htm EX-31.1 uht-ex311_8.htm

 

Exhibit 31.1

CERTIFICATION—Chief Executive Officer

I, Alan B. Miller, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 7, 2021

 

/s/ Alan B. Miller 

President and Chief Executive Officer

 

 

EX-31.2 3 uht-ex312_6.htm EX-31.2 uht-ex312_6.htm

 

Exhibit 31.2

CERTIFICATION—Chief Financial Officer

I, Charles F. Boyle, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 7, 2021

 

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

 

 

EX-32.1 4 uht-ex321_9.htm EX-32.1 uht-ex321_9.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan B. Miller, President and Chief Executive Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

 

/s/ Alan B. Miller

President and Chief Executive Officer

May 7, 2021

 

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-32.2 5 uht-ex322_7.htm EX-32.2 uht-ex322_7.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles F. Boyle, Vice President and Chief Financial Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

 

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

May 7, 2021

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-101.SCH 6 uht-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Statements of Income link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Statements of Income (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Changes in Equity link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Changes in Equity (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - General link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Dividends and Equity Issuance Program link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Acquisitions and Dispositions link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Summarized Financial Information of Equity Affiliates link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Lease Accounting link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Debt and Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Recent Accounting Pronouncements (Policies) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Lease Accounting (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Debt and Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - General - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Acquisitions and Dispositions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Lease Accounting - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Segment Reporting - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 uht-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 uht-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 uht-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Lease and other receivables. Lease receivable, other. Equity method investment summarized financial information assets property plant and equipment net. Equity method investment summarized financial information other assets. Equity Method Investment Summarized Financial Information Other Liabilities Equity Method Investment Summarized Financial Information Mortgage Notes Payable Equity method investment summarized financial information advance payment to loans to related party. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Current Reporting Status Entity Current Reporting Status Entity Shell Company Entity Shell Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Income Statement [Abstract] Statement [Table] Statement [Table] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Related-party principal tenant. UHS Facilities Universal Health Services Inc [Member] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Other Product And Service Other [Member] Management Service Management Service [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Non related party. Non-Related Parties Non Related Party [Member] Statement [Line Items] Statement [Line Items] Revenues: Revenues [Abstract] Lease revenue Operating Lease Lease Income Other revenue Revenue From Contract With Customer Including Assessed Tax Revenues, Total Revenues Expenses: Costs And Expenses [Abstract] Depreciation and amortization Depreciation And Amortization Advisory fees to UHS Cost Of Goods And Services Sold Other operating expenses Other Cost And Expense Operating Costs and Expenses, Total Costs And Expenses Income before equity in income of unconsolidated limited liability companies ("LLCs"), interest expense and gains on sales Operating Income Loss Equity in income of unconsolidated LLCs Income Loss From Equity Method Investments Interest expense, net Interest Income Expense Net Net income Net Income Loss Basic earnings per share Earnings Per Share Basic Diluted earnings per share Earnings Per Share Diluted Weighted average number of shares outstanding - Basic Weighted Average Number Of Shares Outstanding Basic Weighted average number of shares outstanding - Diluted Weighted Average Number Of Diluted Shares Outstanding Bonus rental income. Universal health services hospital Inc. UHS Hospital Facilities Universal Health Services Hospital Inc [Member] Bonus rental Bonus Rental Income Statement Of Income And Comprehensive Income [Abstract] Net income Other comprehensive gain/(loss): Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract] Unrealized derivative gains/(losses) on cash flow hedges Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Total other comprehensive gain/(loss): Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Total comprehensive income/(loss) Comprehensive Income Net Of Tax Amount at the balance sheet date that has been received by the entity that represents collections of cash or other assets related to real estate operations revenue for which revenue has not yet been recognized and money paid in advance to protect the provider of a product or services, such as a lessor, against damage or non-payment by the tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property and other contractual breaches. Statement Of Financial Position [Abstract] Assets: Assets [Abstract] Real Estate Investments: Real Estate Investments [Abstract] Buildings and improvements and construction in progress Real Estate Investment Property At Cost Accumulated depreciation Real Estate Investment Property Accumulated Depreciation Real Estate Investment Property, Net, Total Real Estate Investment Property Net Land Land Net Real Estate Investments Real Estate Investments Investments in limited liability companies ("LLCs") Investments In And Advances To Affiliates At Fair Value Other Assets: Other Assets [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Lease and other receivables from UHS Lease And Other Receivables Lease receivable - other Lease Receivable Other Intangible assets (net of accumulated amortization of $19.0 million and $19.5 million, respectively) Intangible Assets Net Excluding Goodwill Right-of-use land assets, net Operating Lease Right Of Use Asset Deferred charges and other assets, net Deferred Costs And Other Assets Total Assets Assets Liabilities: Liabilities [Abstract] Line of credit borrowings Line Of Credit Mortgage notes payable, non-recourse to us, net Secured Debt Accrued interest Interest Payable Current And Noncurrent Accrued expenses and other liabilities Accrued Liabilities And Other Liabilities Ground lease liabilities, net Operating Lease Liability Tenant reserves, deposits and deferred and prepaid rents Tenant Reserves Deposits And Deferred And Prepaid Rents Total Liabilities Liabilities Equity: Stockholders Equity [Abstract] Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding Preferred Stock Value Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2021 - 13,772,095; 2020 - 13,771,287 Common Stock Value Capital in excess of par value Additional Paid In Capital Common Stock Cumulative net income Retained Earnings Accumulated Deficit Cumulative dividends Cumulative Dividends Accumulated other comprehensive (loss)/income Accumulated Other Comprehensive Income Loss Net Of Tax Total Equity Stockholders Equity Total Liabilities and Equity Liabilities And Stockholders Equity Intangible assets, accumulated amortization Finite Lived Intangible Assets Accumulated Amortization Preferred shares of beneficial interest, par value Preferred Stock Par Or Stated Value Per Share Preferred shares of beneficial interest, shares authorized Preferred Stock Shares Authorized Preferred shares of beneficial interest, issued Preferred Stock Shares Issued Preferred shares of beneficial interest, outstanding Preferred Stock Shares Outstanding Common shares, par value Common Stock Par Or Stated Value Per Share Common shares, shares authorized Common Stock Shares Authorized Common shares, issued Common Stock Shares Issued Common shares, outstanding Common Stock Shares Outstanding Shares of beneficial interest. Statement Of Stockholders Equity [Abstract] Common stock Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common stock Common Stock [Member] Common stock Additional Paid In Capital [Member] Cumulative net income Retained Earnings [Member] Cumulative dividends. Common stock Cumulative Dividends [Member] Accumulated other comprehensive income/(loss) Accumulated Other Comprehensive Income [Member] January 1, 2021 Stockholders Equity Including Portion Attributable To Noncontrolling Interest Balance, Shares Shares Outstanding Shares of Beneficial Interest: Shares Of Beneficial Interest [Abstract] Issued Stock Issued During Period Value New Issues Issued (in shares) Stock Issued During Period Shares New Issues Restricted stock-based compensation expense Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition Dividends Dividends Comprehensive income: Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest [Abstract] Net income Unrealized net gain(loss) on cash flow hedges Subtotal - comprehensive income Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest Balance Balance, Shares Dividends, per share. Dividend, per share Dividends Per Share Increase (decrease) in tenant reserves, deposits, deferred and prepaid rents. Increase decrease in leasing costs. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net income Profit Loss Adjustments to reconcile net income to net cash provided by operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Amortization related to above/below market leases, net Amortization Of Above And Below Market Leases Amortization of debt premium Amortization Of Debt Discount Premium Amortization of deferred financing costs Amortization Of Financing Costs Stock-based compensation expense Share Based Compensation Changes in assets and liabilities: Increase Decrease In Operating Capital [Abstract] Lease receivable Increase Decrease In Leasing Receivables Accrued expenses and other liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Tenant reserves, deposits and deferred and prepaid rents Increase Decrease In Tenant Reserves Deposits Deferred And Prepaid Rents Accrued interest Increase Decrease In Accrued Interest Receivable Net Leasing costs paid Increase Decrease In Leasing Costs Other, net Increase Decrease In Other Operating Capital Net Net cash provided by operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Investments in LLCs Payments To Acquire Investments Advance made to LLC Payments To Fund Longterm Loans To Related Parties Additions to real estate investments, net Real Estate Period Increase Decrease Deposit on real estate assets Payments For Deposits On Real Estate Acquisitions Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Net borrowings on line of credit Proceeds From Lines Of Credit Repayments of mortgage notes payable Repayments Of Secured Debt Financing costs paid Payments Of Financing Costs Dividends paid Payments Of Dividends Issuance of shares of beneficial interest, net Proceeds From Issuance Or Sale Of Equity Net cash provided by/(used in) financing activities Net Cash Provided By Used In Financing Activities Increase/(decrease) in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash and cash equivalents, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash and cash equivalents, end of period Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid Net Invoices accrued for construction and improvements Construction In Progress Expenditures Incurred But Not Yet Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] General Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Related Party Transactions [Abstract] Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Related Party Transactions Disclosure [Text Block] Equity [Abstract] Dividends and Equity Issuance Program Stockholders Equity Note Disclosure [Text Block] Business Combinations [Abstract] Acquisitions and Dispositions Mergers Acquisitions And Dispositions Disclosures [Text Block] Equity Method Investments And Joint Ventures [Abstract] Summarized Financial Information of Equity Affiliates Equity Method Investments Disclosure [Text Block] Accounting Policies [Abstract] Recent Accounting Pronouncements New Accounting Pronouncements And Changes In Accounting Principles [Text Block] Disclosures of leases. Leases [Abstract] Lease Accounting Disclosures Of Leases [Text Block] Debt and financial instruments disclosure. Debt Disclosure [Abstract] Debt and Financial Instruments Debt And Financial Instruments Disclosure [Text Block] Segment Reporting [Abstract] Segment Reporting Segment Reporting Disclosure [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities Schedule Of Property Subject To Or Available For Operating Lease [Text Block] Limited Liability Companies Accounted for Under Equity Method Equity Method Investments [Text Block] Equity Method Investments Summarized Income Statement Information. Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method Equity Method Investments Summarized Income Statement Information Table [Text Block] Equity Method Investments Summarized Combined Balance Sheet Information. Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method Equity Method Investments Summarized Combined Balance Sheet Information Table [Text Block] Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block] Components of lessor lease revenue with UHS facilities and non-related parties. Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions Components Of Lessor Lease Revenue With U H S Facilities And Non Related Parties Table [Text Block] Schedule of Financial Covenants. Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement Schedule Of Financial Covenants Table [Text Block] Outstanding Mortgages, Excluding Net Debt Premium Schedule Of Debt Instruments [Text Block] Number of real estate properties including property under construction. Organization consolidation and presentation of financial statements. Organization consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Limited liability company or limited partner. Limited Liability Companies Limited Liability Company Or Limited Partner [Member] Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Investment, Name Equity Method Investee Name [Domain] Unconsolidated limited liabilities or limited partner. 4 Unconsolidated Limited Liability Companies / Limited Partner Unconsolidated Limited Liabilities Or Limited Partner [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Non-controlling equity interest, ownership percentage Equity Method Investment Ownership Percentage Number of real estate investments Number Of Real Estate Properties Including Property Under Construction Initial lease expiration period. Renewal option terms additional period. Number of renewal options. Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Universal Health Services, Inc Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Hospital Facilities Leased Assets Leased To Others [Member] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Revenue. Revenues Revenue [Member] Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Tenants. Tenants Tenants [Member] Lease Contractual Term Lease Contractual Term [Axis] Lease Contractual Term Lease Contractual Term [Domain] Base rents. Base Rents Base Rents [Member] Bonus rents. Bonus Rents Bonus Rents [Member] Major Property Class Major Property Class [Axis] Major Property Class Major Property Class [Domain] UHS-related hospital facility. Southwest Healthcare System, Inland Valley Campus Southwest Healthcare System Inland Valley Campus [Member] Ownership Ownership [Axis] Ownership Ownership [Domain] Grayson properties two LP. Grayson Properties Two L P Grayson Properties Two L P [Member] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] Denison, Texas. Denison Texas Denison Texas [Member] Universal Health Services, Inc and Catholic Health Initiatives. Universal Health Services Inc And Catholic Health Initiatives Universal Health Services Inc And Catholic Health Initiatives [Member] Wholly-owned subsidiary of Universal Health Services, Inc.; Advisor to UHT Universal Health Services of Delaware Inc Universal Health Services Of Delaware Inc [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Initial lease terms Initial Lease Expiration Period Number of term renewal options Number Of Renewal Options Additional renewal terms Renewal Option Terms Additional Period Number of hospital facilities leased Number Of Real Estate Properties Number of leased properties for medical office buildings and free standing emergency departments. Percentage of revenues generated from leases and tenants Concentration Risk Percentage1 Number of medical office buildings and free standing emergency departments Number Of Leased Properties For Medical Office Buildings And Free Standing Emergency Departments Lease renewal, notice period. Period to purchase respective leased facilities after lease terms. Renewal option terms maximum additional period. Option to renew lease, notice period prior to termination date of current term Lease Renewal Notice Period Period to purchase respective leased facilities at same price after lease terms Period To Purchase Respective Leased Facilities After Lease Terms Renewal period of respective leased facilities at same price after lease terms Renewal Option Terms Maximum Additional Period Operating leases, number of renewal options at existing lease rates. Number of renewal options at existing lease rate Operating Leases Number Of Renewal Options At Existing Lease Rates Operating leases, annual future minimum payments receivable. Schedule Of Operating Leased Assets [Table] Schedule Of Operating Leased Assets [Table] UHS-related hospital facility. McAllen Medical Center Mc Allen Medical Center [Member] UHS-related hospital facility. Wellington Regional Medical Center Wellington Regional Medical Center [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Annual Minimum Rent Operating Leases Annual Future Minimum Payments Receivable Lease expiration, month and year. End of Lease Term Lease Expiration Month And Year Renewal Term (years) Lessor Operating Lease Renewal Term Operating leases, renewal options term at existing lease rate. Operating leases, renewal options at existing lease rate, expiration year. Operating leases, number of renewal options at fair market value lease rates. Operating leases, renewal options term at fair market value lease rates. Operating leases, renewal options at fair market value lease rates, expiration year. UHS-related hospital facility. Wellington Regional Medical Center And Southwest Healthcare System Wellington Regional Medical Center And Southwest Healthcare System [Member] Number of renewal option at existing lease rate Renewal option term at existing lease rate Operating Leases Renewal Options Term At Existing Lease Rate Renewal option at existing lease rate expiration year Operating Leases Renewal Options At Existing Lease Rate Expiration Year Number of renewal options at fair market value lease rates Operating Leases Number Of Renewal Options At Fair Market Value Lease Rates Renewal options term at fair market value lease rates Operating Leases Renewal Options Term At Fair Market Value Lease Rates Renewal options at fair market value lease rates expiration year Operating Leases Renewal Options At Fair Market Value Lease Rates Expiration Year Lease expiration date Lease Expiration Date1 Master flex lease term. Percentage of rentable square feet. Master flex lease term Master Flex Lease Term Percentage of rentable square feet Percentage Of Rentable Square Feet Triple net lease agreement period. Renewal options term. Change in control of trust notice period, description. Triple net lease agreement period Triple Net Lease Agreement Period Renewal option term Renewal Options Term Project manager's aggregate fee Property Management Fee Revenue Change in control of trust notice, description Change In Control Of Trust Notice Period Description Number of ground leases. Operating lease remaining lease term. Lessee operating lease liability payments due after year four. Number of ground leases Number Of Ground Leases Remaining lease terms on ground leases Operating Lease Remaining Lease Term Aggregate lease payments for 2021 Lessee Operating Lease Liability Payments Remainder Of Fiscal Year Aggregate lease payments for 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months Aggregate lease payments for 2023 Lessee Operating Lease Liability Payments Due Year Two Aggregate lease payments for 2024 Lessee Operating Lease Liability Payments Due Year Three Aggregate lease payments for 2025 Lessee Operating Lease Liability Payments Due Year Four Aggregate lease payments for thereafter Lessee Operating Lease Liability Payments Due After Year Four Annual advisory fees as percentage of average invested real estate assets. Average invested real estate assets. Annual advisory fee as percentage of average invested real estate assets Annual Advisory Fees As Percentage Of Average Invested Real Estate Assets Advisory fee Cost, Product and Service [Extensible List] Type Of Cost Good Or Service Extensible List Average invested real estate assets Average Invested Real Estate Assets Percentage of ownership interest related parties. Percentage ownership of outstanding shares Percentage Of Ownership Interest Related Parties Dividends and equity issuance. Dividends and equity issuance. Dividends And Equity Issuance [Table] Dividends And Equity Issuance [Table] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Shelf registration. At-The-Market Equity Issuance Program (ATM) At Market A T M Programs [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Other Expenses Other Expense [Member] Dividends and Equity Issuance [Line Items] Dividends And Equity Issuance [Line Items] Dividends declared and paid Declared and paid dividends, per share Common Stock Dividends Per Share Cash Paid Aggregate sales of threshold amount. Aggregate sales of threshold amount Aggregate Sales Of Threshold Amount Shares issued average price per share. Payments for stock issuance other fees and expenses. Average sale price per share Shares Issued Average Price Per Share Net cash proceeds from stock issued Proceeds From Issuance Of Common Stock Payment of stock issuance cost Payment Of Financing And Stock Issuance Costs Payments for stock issuance Payments For Stock Issuance Other Fees And Expenses Number of acquisitions Number Of Businesses Acquired Number of businesses disposed. Number of dispositions Number Of Businesses Disposed Schedule Of Equity Method Investments [Table] Schedule Of Equity Method Investments [Table] Real Estate Property Ownership Real Estate Properties [Axis] Real Estate Properties Real Estate Properties [Domain] Medical office buildings. Medical office buildings Medical Office Buildings [Member] Schedule Of Equity Method Investments [Line Items] Schedule Of Equity Method Investments [Line Items] Number of real estate investments Property owned by limited liability or limited partner company. Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Equity Method Investments Equity Method Investments [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest Suburban Properties Suburban Properties [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest Brunswick Associates Brunswick Associates [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest Grayson Properties Grayson Properties [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest FTX MOB Phase II limited partnership F T X Mob Phase Two L P [Member] Grayson Properties II LP Ownership Property Owned by LLC/LP Property Owned By Limited Liability Or Limited Partner Company Commitments to invest. Funded investment commitments. Member loan used to repay mortgage loan. Repayment of loan. Construction loan outstanding balance. Third-party term loan Long Term Loans Payable Commitment to investment Investment Commitments Committed investment in equity and debt financing, funded Funded Investment Commitments Member loan used to repay mortgage loan Member Loan Used To Repay Mortgage Loan Repayment of loan Repayment Of Loan Construction loan Construction Loan Construction loan outstanding balance Construction Loan Outstanding Balance Equity method investment, summarized financial information, operating expenses. Equity method investment summarized financial information depreciation and amortization. Equity method investment summarized financial information interest expense. Equity Method Investment, Nonconsolidated Investee Equity Method Investment Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee Equity Method Investment Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee or Group of Investees Equity Method Investment Nonconsolidated Investee Or Group Of Investees [Member] Revenues Operating expenses Equity Method Investment Summarized Financial Information Operating Expenses Depreciation and amortization Equity Method Investment Summarized Financial Information Depreciation And Amortization Interest, net Equity Method Investment Summarized Financial Information Interest Expense Net income Our share of net income Equity method investments accrued expenses and other liabilities. Net property, including construction in progress Equity Method Investment Summarized Financial Information Assets Property Plant And Equipment Net Other assets Equity Method Investment Summarized Financial Information Other Assets Other liabilities Equity Method Investment Summarized Financial Information Other Liabilities Mortgage notes payable, non-recourse to us Equity Method Investment Summarized Financial Information Mortgage Notes Payable Advances payable to us Equity Method Investment Summarized Financial Information Advance Payment To Loans To Related Party Equity Investments in LLCs before amounts included in accrued expenses and other liabilities Amounts included in accrued expenses and other liabilities Equity Method Investments Accrued Expenses And Other Liabilities Our share of equity in LLCs, net Equity Method Investments Debt instrument, maturity, month and year. Right-of-use land assets Right-of-use land liabilities Debt Instrument Maturity Date Debt Instrument Maturity Month And Year Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest FTX MOB Phase II F T X Mob Phase Two [Member] Mortgage Loan Balance Number of trading period. Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member Number Of Trading Period Leases Disclosure [Line Items] Leases Disclosure [Table] Leases Disclosure [Table] Leases Disclosure [Table] Tenant reimbursements. Tenant Reimbursements Tenant Reimbursements [Member] Leases Disclosure [Line Items] Leases Disclosure [Line Items] Kindred Chicago Central Hospital Central Chicago, Illinois. Kindred Chicago Central Hospital Central Chicago, Illinois Kindred Chicago Central Hospital Central Chicago Illinois [Member] Evansville Rehabilitation Hospital Evansville, Indiana. Evansville Rehabilitation Hospital Evansville, Indiana Evansville Rehabilitation Hospital Evansville Indiana [Member] Corpus Christi Corpus Christi, Texas. Corpus Christi Corpus Christi Texas Corpus Christi Corpus Christi Texas [Member] Number of bed in specialty hospital. Number of beds in specialty hospital Number Of Bed In Specialty Hospital Number of ground leases for land. Lessee in connection with ground leases for land Number Of Ground Leases For Land Ground lease liabilities Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Debt Instrument [Table] Debt Instrument [Table] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Credit Agreement Revolving Credit Facility [Member] Revolving credit agreement. Credit Agreement Revolving Credit Agreement [Member] Revolving B facility. Revolving B Facility Revolving B Facility [Member] Short-term Debt, Type Short Term Debt Type [Axis] Short-term Debt, Type Short Term Debt Type [Domain] Letters of Credit Letter Of Credit [Member] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Swingline/Short-Term Loans Short Term Debt [Member] Revolving A facility. Revolving A Facility Revolving A Facility [Member] Variable Rate Variable Rate [Axis] Variable Rate Variable Rate [Domain] LIBOR London Interbank Offered Rate L I B O R [Member] Base Rate Base Rate [Member] Federal funds effective rate. Federal Funds Effective Rate Federal Funds Effective Rate [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 2 Fair Value Inputs Level2 [Member] Derivative Instrument Derivative Instrument Risk [Axis] Derivative Contract Derivative Contract Type [Domain] Interest Rate Swap Interest Rate Swap [Member] Hedging Relationship Derivative Instruments Gain Loss By Hedging Relationship [Axis] Hedging Relationship Hedging Relationship [Domain] Cash Flow Hedge Cash Flow Hedging [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Outstanding borrowing Line Of Credit Facility Maximum Borrowing Capacity Line of credit facility expiration year and month. Line of credit increase in borrowing capacity. Unsecured revolving amended credit agreement terminated date Line Of Credit Facility Expiration Year And Month Proceeds from lines of credit Increase in borrowing capacity Line Of Credit Increase In Borrowing Capacity Margin on base rate. Credit facility, Interest Rate Terms Debt Instrument Interest Rate Terms Margin points added to the reference rate Debt Instrument Basis Spread On Variable Rate1 Margin points added to the base rate Margin On Base Rate Base rate description Debt Instrument Description Of Variable Rate Basis Facility fee payable on commitment Line Of Credit Facility Commitment Fee Percentage Number of extension options. Number of additional six month extension options Number Of Extension Options Outstanding borrowings under revolving credit agreement Letters of credit outstanding Letters Of Credit Outstanding Amount Available borrowing capacity Line Of Credit Facility Remaining Borrowing Capacity Compensating balance Compensating Balance Amount Debt instrument covenant unencumbered leverage ratio. Debt instrument covenant fixed charge coverage ratio. Debt instrument covenant tangible net worth. Debt instrument covenant leverage ratio. Debt instrument covenant compliance secured leverage ratio. Covenant, Tangible net worth Debt Instrument Covenant Tangible Net Worth Covenant, Total leverage Debt Instrument Covenant Leverage Ratio Covenant, Secured leverage Debt Instrument Covenant Compliance Secured Leverage Ratio Covenant, Unencumbered leverage Debt Instrument Covenant Unencumbered Leverage Ratio Covenant, Fixed charge coverage Debt Instrument Covenant Fixed Charge Coverage Ratio Tangible net worth. Leverage ratio. Secured leverage ratio. Unencumbered leverage ratio. Fixed charge coverage ratio. Tangible net worth Tangible Net Worth Total leverage Leverage Ratio Secured leverage Secured Leverage Ratio Unencumbered leverage Unencumbered Leverage Ratio Fixed charge coverage Fixed Charge Coverage Ratio SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type Mortgage Loans On Real Estate Loan Type [Axis] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type Mortgage Loans On Real Estate Loan Type [Domain] Seven hundred shadow lane and goldring medical office building fixed rate mortgage loan. 700 Shadow Lane and Goldring MOBs Fixed Rate Mortgage Loan Seven Hundred Shadow Lane And Goldring Medical Office Building Fixed Rate Mortgage Loan [Member] BRB medical office building fixed rate mortgage loan. BRB Medical Office Building Fixed Rate Mortgage Loan B R B Medical Office Building Fixed Rate Mortgage Loan [Member] Desert valley medical center fixed rate mortgage loan. Desert Valley Medical Center Fixed Rate Mortgage Loan Desert Valley Medical Center Fixed Rate Mortgage Loan [Member] Two seven zero four north Tenaya way fixed rate mortgage loan. 2704 North Tenaya Way Fixed Rate Mortgage Loan Two Seven Zero Four North Tenaya Way Fixed Rate Mortgage Loan [Member] Summerlin hospital medical office building three fixed rate mortgage loan. Summerlin Hospital Medical Office Building III Fixed Rate Mortgage Loan Summerlin Hospital Medical Office Building Three Fixed Rate Mortgage Loan [Member] Debt Instrument 100% consolidated Tuscan Professional Building Fixed Rate Mortgage Loan Tuscany Professional Building Fixed Rate Mortgage Loan [Member] Phoenix children's east valley care center fixed rate mortgage loan. Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan [Member] Rosenberg children's medical plaza fixed rate mortgage loan. Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan Rosenberg Children Medical Plaza Fixed Rate Mortgage Loan [Member] Outstanding Balance Non Recourse Debt Debt Instrument Interest Rate Stated Percentage Debt Instrument Interest Rate Stated Percentage Financing fees net. Less net financing fees Financing Fees Net Plus net debt premium Debt Instrument Unamortized Premium Total mortgages notes payable, non-recourse to us, net Mortgage debt. Mortgage loan fair value Long Term Debt Fair Value Mortgage debt Mortgage Debt Number of interest rate cap agreements Derivative Number Of Instruments Held Derivative instruments, fixed rate Derivative Fixed Interest Rate Notional amount Derivative Notional Amount Expiration date of interest rate Derivative Maturity Dates Derivative interest rate cap, net payment received or accrued from counter parties. Derivative interest rate cap payment received or accrued from counter parties. Derivative interest rate cap payment offset due to counter parties. Liability derivatives, fair value Derivative Fair Value Of Derivative Liability Derivative interest rate cap, net payment received or accrued from counterparties Derivative Interest Rate Cap Net Payment Received Or Accrued From Counter Parties Derivative interest rate cap, payment received or accrued from counterparties Derivative Interest Rate Cap Payment Received Or Accrued From Counter Parties Derivative interest rate cap, offset due to counterparties Derivative Interest Rate Cap Payment Offset Due To Counter Parties Number of reportable segments Number Of Reportable Segments EX-101.PRE 10 uht-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 uht-10q_20210331_htm.xml IDEA: XBRL DOCUMENT 0000798783 2021-01-01 2021-03-31 0000798783 2021-04-30 0000798783 uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember 2020-01-01 2020-03-31 0000798783 uht:NonRelatedPartyMember 2021-01-01 2021-03-31 0000798783 uht:NonRelatedPartyMember 2020-01-01 2020-03-31 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-03-31 0000798783 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-03-31 0000798783 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-03-31 0000798783 2020-01-01 2020-03-31 0000798783 us-gaap:ManagementServiceMember 2021-01-01 2021-03-31 0000798783 us-gaap:ManagementServiceMember 2020-01-01 2020-03-31 0000798783 uht:UniversalHealthServicesHospitalIncMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesHospitalIncMember 2020-01-01 2020-03-31 0000798783 2021-03-31 0000798783 2020-12-31 0000798783 us-gaap:CommonStockMember 2020-12-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000798783 us-gaap:RetainedEarningsMember 2020-12-31 0000798783 uht:CumulativeDividendsMember 2020-12-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000798783 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000798783 uht:CumulativeDividendsMember 2021-01-01 2021-03-31 0000798783 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000798783 us-gaap:CommonStockMember 2021-03-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000798783 us-gaap:RetainedEarningsMember 2021-03-31 0000798783 uht:CumulativeDividendsMember 2021-03-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000798783 us-gaap:CommonStockMember 2019-12-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000798783 us-gaap:RetainedEarningsMember 2019-12-31 0000798783 uht:CumulativeDividendsMember 2019-12-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000798783 2019-12-31 0000798783 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000798783 uht:CumulativeDividendsMember 2020-01-01 2020-03-31 0000798783 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000798783 us-gaap:CommonStockMember 2020-03-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000798783 us-gaap:RetainedEarningsMember 2020-03-31 0000798783 uht:CumulativeDividendsMember 2020-03-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000798783 2020-03-31 0000798783 srt:MinimumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2021-03-31 0000798783 srt:MaximumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2021-03-31 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2021-03-31 0000798783 srt:MinimumMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 srt:MaximumMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesIncMember 2021-03-31 0000798783 us-gaap:AssetsLeasedToOthersMember uht:UniversalHealthServicesIncMember 2021-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-03-31 0000798783 uht:TenantsMember uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:TenantsMember uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-03-31 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-03-31 0000798783 uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-03-31 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-03-31 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 srt:MinimumMember uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 srt:MaximumMember uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-12-31 0000798783 uht:BaseRentsMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:BaseRentsMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-12-31 0000798783 uht:BonusRentsMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:BonusRentsMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-12-31 0000798783 uht:GraysonPropertiesTwoLPMember uht:DenisonTexasMember 2019-09-30 0000798783 uht:UniversalHealthServicesIncMember 2019-09-01 2019-09-30 0000798783 uht:UniversalHealthServicesIncAndCatholicHealthInitiativesMember 2019-07-01 2019-07-31 0000798783 uht:UniversalHealthServicesIncAndCatholicHealthInitiativesMember 2019-07-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2021-01-01 2021-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2020-01-01 2020-03-31 0000798783 uht:UniversalHealthServicesIncMember 2020-12-31 0000798783 uht:AtMarketATMProgramsMember 2020-06-30 0000798783 uht:AtMarketATMProgramsMember 2021-01-01 2021-03-31 0000798783 uht:AtMarketATMProgramsMember 2020-04-01 2020-06-30 0000798783 us-gaap:OtherExpenseMember uht:AtMarketATMProgramsMember 2021-01-01 2021-03-31 0000798783 uht:MedicalOfficeBuildingsMember uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2021-03-31 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 uht:BrunswickAssociatesMember 2021-03-31 0000798783 uht:GraysonPropertiesMember 2021-03-31 0000798783 srt:MaximumMember uht:FTXMobPhaseTwoLPMember 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember 2021-01-01 2021-03-31 0000798783 srt:MaximumMember uht:DenisonTexasMember uht:GraysonPropertiesTwoLPMember 2021-03-31 0000798783 uht:GraysonPropertiesTwoLPMember 2021-03-31 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-01-01 2021-03-31 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-03-31 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-03-31 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-12-31 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2020-12-31 0000798783 uht:FTXMobPhaseTwoLPMember 2021-01-01 2021-03-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2021-03-31 0000798783 uht:FTXMobPhaseTwoMember us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 uht:FTXMobPhaseTwoMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-03-31 0000798783 srt:MinimumMember 2021-01-01 2021-03-31 0000798783 srt:MaximumMember 2021-01-01 2021-03-31 0000798783 uht:BaseRentsMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:BaseRentsMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-03-31 0000798783 uht:BonusRentsMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:BonusRentsMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-03-31 0000798783 uht:TenantReimbursementsMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-03-31 0000798783 uht:TenantReimbursementsMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-03-31 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2021-01-01 2021-03-31 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2020-01-01 2020-03-31 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2021-01-01 2021-03-31 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2020-01-01 2020-03-31 0000798783 uht:KindredChicagoCentralHospitalCentralChicagoIllinoisMember 2021-01-01 2021-03-31 0000798783 uht:KindredChicagoCentralHospitalCentralChicagoIllinoisMember 2020-01-01 2020-12-31 0000798783 uht:EvansvilleRehabilitationHospitalEvansvilleIndianaMember 2021-01-01 2021-03-31 0000798783 uht:CorpusChristiCorpusChristiTexasMember 2021-01-01 2021-03-31 0000798783 us-gaap:RevolvingCreditFacilityMember 2021-03-31 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LetterOfCreditMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:ShortTermDebtMember 2018-03-27 0000798783 uht:RevolvingBFacilityMember 2020-01-01 2020-06-30 0000798783 uht:RevolvingBFacilityMember 2020-06-30 0000798783 uht:RevolvingAFacilityMember 2021-01-01 2021-03-31 0000798783 srt:MinimumMember uht:RevolvingAFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-27 0000798783 srt:MaximumMember uht:RevolvingAFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-27 0000798783 srt:MinimumMember uht:RevolvingAFacilityMember us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 srt:MaximumMember uht:RevolvingAFacilityMember us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 srt:MinimumMember uht:RevolvingAFacilityMember uht:FederalFundsEffectiveRateMember 2018-03-27 2018-03-27 0000798783 srt:MinimumMember uht:RevolvingAFacilityMember 2018-03-27 2018-03-27 0000798783 srt:MaximumMember uht:RevolvingAFacilityMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-03-31 0000798783 uht:RevolvingAFacilityMember us-gaap:BaseRateMember 2021-01-01 2021-03-31 0000798783 uht:RevolvingBFacilityMember 2021-01-01 2021-03-31 0000798783 srt:MinimumMember uht:RevolvingBFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-27 0000798783 srt:MaximumMember uht:RevolvingBFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-27 0000798783 srt:MinimumMember uht:RevolvingBFacilityMember us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 srt:MaximumMember uht:RevolvingBFacilityMember us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 srt:MinimumMember uht:RevolvingBFacilityMember uht:FederalFundsEffectiveRateMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 srt:MinimumMember uht:RevolvingBFacilityMember 2018-03-27 2018-03-27 0000798783 srt:MaximumMember uht:RevolvingBFacilityMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-03-31 0000798783 uht:RevolvingBFacilityMember us-gaap:BaseRateMember 2021-01-01 2021-03-31 0000798783 srt:MaximumMember 2021-03-31 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:BRBMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:DesertValleyMedicalCenterFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2021-03-31 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:BRBMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:DesertValleyMedicalCenterFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2021-01-01 2021-03-31 0000798783 us-gaap:FairValueInputsLevel2Member 2021-03-31 0000798783 us-gaap:FairValueInputsLevel2Member 2020-12-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-01 2020-03-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-01-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-09-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-07-01 2019-09-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0000798783 us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-03-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-03-31 shares iso4217:USD iso4217:USD shares pure uht:Property uht:Time uht:RenewalOption uht:Lease uht:Acquisition uht:Disposition uht:Bed uht:Land uht:Option uht:Derivative uht:Segment false Q1 0000798783 --12-31 3 1 2 us-gaap:ManagementServiceMember us-gaap:ManagementServiceMember 0.0050 0.0050 1 1 1 3 1 2 0.0050 0.0050 1 1 1 P5Y P10Y P10Y 2021-02 125000000 0.60 0.30 0.60 0.0150 10-Q true 2021-03-31 2021 false 1-9321 UNIVERSAL HEALTH REALTY INCOME TRUST MD 23-6858580 UNIVERSAL CORPORATE CENTER 367 SOUTH GULPH ROAD KING OF PRUSSIA PA 19406 610 265-0688 Shares of beneficial interest, $0.01 par value UHT NYSE Yes Yes Large Accelerated Filer false false false 13772112 7132000 5881000 13092000 12842000 226000 214000 249000 270000 20699000 19207000 6787000 6380000 1062000 1016000 5602000 5383000 13451000 12779000 7248000 6428000 471000 435000 -2133000 -2309000 5586000 4554000 0.41 0.33 0.41 0.33 13750 13736 13771 13758 1695000 1380000 5586000 4554000 3348000 -4671000 3348000 -4671000 8934000 -117000 608366000 605292000 222521000 216648000 385845000 388644000 55157000 55157000 441002000 443801000 9087000 4278000 6171000 5742000 3252000 3199000 7780000 7504000 19000000.0 19500000 11013000 11742000 8907000 8914000 8582000 8829000 495794000 494009000 247650000 236200000 58403000 58895000 346000 351000 11375000 19802000 8907000 8914000 10446000 10842000 337127000 335004000 0.01 0.01 5000000 5000000 0 0 0 0 0.01 0.01 95000000 95000000 13772095 13772095 13771287 13771287 138000 138000 267667000 267368000 686313000 680727000 794984000 785413000 -467000 -3815000 158667000 159005000 495794000 494009000 13771000 138000 267368000 680727000 -785413000 -3815000 159005000 1000 57000 57000 242000 242000 0.695 9571000 9571000 5586000 5586000 3348000 3348000 5586000 3348000 8934000 13772000 138000 267667000 686313000 -794984000 -467000 158667000 13757000 138000 266723000 661280000 -747417000 1010000 181734000 1000 50000 50000 197000 197000 0.685 9424000 9424000 4554000 4554000 -4671000 -4671000 4554000 -4671000 -117000 13758000 138000 266970000 665834000 -756841000 -3661000 172440000 5586000 4554000 6787000 6380000 -45000 -46000 -12000 -13000 216000 157000 242000 197000 329000 -181000 -633000 -867000 -396000 65000 5000 25000 365000 182000 -204000 264000 11250000 10137000 1544000 1468000 3500000 -6974000 -5521000 200000 -12218000 -6989000 11450000 6250000 510000 432000 35000 35000 9564000 9424000 56000 50000 1397000 -3591000 429000 -443000 5742000 6110000 6171000 5667000 1935000 2190000 468000 3151000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) General</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2021. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.  As of March 31, 2021, we had investments in five jointly-owned LLCs/LPs. We currently account for our share of the income/loss from these investments by the equity method (see Note 5). These LLCs are included in our consolidated financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.    </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2020.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. </p> 0.33 0.95 5 <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases:<span style="font-style:normal;"> We commenced operations in 1986 by purchasing properties from certain subsidiaries of UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and renewal terms for each of the three hospital facilities leased to wholly-owned subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with wholly-owned subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The combined revenues generated from the leases on the three acute care hospital facilities leased to wholly-owned subsidiaries of UHS accounted for approximately 22% of our consolidated revenues for each of the three months ended March 31, 2021 and 2020. In addition to these three UHS hospital facilities, one of our hospital facilities is leased to a joint venture between a subsidiary of UHS and a third party, and we have eighteen medical office buildings (“MOBs”) or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us that include tenants which are subsidiaries or joint ventures of UHS. The aggregate revenues generated from UHS-related tenants comprised approximately 36% and 32% of our consolidated revenues during the three-month periods ended March 31, 2021 and 2020, respectively. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of the three acute care hospitals with wholly-owned subsidiaries of UHS, as reflected below, UHS has the option, among other things, to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities from us at their appraised fair market value upon any of the following:  (i) at the end of the lease terms or any renewal terms; (ii) upon one month’s notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the lease in the event that UHS provides notice to us of their intent to offer a substitution property/properties in exchange for one (or more) of the three hospital facilities leased from us, should we be unable to reach an agreement with UHS on the properties to be substituted. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below details the existing lease terms and renewal options for our <span style="-sec-ix-hidden:F_000296">three</span> acute care hospitals operated by wholly-owned subsidiaries of UHS:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Hospital Name</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000303">5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000304">10</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000305">10</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has <span style="-sec-ix-hidden:F_000306_2">one</span> 5-year renewal option at the existing lease rate (through 2031).  </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has <span style="-sec-ix-hidden:F_000309_2">two</span> 5-year renewal options at fair market value lease rates (2022 through 2031).</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right </span><span style="color:#000000;">to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has proposed exchanging potential substitution properties, with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.</span><span style="color:#0070C0;">  </span><span style="Background-color:#FFFFFF;">The proposed substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of the Board have approved the proposed property substitution subject to satisfactory due diligence and completion of definitive agreements. The effective date of the property substitution is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on </span><span style="Background-color:#FFFFFF;">the Inland Valley Campus, we earned $1.1 million of lease revenue during the three-month period ended March 31, 2021 ($662,000 in base rental and $454,000 in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).</span><span style="color:#000000;">  </span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, we entered into an agreement whereby we own a 95% non-controlling ownership interest in Grayson Properties II L.P., which developed, constructed, owns and operates the Texoma Medical Plaza II, an MOB located in Denison, Texas.  This MOB, which was substantially completed in December 2020, is located on the campus of Texoma Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS.  A 10-year master flex lease was executed with the wholly-owned subsidiary of UHS for over 50% of the rentable square feet of the MOB and commenced in December 2020 upon the issuance of the certificate of occupancy. We account for this LP on an unconsolidated basis pursuant to the equity method since it is not a variable interest entity and we do not have a controlling voting interest.     </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late July 2019, Des Moines Medical Properties, LLC, a wholly-owned subsidiary of ours, entered into an agreement to build and lease a newly constructed UHS-related behavioral health care hospital located in Clive, Iowa.  The lease on this facility, which is triple net and has an initial term of 20 years with five 10-year renewal options, was executed with Clive Behavioral Health, LLC, a joint venture between a wholly-owned subsidiary of UHS and Catholic Health Initiatives - Iowa, Corp (“JV”). Construction of this hospital, for which we engaged a wholly-owned subsidiary of UHS to act as project manager for an aggregate fee of approximately $750,000, was substantially completed in December 2020 and the property received a temporary certificate of occupancy on December 31, 2020.  The hospital lease commenced upon the issuance of the temporary certificate of occupancy.  Pursuant to the lease on this facility, the JV has the option to, among other things, renew the lease at the terms specified in the lease agreement by providing notice to us at least 270 days prior to the termination of the then current term. The JV also has the right to purchase the leased facility from us at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days’ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the JV decline to exercise its purchase right). Additionally, the JV has rights of first offer to purchase the facility prior to any third-party sale. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the lease revenue currently earned pursuant to these leases.  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are the lessee on twelve ground leases with subsidiaries of UHS (for consolidated and unconsolidated investments). The remaining lease terms on the ground leases with subsidiaries of UHS range from approximately 28 years to approximately 78 years.  The annual aggregate lease payments on these properties are approximately $508,000 for the year ended 2021 and $508,000 for each </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the years ended 2022</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2023</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2024</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and an aggregate of $</span>29.0<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million thereafter</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;">See Note 7 for further disclosure around our lease </span><span style="color:#000000;">accounting</span><span style="color:#000000;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#FF0000;font-size:14pt;"> </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Officers and Employees:<span style="font-style:normal;"> Our officers are all employees of a wholly-owned subsidiary of UHS and although as of March 31, 2021 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Advisory Agreement:   <span style="font-style:normal;">UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an advisory agreement dated December 24, 1986, and as amended and restated as of January 1, 2019 (the “Advisory Agreement”). Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. </span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our advisory fee for the three months ended March 31, 2021 and 2020, was computed at 0.70% of our average invested real estate assets, as derived from our condensed consolidated balance sheets.  Based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the advisory fee computation remained unchanged for 2021, as compared to the last three years. The average real estate assets for advisory fee calculation purposes exclude certain items from our condensed consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, lease receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $1.1 million and $1.0 million for the three months ended March 31, 2021 and 2020, and were based upon average invested real estate assets of $607 million and $581 million, respectively.    </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share Ownership:<span style="font-style:normal;"> As of March 31, 2021 and December 31, 2020, UHS owned 5.7% of our outstanding shares of beneficial interest.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">SEC reporting requirements of UHS:<span style="font-style:normal;"> UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 36% and 32% of our consolidated revenues during the three-month periods ended March 31, 2021 and 2020, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein</span>.</p> P13Y P15Y 6 P5Y 3 0.22 0.22 18 0.36 0.32 P90D P180D P180D The table below details the existing lease terms and renewal options for our <span style="-sec-ix-hidden:F_000296">three</span> acute care hospitals operated by wholly-owned subsidiaries of UHS: <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Hospital Name</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000303">5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000304">10</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000305">10</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has <span style="-sec-ix-hidden:F_000306_2">one</span> 5-year renewal option at the existing lease rate (through 2031).  </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has <span style="-sec-ix-hidden:F_000309_2">two</span> 5-year renewal options at fair market value lease rates (2022 through 2031).</p></td></tr></table></div> 5485000 2026-12 3030000 2021-12 2648000 2021-12 P5Y 2031 P5Y 2022 2031 2021-12-31 1100000 662000 454000 4400000 2600000 1800000 0.95 P10Y 0.50 P20Y 5 P10Y 750000 P270D P270D upon 30 days’ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the JV decline to exercise its purchase right) 12 P28Y P78Y 508000 508000 508000 508000 508000 29000000.0 0.0070 0.0070 1100000 1000000.0 607000000 581000000 0.057 0.057 0.36 0.32 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(3) Dividends and Equity Issuance Program</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends and dividend equivalents:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2021, we declared and paid dividends of approximately $9.6 million, or $.695 per share. We declared and paid dividends of approximately $9.4 million, or $.685 per share, during the first quarter of 2020.  Dividend equivalents, which were applicable to shares of unvested restricted stock, were accrued during the first quarter of 2021 and will be paid upon vesting of the restricted stock.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Issuance Program:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2020, we commenced an at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of $100 million to or through our agent banks. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective in June 2020. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No shares were issued pursuant to this ATM equity program during the first quarter of 2021.  Pursuant to this ATM program, since the program commenced in the second quarter of 2020, we have issued 2,704 shares at an average price of $101.30 per share, which generated approximately $270,000 of net proceeds (net of approximately $4,000, consisting of compensation to BofA Securities, Inc.). Additionally, as of March 31, 2021, we have paid or incurred approximately $507,000 in various fees and expenses related to the commencement of our ATM program. </p> 9600000 0.695 9400000 0.685 100000000 0 2704 101.30 270000000 4000000 507000000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) Acquisitions and Dispositions</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31, 2021:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acquisitions:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no acquisitions during the first three months of 2021.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dispositions:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no dispositions during the first three months of 2021.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31, 2020:    </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acquisitions:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no acquisitions during the first three months of 2020.<span style="color:#FF0000;">  </span> </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dispositions:    </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no dispositions during the first three months of 2020.</p> 0 0 0 0 <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(5) Summarized Financial Information of Equity Affiliates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with U.S. GAAP and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Distributions received from equity method investees in the consolidated statements of cash flows are classified based upon the nature of the distribution. Returns on investments are presented net of equity in income from unconsolidated investments as cash flows from operating activities.  Returns of investments are classified as cash flows from investing activities. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2021, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. We account for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities which we are the primary beneficiary nor do we have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash funding is typically advanced as equity or member loans. These entities maintain property insurance on the properties.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following property table represents the five LLCs/LPs in which we own a non-controlling interest and were accounted for under the equity method as of March 31, 2021:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of LLC/LP</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC/LP</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)(e.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (b.)(f.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (c.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties II (d.)(f.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza II</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This LLC has a third-party term loan of $9.2 million, which is non-recourse to us, outstanding as of March 31, 2021.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan of $13.3 million, which is non-recourse to us, outstanding as of March 31, 2021.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have committed to invest up to $2.5 million in equity and debt financing, of which $2.4 million has been funded as of March 31, 2021. During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction on this MOB</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which is</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> located in Denison, Texas on the campus of a hospital owned and operated by a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wholly-owned</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> subsidiary of UHS</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was substantially completed in December 2020. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have committed to invest up to $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in equity and debt </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financing</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ne </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> which has been funded as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This LP </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million third-party construction loan </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commitment, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which is non-recourse to us</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has an </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outstanding balance of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span>12.4<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The LLC is the lessee with a third-party lessor under a ground lease for land.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">These LPs are the lessees with UHS-related parties for the land related to these properties.</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined statements of income (unaudited) for the four LLCs/LPs accounted for under the equity method at March 31, 2021 and 2020.     </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,516</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">521</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">729</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs/LPs that were accounted for under the equity method as of March 31, 2021 and December 31, 2020:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including construction in progress</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,822</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,817</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,818</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,639</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities (a.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,543</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,896</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,735</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advances payable to us (b.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,700</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,055</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,639</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in LLCs before amounts included in</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   accrued expenses and other liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,087</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,278</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Amounts included in accrued expenses and other liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,700</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in LLCs, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,387</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,258</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Other assets and other liabilities as of both March 31, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.  <br/></span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, and December 31, 2020, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of LLC/LP</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3/31/2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (5.00% fixed rate mortgage loan) (b.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,777</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000435">Repaid in Feb., 2021</span></p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (5.034% fixed rate mortgage loan) (c.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,295</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (3.64% fixed rate mortgage loan)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,250</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2024</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties II (3.70% fixed rate construction loan) (d.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,416</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,336</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2025</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,896</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,735</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Upon maturity in February, 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.</span><span style="color:#000000;"> </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">This loan is scheduled to mature within the next twelve months, at which time the entity intends to refinance pursuant to a new mortgage loan.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.</span></p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.</p> 0.33 0.95 5 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following property table represents the five LLCs/LPs in which we own a non-controlling interest and were accounted for under the equity method as of March 31, 2021:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of LLC/LP</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC/LP</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)(e.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (b.)(f.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (c.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties II (d.)(f.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza II</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This LLC has a third-party term loan of $9.2 million, which is non-recourse to us, outstanding as of March 31, 2021.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan of $13.3 million, which is non-recourse to us, outstanding as of March 31, 2021.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have committed to invest up to $2.5 million in equity and debt financing, of which $2.4 million has been funded as of March 31, 2021. During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction on this MOB</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which is</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> located in Denison, Texas on the campus of a hospital owned and operated by a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wholly-owned</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> subsidiary of UHS</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was substantially completed in December 2020. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have committed to invest up to $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in equity and debt </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financing</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ne </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> which has been funded as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This LP </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million third-party construction loan </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commitment, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which is non-recourse to us</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has an </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outstanding balance of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span>12.4<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The LLC is the lessee with a third-party lessor under a ground lease for land.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">These LPs are the lessees with UHS-related parties for the land related to these properties.</p></td></tr></table></div> 0.33 St. Matthews Medical Plaza II 0.74 Mid Coast Hospital MOB 0.95 Texoma Medical Plaza 0.95 Forney Medical Plaza II 0.95 Texoma Medical Plaza II 9200000 13300000 2500000 2400000 4700000 3500000 4800000 13100000 12400000 Below are the condensed combined statements of income (unaudited) for the four LLCs/LPs accounted for under the equity method at March 31, 2021 and 2020.     <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,788</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,516</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">521</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">729</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    </p> 2788000 2516000 1107000 1028000 521000 442000 431000 318000 729000 728000 471000 435000 <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs/LPs that were accounted for under the equity method as of March 31, 2021 and December 31, 2020:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including construction in progress</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,822</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,817</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,818</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,639</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities (a.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,543</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,896</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,735</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advances payable to us (b.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,700</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,055</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,639</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in LLCs before amounts included in</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   accrued expenses and other liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,087</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,278</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Amounts included in accrued expenses and other liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,700</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in LLCs, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,387</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,258</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Other assets and other liabilities as of both March 31, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.  <br/></span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 41822000 42374000 8817000 8818000 50639000 51192000 8543000 9402000 34896000 39735000 3500000 3700000 2055000 50639000 51192000 9087000 4278000 2700000 3020000 6387000 1258000 4300000 4300000 4300000 4300000 2023-03 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of LLC/LP</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3/31/2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (5.00% fixed rate mortgage loan) (b.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,777</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000435">Repaid in Feb., 2021</span></p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (5.034% fixed rate mortgage loan) (c.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,295</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (3.64% fixed rate mortgage loan)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,250</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2024</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties II (3.70% fixed rate construction loan) (d.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,416</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,336</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2025</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,896</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,735</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Upon maturity in February, 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.</span><span style="color:#000000;"> </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">This loan is scheduled to mature within the next twelve months, at which time the entity intends to refinance pursuant to a new mortgage loan.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.</span></p></td></tr></table></div> 4777000 13295000 13372000 2021-09 9185000 9250000 2024-12 12416000 12336000 2025-06 34896000 39735000 3500000 13100000 P60D P90D <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6) Recent Accounting Pronouncements</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accounting for Lease Concessions Granted in Connection with the COVID-19 Pandemic</span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On April 8, 2020, the Financial Accounting Standards Board ("FASB") held a public meeting and shortly afterwards issued a question-and-answer ("Q&amp;A") document which was intended to provide accounting relief for lease concessions related to the COVID-19 pandemic. The accounting relief permits an entity to choose to forgo the evaluation of the enforceable rights and obligations of a lease contract, which is a requirement of Accounting Standards Codification Topic 842, </span><span style="font-style:italic;Background-color:#FFFFFF;">Leases, </span><span style="Background-color:#FFFFFF;">which we adopted on January 1, 2019, as long as the total rent payments after the lease concessions are substantially the same, or less than, the total payments previously required by the lease. An entity may account for COVID-19 related lease concessions either (i) as if they were part of the enforceable rights and obligations of the parties under the existing lease contract; or (ii) as a lease modification. To the extent that a rent concession is granted as a deferral of payments, but the total lease payments are substantially the same, lessors are allowed to account for the concession as if no change had been made to the original lease contract.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">      </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Based on the Q&amp;A, an entity is not required to account for all lease concessions related to the effects of the COVID-19 pandemic under one elected option, however, the entity is required to apply the elected option consistently to leases with similar characteristics and in similar circumstances. The COVID-19 pandemic did not start to adversely impact the economic conditions in the United States until late March 2020 and did not have a material effect on our operations or financial results during the three months ended March 31, 2021 or the year ended December 31, 2020.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reference Rate Reform</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, “Reference Rate Reform.” The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. We will evaluate the impact of the guidance and may apply elections as applicable as additional changes in the market occur.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accounting for Lease Concessions Granted in Connection with the COVID-19 Pandemic</span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On April 8, 2020, the Financial Accounting Standards Board ("FASB") held a public meeting and shortly afterwards issued a question-and-answer ("Q&amp;A") document which was intended to provide accounting relief for lease concessions related to the COVID-19 pandemic. The accounting relief permits an entity to choose to forgo the evaluation of the enforceable rights and obligations of a lease contract, which is a requirement of Accounting Standards Codification Topic 842, </span><span style="font-style:italic;Background-color:#FFFFFF;">Leases, </span><span style="Background-color:#FFFFFF;">which we adopted on January 1, 2019, as long as the total rent payments after the lease concessions are substantially the same, or less than, the total payments previously required by the lease. An entity may account for COVID-19 related lease concessions either (i) as if they were part of the enforceable rights and obligations of the parties under the existing lease contract; or (ii) as a lease modification. To the extent that a rent concession is granted as a deferral of payments, but the total lease payments are substantially the same, lessors are allowed to account for the concession as if no change had been made to the original lease contract.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">      </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Based on the Q&amp;A, an entity is not required to account for all lease concessions related to the effects of the COVID-19 pandemic under one elected option, however, the entity is required to apply the elected option consistently to leases with similar characteristics and in similar circumstances. The COVID-19 pandemic did not start to adversely impact the economic conditions in the United States until late March 2020 and did not have a material effect on our operations or financial results during the three months ended March 31, 2021 or the year ended December 31, 2020.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reference Rate Reform</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, “Reference Rate Reform.” The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. We will evaluate the impact of the guidance and may apply elections as applicable as additional changes in the market occur.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(7) Lease Accounting</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted the new lease standard on January 1, 2019 and applied it to leases that were in place on the effective date as both a lessor and lessee. We adopted ASC 842 effective January 1, 2019 under the modified retrospective approach and elected the optional transition method to apply the provisions of ASC 842 as of the adoption date, rather than the earliest period presented. We elected to apply certain adoption related practical expedients for all leases that commenced prior to the election date. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:inherit;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">As Lessor:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease our operating properties to customers under agreements that are classified as operating leases. <span style="color:#000000;">We recognize the total minimum lease payments provided for under the leases on a straight-line basis over the lease term. Generally, under the terms of our leases, the majority of our rental expenses, including common area maintenance, real estate taxes and insurance, are recovered from our customers. We record amounts reimbursed by customers in the period that the applicable expenses are incurred, which is generally ratably throughout the term of the lease. </span> We<span style="font-family:inherit;"> have elected the package of practical expedients that allows lessors to not separate lease and non-lease components by class of underlying asset. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.  We assessed these criteria and concluded that the timing and pattern of transfer for rental revenue and the associated tenant reimbursements are the same, and as our leases qualify as operating leases, we accounted for and presented rental revenue and tenant reimbursements as a single component under Lease revenue in our consolidated statements of income for the three months ended March 31, 2021 and 2020.  </span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three month periods ended March 31, 2021 and 2020 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the lease term. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UHS facilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base rents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,244</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bonus rents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,695</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant reimbursements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease revenue - UHS facilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,132</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,881</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-related parties:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base rents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,505</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,378</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant reimbursements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,587</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,464</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease revenue - Non-related parties</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,092</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,842</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disclosures Related to Certain Hospital Facilities:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right </span><span style="color:#000000;">to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has proposed exchanging potential substitution properties, with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.</span><span style="color:#0070C0;">  </span><span style="Background-color:#FFFFFF;">The proposed substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of the Board have approved the proposed property substitution subject to satisfactory due diligence and completion of definitive agreements. The effective date of the property substitution is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on </span><span style="Background-color:#FFFFFF;">the Inland Valley Campus, we earned $1.1 million of lease revenue during the three-month period ended March 31, 2021 ($662,000 in base rental and $454,000 in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental). </span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kindred Hospital Chicago Central:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The existing lease on Kindred Hospital Chicago Central, a 95-bed specialty hospital located in Chicago, Illinois, is scheduled to expire on December 31, 2021. The tenant of the facility has recently notified us that they do not intend to renew the lease upon its scheduled expiration. We have begun marketing this property to potential new tenants. However, should this property be vacant for an extended period of time, or should we experience a decrease in the lease rate on a future lease as compared to the current lease, or incur substantial renovation costs to make the property suitable for another operator/tenant, our future results of operations could be unfavorably impacted.  Pursuant to the terms of the lease, we earned approximately $390,000 of lease revenue during the three-month period ended March 31, 2021 and $1.6 million of lease revenue during the twelve-month period ended December 31, 2020.  </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Vacancies - Evansville, Indiana and Corpus Christi, Texas:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The leases on two hospital facilities, located in Evansville, Indiana, and Corpus Christi, Texas, expired on May 31, 2019 and June 1, 2019, respectively. The former tenant of the hospital located in Evansville, Indiana, entered into a short-term lease with us, which covered the period of June 1, 2019 through September 30, 2019. The hospital located in Evansville, Indiana, has remained vacant since September 30, 2019 and the hospital located in Corpus Christi, Texas, has remained vacant since June 1, 2019.  </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to market each property for lease to new tenants. However, should these properties continue to remain owned and vacant for an extended period of time, or should we experience decreased lease rates on future leases, as compared to prior/expired lease rates, or incur substantial renovation costs to make the properties suitable for other operators/tenants, our future results of operations could be materially unfavorably impacted. </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:inherit;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">As Lessee:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are the lessee with various third parties, including subsidiaries of UHS, in connection with ground leases for land at fourteen of our consolidated properties. Our right-of-use land assets represent our right to use the land for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right-of-use assets and lease liabilities were recognized upon adoption of Topic 842 based on the present value of lease payments over the lease term. We utilized our estimated incremental borrowing rate, which was derived from information available as of January 1, 2019, in determining the present value of lease payments.<span style="color:#000000;font-size:9pt;font-family:Arial;"> </span>A right-of-use asset and lease liability are not recognized for leases with an initial term of 12 months or less, as these short-term leases are accounted for similar to previous guidance for operating leases.  We do not currently have any ground leases with an initial term of 12 months or less. <span style="color:#000000;font-family:Times New Roman;">As of March 31, 2021, our condensed consolidated balance sheet includes right-of-use land assets of approximately $8.9 million and ground lease liabilities of approximately $8.9 million. </span><span style="font-family:Times New Roman;">There were no newly leased assets for which a right-of-use asset was recorded in exchange for a new lease liability during the three months ended March 31, 2021.</span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three month periods ended March 31, 2021 and 2020 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the lease term. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UHS facilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base rents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,146</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,244</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bonus rents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,695</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant reimbursements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease revenue - UHS facilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,132</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,881</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-related parties:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base rents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,505</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,378</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant reimbursements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,587</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,464</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease revenue - Non-related parties</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,092</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,842</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 5146000 4244000 1695000 1380000 291000 257000 7132000 5881000 10505000 10378000 2587000 2464000 13092000 12842000 2021-12-31 1100000 662000 454000 4400000 2600000 1800000 95 2021-12-31 390000 1600000 2019-05-31 2019-06-01 14 8900000 8900000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(8) Debt and Financial Instruments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Debt:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $350 million revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our ATM equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we entered into the first amendment (the “First Amendment”) to the revolving credit agreement (“Credit Agreement”), pursuant to which, among other things, an additional tranche of revolving credit commitments in the amount of $50 million, designated as the “Revolving B Facility”, was established thereby increasing the aggregate revolving credit commitment to $350 million from $300 million. The Credit Agreement, as amended, which is scheduled to mature in March 2022, provides for a revolving credit facility in an aggregate principal amount of $350 million, including a $40 million sublimit for letters of credit and a $30 million sublimit for swingline/short-term loans.  Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust’s wholly-owned subsidiaries.  The remainder of the revolving credit commitments provided under the Credit Agreement that were in effect prior to giving effect to the First Amendment, has been designated as the “Revolving A Facility”.  </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings made pursuant to the Revolving</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will bear interest, at our option, at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one, two, three, or six</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">month LIBOR plus an applicable margin ranging from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.35</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% or at the Base Rate plus an applicable margin ranging from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.10</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Credit Agreement defines “Base Rate” as </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000488_2">1/2</span></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of 1%, and; (c) one month LIBOR plus </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  A facility fee of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.15</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% will be charged on the total commitment of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revolving</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A Facility of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the applicable margin over the LIBOR rate was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%, the margin over the Base Rate was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%, and the facility fee was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Credit Agreement also provides for options to extend the maturity date and borrowing availability for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">two</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> additional six-month periods for the Revolving A Facility.</span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Borrowings made pursuant to the Revolving B Facility will bear interest, at our option, at one, two, three, or six months LIBOR plus an applicable margin ranging from 1.85% to 2.10% or at the Base Rate plus an applicable margin ranging from 0.85% to 1.10%.  The Credit Agreement defines “Base Rate” as the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus <span style="-sec-ix-hidden:F_000502_2">1/2</span> of 1% and (c) one month LIBOR plus 1%.  The initial applicable margin is 1.95% for LIBOR loans and 0.95% for Base Rate loans.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Revolving B Facility of the Credit Agreement.  The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At March 31, 2021, the applicable margin over the LIBOR rate was </span>1.95<span style="Background-color:#FFFFFF;">%, the margin over the Base Rate was </span>0.95<span style="Background-color:#FFFFFF;">% and the facility fee was 0.20%.</span>   </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2021, we had $247.7 million of outstanding borrowings and $5.6 million of letters of credit outstanding under our Credit Agreement.  We had $96.7 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2021. There are no compensating balance requirements. At December 31, 2020, we had $236.2 million of outstanding borrowings outstanding against our revolving credit agreement and $108.2 million of available borrowing capacity. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2021 and December 31, 2020. We also believe that we would remain in compliance if, based on the assumption that the majority of the potential new borrowings will be used to fund investments, the full amount of our commitment was borrowed.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000516">&gt; =$125,000</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,654</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,263</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000517">&lt; 60%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000518">&lt; 30%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000519">&lt; 60%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000520">&gt; 1.50x</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8x</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7x</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2021 (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Facility Name</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<span style="font-family:Calibri;"> </span>thousands) (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,381</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2022</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,449</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2022</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,474</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2023</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2704 North Tenaya Way fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,538</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November, 2023</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III fixed</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   rate mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,984</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April, 2024</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,789</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2025</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children’s East Valley Care Center fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,656</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.95</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2030</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosenberg Children's Medical Plaza fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,450</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.42</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2033</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total, excluding net debt premium and net financing fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,721</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Less net financing fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(447</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Plus net debt premium</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total mortgages notes payable, non-recourse to us, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.58%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. </span></p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages outstanding as of March 31, 2021 had a combined fair value of approximately $61.6 million.  At December 31, 2020, we had various mortgages, all of which were non-recourse to us, included in our condensed consolidated balance sheet. The combined outstanding balance of these various mortgages at December 31, 2020 was $59.2 million and had a combined fair value of approximately $62.0 million. The fair value of our debt was computed based upon quotes received from financial institutions.  We consider these to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments.  Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financial Instruments:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, we entered into <span style="-sec-ix-hidden:F_000562_2">an</span> interest rate swap agreement on a total notional amount of $55 million with a fixed interest rate of 0.565% that we designated as a cash flow hedge.  The interest rate swap became effective on March 25, 2020 and is scheduled to mature on March 25, 2027. If the one-month LIBOR is above 0.565%, the counterparty pays us, and if the one-month LIBOR is less than 0.565%, we pay the counterparty, the difference between the fixed rate of 0.565% and one-month LIBOR.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, we entered into <span style="-sec-ix-hidden:F_000569_2">an</span> interest rate swap agreement on a total notional amount of $35 million with a fixed interest rate of 1.4975% that we designated as a cash flow hedge.  The interest rate swap became effective on January 15, 2020 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.4975%, the counterparty pays us, and if the one-month LIBOR is less than 1.4975%, we pay the counterparty, the difference between the fixed rate of 1.4975% and one-month LIBOR.  </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the third quarter of 2019, we entered into <span style="-sec-ix-hidden:F_000576_2">an</span> interest rate swap agreement on a total notional amount of $50 million with a fixed interest rate of 1.144% that we designated as a cash flow hedge. The interest rate swap became effective on September 16, 2019 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.144%, the counterparty pays us, and if the one-month LIBOR is less than 1.144%, we pay the counterparty, the difference between the fixed rate of 1.144% and one-month LIBOR. </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from third parties.  We consider those inputs to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. At March 31, 2021, the fair value of our interest rate swaps was a net liability of $467,000 which is included in accrued expenses and other liabilities on the accompanying condensed consolidated balance sheet. During the first quarter of 2021, we paid or accrued approximately $305,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps.  From inception of the swap agreements through March 31, 2021 we paid or accrued approximately $931,000 in net payments made to the counterparty by us pursuant to the terms of the swap (consisting of approximately $199,000 in payments or accruals made to us by the counterparty, offset by approximately $1.1 million of payments due to the counterparty from us).  Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or a liability, with a corresponding amount recorded in accumulated other </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comprehensive income (“AOCI”) within shareholders’ equity.  Amounts are classified from AOCI to the income statement in the period or periods the hedged transaction affects earnings.</span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> 350000000 50000000 350000000 300000000 2022-03 350000000 40000000 30000000 one, two, three, or six-month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. 0.0110 0.0135 0.0010 0.0035 the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%. 0.01 0.0015 0.0035 0.0120 0.0020 0.0020 2 one, two, three, or six months LIBOR plus an applicable margin ranging from 1.85% to 2.10% or at the Base Rate plus an applicable margin ranging from 0.85% to 1.10%. 0.0185 0.0210 0.0085 0.0110 the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%. 0.01 0.0195 0.0095 0.0015 0.0035 0.0195 0.0095 0.0020 247700000 5600 96700000 0 236200000 108200000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000516">&gt; =$125,000</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,654</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,263</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000517">&lt; 60%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000518">&lt; 30%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000519">&lt; 60%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000520">&gt; 1.50x</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8x</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7x</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 147654000 147263000 0.453 0.448 0.085 0.086 0.433 0.414 0.048 0.047 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2021 (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Facility Name</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<span style="font-family:Calibri;"> </span>thousands) (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,381</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2022</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,449</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2022</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,474</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2023</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2704 North Tenaya Way fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,538</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November, 2023</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III fixed</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   rate mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,984</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April, 2024</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,789</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2025</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children’s East Valley Care Center fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,656</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.95</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2030</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosenberg Children's Medical Plaza fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,450</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.42</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2033</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total, excluding net debt premium and net financing fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,721</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Less net financing fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(447</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Plus net debt premium</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total mortgages notes payable, non-recourse to us, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.58%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. </span></p></td></tr></table></div> 5381000 0.0454 2022-06 5449000 0.0427 2022-12 4474000 0.0362 2023-01 6538000 0.0495 2023-11 12984000 0.0403 2024-04 2789000 0.0556 2025-06 8656000 0.0395 2030-01 12450000 0.0442 2033-09 58721000 447000 129000 58403000 61600000 59200000 62000000.0 55000000 0.00565 2027-03-25 0.00565 0.00565 0.00565 35000000 0.014975 2024-09-16 0.014975 0.014975 0.014975 50000000 0.01144 2024-09-16 0.01144 0.01144 0.01144 467000000000 305000 931000 199000 1100000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(9) Segment Reporting</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  No individual property meets the requirements necessary to be considered its own segment.</p> 1 The LLC is the lessee with a third-party lessor under a ground lease for land. These LPs are the lessees with UHS-related parties for the land related to these properties. All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. Includes bonus rental on UHS hospital facilities of $1,695 and $1,380 for the three-month periods ended March 31, 2021 and 2020, respectively. UHS has one 5-year renewal option at the existing lease rate (through 2031).   UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031). This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan of $13.3 million, which is non-recourse to us, outstanding as of March 31, 2021. We have committed to invest up to $2.5 million in equity and debt financing, of which $2.4 million has been funded as of March 31, 2021. During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. Construction on this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, none of which has been funded as of March 31, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $12.4 million as of March 31, 2021. Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023. Upon maturity in February, 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023. This LLC has a third-party term loan of $9.2 million, which is non-recourse to us, outstanding as of March 31, 2021. Other assets and other liabilities as of both March 31, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS. This loan is scheduled to mature within the next twelve months, at which time the entity intends to refinance pursuant to a new mortgage loan. XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2021
Apr. 30, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Entity Registrant Name UNIVERSAL HEALTH REALTY INCOME TRUST  
Entity Central Index Key 0000798783  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   13,772,112
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity File Number 1-9321  
Entity Tax Identification Number 23-6858580  
Entity Address, Address Line One UNIVERSAL CORPORATE CENTER  
Entity Address, Address Line Two 367 SOUTH GULPH ROAD  
Entity Address, City or Town KING OF PRUSSIA  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19406  
City Area Code 610  
Local Phone Number 265-0688  
Entity Interactive Data Current Yes  
Title of 12(b) Security Shares of beneficial interest, $0.01 par value  
Trading Symbol UHT  
Security Exchange Name NYSE  
Entity Incorporation, State or Country Code MD  
Document Quarterly Report true  
Document Transition Report false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Income - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenues:    
Revenues, Total $ 20,699 $ 19,207
Expenses:    
Depreciation and amortization 6,787 6,380
Other operating expenses 5,602 5,383
Costs and Expenses, Total 13,451 12,779
Income before equity in income of unconsolidated limited liability companies ("LLCs"), interest expense and gains on sales 7,248 6,428
Equity in income of unconsolidated LLCs 471 435
Interest expense, net (2,133) (2,309)
Net income $ 5,586 $ 4,554
Basic earnings per share $ 0.41 $ 0.33
Diluted earnings per share $ 0.41 $ 0.33
Weighted average number of shares outstanding - Basic 13,750 13,736
Weighted average number of shares outstanding - Diluted 13,771 13,758
Non-Related Parties    
Revenues:    
Lease revenue $ 13,092 $ 12,842
Other    
Revenues:    
Other revenue 249 270
Management Service    
Expenses:    
Advisory fees to UHS 1,062 1,016
UHS Facilities    
Revenues:    
Lease revenue [1] 7,132 5,881
UHS Facilities | Other    
Revenues:    
Other revenue $ 226 $ 214
[1] Includes bonus rental on UHS hospital facilities of $1,695 and $1,380 for the three-month periods ended March 31, 2021 and 2020, respectively.
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Income (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
UHS Hospital Facilities    
Bonus rental $ 1,695 $ 1,380
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]    
Net income $ 5,586 $ 4,554
Other comprehensive gain/(loss):    
Unrealized derivative gains/(losses) on cash flow hedges 3,348 (4,671)
Total other comprehensive gain/(loss): 3,348 (4,671)
Total comprehensive income/(loss) $ 8,934 $ (117)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Real Estate Investments:    
Buildings and improvements and construction in progress $ 608,366 $ 605,292
Accumulated depreciation (222,521) (216,648)
Real Estate Investment Property, Net, Total 385,845 388,644
Land 55,157 55,157
Net Real Estate Investments 441,002 443,801
Investments in limited liability companies ("LLCs") 9,087 4,278
Other Assets:    
Cash and cash equivalents 6,171 5,742
Lease and other receivables from UHS 3,252 3,199
Lease receivable - other 7,780 7,504
Intangible assets (net of accumulated amortization of $19.0 million and $19.5 million, respectively) 11,013 11,742
Right-of-use land assets, net 8,907 8,914
Deferred charges and other assets, net 8,582 8,829
Total Assets 495,794 494,009
Liabilities:    
Line of credit borrowings 247,650 236,200
Mortgage notes payable, non-recourse to us, net 58,403 [1] 58,895
Accrued interest 346 351
Accrued expenses and other liabilities 11,375 19,802
Ground lease liabilities, net 8,907 8,914
Tenant reserves, deposits and deferred and prepaid rents 10,446 10,842
Total Liabilities 337,127 335,004
Equity:    
Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding
Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2021 - 13,772,095; 2020 - 13,771,287 138 138
Capital in excess of par value 267,667 267,368
Cumulative net income 686,313 680,727
Cumulative dividends (794,984) (785,413)
Accumulated other comprehensive (loss)/income (467) (3,815)
Total Equity 158,667 159,005
Total Liabilities and Equity $ 495,794 $ 494,009
[1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2021
Dec. 31, 2020
Statement Of Financial Position [Abstract]    
Intangible assets, accumulated amortization $ 19.0 $ 19.5
Preferred shares of beneficial interest, par value $ 0.01 $ 0.01
Preferred shares of beneficial interest, shares authorized 5,000,000 5,000,000
Preferred shares of beneficial interest, issued 0 0
Preferred shares of beneficial interest, outstanding 0 0
Common shares, par value $ 0.01 $ 0.01
Common shares, shares authorized 95,000,000 95,000,000
Common shares, issued 13,772,095 13,771,287
Common shares, outstanding 13,772,095 13,771,287
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Changes in Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common stock
Common stock
Cumulative net income
Common stock
Accumulated other comprehensive income/(loss)
January 1, 2021 at Dec. 31, 2019 $ 181,734 $ 138 $ 266,723 $ 661,280 $ (747,417) $ 1,010
Balance, Shares at Dec. 31, 2019   13,757        
Shares of Beneficial Interest:            
Issued 50   50      
Issued (in shares)   1        
Restricted stock-based compensation expense 197   197      
Dividends (9,424)       (9,424)  
Comprehensive income:            
Net income 4,554     4,554    
Unrealized net gain(loss) on cash flow hedges (4,671)         (4,671)
Subtotal - comprehensive income (117)     4,554   (4,671)
Balance at Mar. 31, 2020 172,440 $ 138 266,970 665,834 (756,841) (3,661)
Balance, Shares at Mar. 31, 2020   13,758        
January 1, 2021 at Dec. 31, 2020 159,005 $ 138 267,368 680,727 (785,413) (3,815)
Balance, Shares at Dec. 31, 2020   13,771        
Shares of Beneficial Interest:            
Issued 57   57      
Issued (in shares)   1        
Restricted stock-based compensation expense 242   242      
Dividends (9,571)       (9,571)  
Comprehensive income:            
Net income 5,586     5,586    
Unrealized net gain(loss) on cash flow hedges 3,348         3,348
Subtotal - comprehensive income 8,934     5,586   3,348
Balance at Mar. 31, 2021 $ 158,667 $ 138 $ 267,667 $ 686,313 $ (794,984) $ (467)
Balance, Shares at Mar. 31, 2021   13,772        
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Changes in Equity (Parenthetical) - $ / shares
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Statement Of Stockholders Equity [Abstract]    
Dividend, per share $ 0.695 $ 0.685
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net income $ 5,586 $ 4,554
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 6,787 6,380
Amortization related to above/below market leases, net (45) (46)
Amortization of debt premium (12) (13)
Amortization of deferred financing costs 216 157
Stock-based compensation expense 242 197
Changes in assets and liabilities:    
Lease receivable (329) 181
Accrued expenses and other liabilities (633) (867)
Tenant reserves, deposits and deferred and prepaid rents (396) 65
Accrued interest (5) (25)
Leasing costs paid (365) (182)
Other, net 204 (264)
Net cash provided by operating activities 11,250 10,137
Cash flows from investing activities:    
Investments in LLCs (1,544) (1,468)
Advance made to LLC (3,500)  
Additions to real estate investments, net (6,974) (5,521)
Deposit on real estate assets (200)  
Net cash used in investing activities (12,218) (6,989)
Cash flows from financing activities:    
Net borrowings on line of credit 11,450 6,250
Repayments of mortgage notes payable (510) (432)
Financing costs paid (35) (35)
Dividends paid (9,564) (9,424)
Issuance of shares of beneficial interest, net 56 50
Net cash provided by/(used in) financing activities 1,397 (3,591)
Increase/(decrease) in cash and cash equivalents 429 (443)
Cash and cash equivalents, beginning of period 5,742 6,110
Cash and cash equivalents, end of period 6,171 5,667
Supplemental disclosures of cash flow information:    
Interest paid 1,935 2,190
Invoices accrued for construction and improvements $ 468 $ 3,151
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.1
General
3 Months Ended
Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
General

(1) General

This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2021. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.  As of March 31, 2021, we had investments in five jointly-owned LLCs/LPs. We currently account for our share of the income/loss from these investments by the equity method (see Note 5). These LLCs are included in our consolidated financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.    

The condensed consolidated financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2020.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions
3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties from certain subsidiaries of UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and renewal terms for each of the three hospital facilities leased to wholly-owned subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with wholly-owned subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the three acute care hospital facilities leased to wholly-owned subsidiaries of UHS accounted for approximately 22% of our consolidated revenues for each of the three months ended March 31, 2021 and 2020. In addition to these three UHS hospital facilities, one of our hospital facilities is leased to a joint venture between a subsidiary of UHS and a third party, and we have eighteen medical office buildings (“MOBs”) or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us that include tenants which are subsidiaries or joint ventures of UHS. The aggregate revenues generated from UHS-related tenants comprised approximately 36% and 32% of our consolidated revenues during the three-month periods ended March 31, 2021 and 2020, respectively.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of the three acute care hospitals with wholly-owned subsidiaries of UHS, as reflected below, UHS has the option, among other things, to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities from us at their appraised fair market value upon any of the following:  (i) at the end of the lease terms or any renewal terms; (ii) upon one month’s notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the lease in the event that UHS provides notice to us of their intent to offer a substitution property/properties in exchange for one (or more) of the three hospital facilities leased from us, should we be unable to reach an agreement with UHS on the properties to be substituted. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2026

 

 

5

 

(a.)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b.)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(b.)

 

(a.)

UHS has one 5-year renewal option at the existing lease rate (through 2031).  

(b.)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

 

As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has proposed exchanging potential substitution properties, with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.  The proposed substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of the Board have approved the proposed property substitution subject to satisfactory due diligence and completion of definitive agreements. The effective date of the property substitution is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on the Inland Valley Campus, we earned $1.1 million of lease revenue during the three-month period ended March 31, 2021 ($662,000 in base rental and $454,000 in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).  

In September 2019, we entered into an agreement whereby we own a 95% non-controlling ownership interest in Grayson Properties II L.P., which developed, constructed, owns and operates the Texoma Medical Plaza II, an MOB located in Denison, Texas.  This MOB, which was substantially completed in December 2020, is located on the campus of Texoma Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS.  A 10-year master flex lease was executed with the wholly-owned subsidiary of UHS for over 50% of the rentable square feet of the MOB and commenced in December 2020 upon the issuance of the certificate of occupancy. We account for this LP on an unconsolidated basis pursuant to the equity method since it is not a variable interest entity and we do not have a controlling voting interest.    

In late July 2019, Des Moines Medical Properties, LLC, a wholly-owned subsidiary of ours, entered into an agreement to build and lease a newly constructed UHS-related behavioral health care hospital located in Clive, Iowa.  The lease on this facility, which is triple net and has an initial term of 20 years with five 10-year renewal options, was executed with Clive Behavioral Health, LLC, a joint venture between a wholly-owned subsidiary of UHS and Catholic Health Initiatives - Iowa, Corp (“JV”). Construction of this hospital, for which we engaged a wholly-owned subsidiary of UHS to act as project manager for an aggregate fee of approximately $750,000, was substantially completed in December 2020 and the property received a temporary certificate of occupancy on December 31, 2020.  The hospital lease commenced upon the issuance of the temporary certificate of occupancy.  Pursuant to the lease on this facility, the JV has the option to, among other things, renew the lease at the terms specified in the lease agreement by providing notice to us at least 270 days prior to the termination of the then current term. The JV also has the right to purchase the leased facility from us at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days’ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the JV decline to exercise its purchase right). Additionally, the JV has rights of first offer to purchase the facility prior to any third-party sale.

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the lease revenue currently earned pursuant to these leases.  

 

We are the lessee on twelve ground leases with subsidiaries of UHS (for consolidated and unconsolidated investments). The remaining lease terms on the ground leases with subsidiaries of UHS range from approximately 28 years to approximately 78 years.  The annual aggregate lease payments on these properties are approximately $508,000 for the year ended 2021 and $508,000 for each

of the years ended 2022, 2023, 2024 and 2025, and an aggregate of $29.0 million thereafter. See Note 7 for further disclosure around our lease accounting.

 

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of March 31, 2021 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

 

Advisory Agreement:   UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an advisory agreement dated December 24, 1986, and as amended and restated as of January 1, 2019 (the “Advisory Agreement”). Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory.

Our advisory fee for the three months ended March 31, 2021 and 2020, was computed at 0.70% of our average invested real estate assets, as derived from our condensed consolidated balance sheets.  Based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the advisory fee computation remained unchanged for 2021, as compared to the last three years. The average real estate assets for advisory fee calculation purposes exclude certain items from our condensed consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, lease receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $1.1 million and $1.0 million for the three months ended March 31, 2021 and 2020, and were based upon average invested real estate assets of $607 million and $581 million, respectively.    

 

Share Ownership: As of March 31, 2021 and December 31, 2020, UHS owned 5.7% of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 36% and 32% of our consolidated revenues during the three-month periods ended March 31, 2021 and 2020, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Dividends and Equity Issuance Program
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Dividends and Equity Issuance Program

(3) Dividends and Equity Issuance Program

Dividends and dividend equivalents:

During the first quarter of 2021, we declared and paid dividends of approximately $9.6 million, or $.695 per share. We declared and paid dividends of approximately $9.4 million, or $.685 per share, during the first quarter of 2020.  Dividend equivalents, which were applicable to shares of unvested restricted stock, were accrued during the first quarter of 2021 and will be paid upon vesting of the restricted stock.

Equity Issuance Program:

During the second quarter of 2020, we commenced an at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of $100 million to or through our agent banks. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective in June 2020.

No shares were issued pursuant to this ATM equity program during the first quarter of 2021.  Pursuant to this ATM program, since the program commenced in the second quarter of 2020, we have issued 2,704 shares at an average price of $101.30 per share, which generated approximately $270,000 of net proceeds (net of approximately $4,000, consisting of compensation to BofA Securities, Inc.). Additionally, as of March 31, 2021, we have paid or incurred approximately $507,000 in various fees and expenses related to the commencement of our ATM program.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Acquisitions and Dispositions
3 Months Ended
Mar. 31, 2021
Business Combinations [Abstract]  
Acquisitions and Dispositions

(4) Acquisitions and Dispositions

Three Months Ended March 31, 2021:

Acquisitions:

There were no acquisitions during the first three months of 2021.

Dispositions:

There were no dispositions during the first three months of 2021.

 

Three Months Ended March 31, 2020:    

Acquisitions:

There were no acquisitions during the first three months of 2020.  

Dispositions:    

There were no dispositions during the first three months of 2020.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Summarized Financial Information of Equity Affiliates
3 Months Ended
Mar. 31, 2021
Equity Method Investments And Joint Ventures [Abstract]  
Summarized Financial Information of Equity Affiliates

(5) Summarized Financial Information of Equity Affiliates

In accordance with U.S. GAAP and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

Distributions received from equity method investees in the consolidated statements of cash flows are classified based upon the nature of the distribution. Returns on investments are presented net of equity in income from unconsolidated investments as cash flows from operating activities.  Returns of investments are classified as cash flows from investing activities.

At March 31, 2021, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. We account for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities which we are the primary beneficiary nor do we have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash funding is typically advanced as equity or member loans. These entities maintain property insurance on the properties.

The following property table represents the five LLCs/LPs in which we own a non-controlling interest and were accounted for under the equity method as of March 31, 2021:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)(e.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)(f.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

Grayson Properties II (d.)(f.)

 

 

95

%

 

Texoma Medical Plaza II

 

(a.)

This LLC has a third-party term loan of $9.2 million, which is non-recourse to us, outstanding as of March 31, 2021.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan of $13.3 million, which is non-recourse to us, outstanding as of March 31, 2021.

(c.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.4 million has been funded as of March 31, 2021. During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

(d.)

Construction on this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, none of which has been funded as of March 31, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $12.4 million as of March 31, 2021.

(e.)

The LLC is the lessee with a third-party lessor under a ground lease for land.

(f.)

These LPs are the lessees with UHS-related parties for the land related to these properties.

Below are the condensed combined statements of income (unaudited) for the four LLCs/LPs accounted for under the equity method at March 31, 2021 and 2020.    

 

 

 

Three Months Ended

March 31,

 

 

 

2021

 

 

2020

 

 

 

(amounts in thousands)

 

Revenues

 

$

2,788

 

 

$

2,516

 

Operating expenses

 

 

1,107

 

 

 

1,028

 

Depreciation and amortization

 

 

521

 

 

 

442

 

Interest, net

 

 

431

 

 

 

318

 

Net income

 

$

729

 

 

$

728

 

Our share of net income

 

$

471

 

 

$

435

 

   

Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs/LPs that were accounted for under the equity method as of March 31, 2021 and December 31, 2020:

 

 

 

March 31,

2021

 

 

December 31,

2020

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

41,822

 

 

$

42,374

 

Other assets (a.)

 

 

8,817

 

 

 

8,818

 

Total assets

 

$

50,639

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Other liabilities (a.)

 

$

8,543

 

 

$

9,402

 

Mortgage notes payable, non-recourse to us

 

 

34,896

 

 

 

39,735

 

Advances payable to us (b.)

 

 

3,500

 

 

 

-

 

Equity

 

 

3,700

 

 

 

2,055

 

Total liabilities and equity

 

$

50,639

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Investments in LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

9,087

 

 

$

4,278

 

   Amounts included in accrued expenses and other liabilities

 

 

(2,700

)

 

 

(3,020

)

Our share of equity in LLCs, net

 

$

6,387

 

 

$

1,258

 

 

 

(a.)

Other assets and other liabilities as of both March 31, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.

 

(b.)

Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.  

 

As of March 31, 2021, and December 31, 2020, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

3/31/2021

 

 

12/31/2020

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan) (b.)

 

$

-

 

 

$

4,777

 

 

Repaid in Feb., 2021

Grayson Properties (5.034% fixed rate mortgage loan) (c.)

 

 

13,295

 

 

 

13,372

 

 

September, 2021

Brunswick Associates (3.64% fixed rate mortgage loan)

 

 

9,185

 

 

 

9,250

 

 

December, 2024

Grayson Properties II (3.70% fixed rate construction loan) (d.)

 

 

12,416

 

 

 

12,336

 

 

June, 2025

 

 

$

34,896

 

 

$

39,735

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

 

(b.)

Upon maturity in February, 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

 

(c.)

This loan is scheduled to mature within the next twelve months, at which time the entity intends to refinance pursuant to a new mortgage loan.

 

(d.)

This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.

Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Recent Accounting Pronouncements
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Recent Accounting Pronouncements

(6) Recent Accounting Pronouncements

 

Accounting for Lease Concessions Granted in Connection with the COVID-19 Pandemic

On April 8, 2020, the Financial Accounting Standards Board ("FASB") held a public meeting and shortly afterwards issued a question-and-answer ("Q&A") document which was intended to provide accounting relief for lease concessions related to the COVID-19 pandemic. The accounting relief permits an entity to choose to forgo the evaluation of the enforceable rights and obligations of a lease contract, which is a requirement of Accounting Standards Codification Topic 842, Leases, which we adopted on January 1, 2019, as long as the total rent payments after the lease concessions are substantially the same, or less than, the total payments previously required by the lease. An entity may account for COVID-19 related lease concessions either (i) as if they were part of the enforceable rights and obligations of the parties under the existing lease contract; or (ii) as a lease modification. To the extent that a rent concession is granted as a deferral of payments, but the total lease payments are substantially the same, lessors are allowed to account for the concession as if no change had been made to the original lease contract.

      

Based on the Q&A, an entity is not required to account for all lease concessions related to the effects of the COVID-19 pandemic under one elected option, however, the entity is required to apply the elected option consistently to leases with similar characteristics and in similar circumstances. The COVID-19 pandemic did not start to adversely impact the economic conditions in the United States until late March 2020 and did not have a material effect on our operations or financial results during the three months ended March 31, 2021 or the year ended December 31, 2020.

Reference Rate Reform

In March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, “Reference Rate Reform.” The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. We will evaluate the impact of the guidance and may apply elections as applicable as additional changes in the market occur.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Lease Accounting
3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
Lease Accounting

(7) Lease Accounting

 

 

We adopted the new lease standard on January 1, 2019 and applied it to leases that were in place on the effective date as both a lessor and lessee. We adopted ASC 842 effective January 1, 2019 under the modified retrospective approach and elected the optional transition method to apply the provisions of ASC 842 as of the adoption date, rather than the earliest period presented. We elected to apply certain adoption related practical expedients for all leases that commenced prior to the election date. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.

As Lessor:

We lease our operating properties to customers under agreements that are classified as operating leases. We recognize the total minimum lease payments provided for under the leases on a straight-line basis over the lease term. Generally, under the terms of our leases, the majority of our rental expenses, including common area maintenance, real estate taxes and insurance, are recovered from our customers. We record amounts reimbursed by customers in the period that the applicable expenses are incurred, which is generally ratably throughout the term of the lease.  We have elected the package of practical expedients that allows lessors to not separate lease and non-lease components by class of underlying asset. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.  We assessed these criteria and concluded that the timing and pattern of transfer for rental revenue and the associated tenant reimbursements are the same, and as our leases qualify as operating leases, we accounted for and presented rental revenue and tenant reimbursements as a single component under Lease revenue in our consolidated statements of income for the three months ended March 31, 2021 and 2020.  

The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three month periods ended March 31, 2021 and 2020 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the lease term. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.

 

 

Three Months Ended

 

 

March 31,

 

 

2021

 

 

2020

 

UHS facilities:

 

 

 

 

 

 

 

Base rents

$

5,146

 

 

$

4,244

 

Bonus rents

 

1,695

 

 

 

1,380

 

Tenant reimbursements

 

291

 

 

 

257

 

Lease revenue - UHS facilities

$

7,132

 

 

$

5,881

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-related parties:

 

 

 

 

 

 

 

Base rents

 

10,505

 

 

 

10,378

 

Tenant reimbursements

 

2,587

 

 

 

2,464

 

Lease revenue - Non-related parties

$

13,092

 

 

$

12,842

 

 

Disclosures Related to Certain Hospital Facilities:

Southwest Healthcare System, Inland Valley Campus:

As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has proposed exchanging potential substitution properties, with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.  The proposed substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of the Board have approved the proposed property substitution subject to satisfactory due diligence and completion of definitive agreements. The effective date of the property substitution is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on the Inland Valley Campus, we earned $1.1 million of lease revenue during the three-month period ended March 31, 2021 ($662,000 in base rental and $454,000 in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).

Kindred Hospital Chicago Central:

The existing lease on Kindred Hospital Chicago Central, a 95-bed specialty hospital located in Chicago, Illinois, is scheduled to expire on December 31, 2021. The tenant of the facility has recently notified us that they do not intend to renew the lease upon its scheduled expiration. We have begun marketing this property to potential new tenants. However, should this property be vacant for an extended period of time, or should we experience a decrease in the lease rate on a future lease as compared to the current lease, or incur substantial renovation costs to make the property suitable for another operator/tenant, our future results of operations could be unfavorably impacted.  Pursuant to the terms of the lease, we earned approximately $390,000 of lease revenue during the three-month period ended March 31, 2021 and $1.6 million of lease revenue during the twelve-month period ended December 31, 2020.  

Vacancies - Evansville, Indiana and Corpus Christi, Texas:

The leases on two hospital facilities, located in Evansville, Indiana, and Corpus Christi, Texas, expired on May 31, 2019 and June 1, 2019, respectively. The former tenant of the hospital located in Evansville, Indiana, entered into a short-term lease with us, which covered the period of June 1, 2019 through September 30, 2019. The hospital located in Evansville, Indiana, has remained vacant since September 30, 2019 and the hospital located in Corpus Christi, Texas, has remained vacant since June 1, 2019.  

We continue to market each property for lease to new tenants. However, should these properties continue to remain owned and vacant for an extended period of time, or should we experience decreased lease rates on future leases, as compared to prior/expired lease rates, or incur substantial renovation costs to make the properties suitable for other operators/tenants, our future results of operations could be materially unfavorably impacted.

 

As Lessee:

We are the lessee with various third parties, including subsidiaries of UHS, in connection with ground leases for land at fourteen of our consolidated properties. Our right-of-use land assets represent our right to use the land for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right-of-use assets and lease liabilities were recognized upon adoption of Topic 842 based on the present value of lease payments over the lease term. We utilized our estimated incremental borrowing rate, which was derived from information available as of January 1, 2019, in determining the present value of lease payments. A right-of-use asset and lease liability are not recognized for leases with an initial term of 12 months or less, as these short-term leases are accounted for similar to previous guidance for operating leases.  We do not currently have any ground leases with an initial term of 12 months or less. As of March 31, 2021, our condensed consolidated balance sheet includes right-of-use land assets of approximately $8.9 million and ground lease liabilities of approximately $8.9 million. There were no newly leased assets for which a right-of-use asset was recorded in exchange for a new lease liability during the three months ended March 31, 2021.

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Debt and Financial Instruments
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Debt and Financial Instruments

(8) Debt and Financial Instruments

Debt:

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $350 million revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our ATM equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

In June 2020, we entered into the first amendment (the “First Amendment”) to the revolving credit agreement (“Credit Agreement”), pursuant to which, among other things, an additional tranche of revolving credit commitments in the amount of $50 million, designated as the “Revolving B Facility”, was established thereby increasing the aggregate revolving credit commitment to $350 million from $300 million. The Credit Agreement, as amended, which is scheduled to mature in March 2022, provides for a revolving credit facility in an aggregate principal amount of $350 million, including a $40 million sublimit for letters of credit and a $30 million sublimit for swingline/short-term loans.  Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust’s wholly-owned subsidiaries.  The remainder of the revolving credit commitments provided under the Credit Agreement that were in effect prior to giving effect to the First Amendment, has been designated as the “Revolving A Facility”.  

Borrowings made pursuant to the Revolving A Facility will bear interest, at our option, at one, two, three, or six-month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines “Base Rate” as the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Revolving A Facility of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At March 31, 2021, the applicable margin over the LIBOR rate was 1.20%, the margin over the Base Rate was 0.20%, and the facility fee was 0.20%. The Credit Agreement also provides for options to extend the maturity date and borrowing availability for two additional six-month periods for the Revolving A Facility.

Borrowings made pursuant to the Revolving B Facility will bear interest, at our option, at one, two, three, or six months LIBOR plus an applicable margin ranging from 1.85% to 2.10% or at the Base Rate plus an applicable margin ranging from 0.85% to 1.10%.  The Credit Agreement defines “Base Rate” as the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%.  The initial applicable margin is 1.95% for LIBOR loans and 0.95% for Base Rate loans.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Revolving B Facility of the Credit Agreement.  The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At March 31, 2021, the applicable margin over the LIBOR rate was 1.95%, the margin over the Base Rate was 0.95% and the facility fee was 0.20%.  

At March 31, 2021, we had $247.7 million of outstanding borrowings and $5.6 million of letters of credit outstanding under our Credit Agreement.  We had $96.7 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2021. There are no compensating balance requirements. At December 31, 2020, we had $236.2 million of outstanding borrowings outstanding against our revolving credit agreement and $108.2 million of available borrowing capacity.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2021 and December 31, 2020. We also believe that we would remain in compliance if, based on the assumption that the majority of the potential new borrowings will be used to fund investments, the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

March 31,

2021

 

December 31,

2020

 

Tangible net worth

 

> =$125,000

 

$

147,654

 

$

147,263

 

Total leverage

 

< 60%

 

 

45.3

%

 

44.8

%

Secured leverage

 

< 30%

 

 

8.5

%

 

8.6

%

Unencumbered leverage

 

< 60%

 

 

43.3

%

 

41.4

%

Fixed charge coverage

 

> 1.50x

 

4.8x

 

4.7x

 

 

 

 

As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2021 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

$

5,381

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

5,449

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,474

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,538

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

12,984

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

2,789

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

8,656

 

 

 

3.95

%

 

January, 2030

Rosenberg Children's Medical Plaza fixed rate mortgage loan

 

 

12,450

 

 

 

4.42

%

 

September, 2033

Total, excluding net debt premium and net financing fees

 

 

58,721

 

 

 

 

 

 

 

     Less net financing fees

 

 

(447

)

 

 

 

 

 

 

     Plus net debt premium

 

 

129

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

58,403

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. 

The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages outstanding as of March 31, 2021 had a combined fair value of approximately $61.6 million.  At December 31, 2020, we had various mortgages, all of which were non-recourse to us, included in our condensed consolidated balance sheet. The combined outstanding balance of these various mortgages at December 31, 2020 was $59.2 million and had a combined fair value of approximately $62.0 million. The fair value of our debt was computed based upon quotes received from financial institutions.  We consider these to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments.  Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

Financial Instruments:

In March 2020, we entered into an interest rate swap agreement on a total notional amount of $55 million with a fixed interest rate of 0.565% that we designated as a cash flow hedge.  The interest rate swap became effective on March 25, 2020 and is scheduled to mature on March 25, 2027. If the one-month LIBOR is above 0.565%, the counterparty pays us, and if the one-month LIBOR is less than 0.565%, we pay the counterparty, the difference between the fixed rate of 0.565% and one-month LIBOR.

In January 2020, we entered into an interest rate swap agreement on a total notional amount of $35 million with a fixed interest rate of 1.4975% that we designated as a cash flow hedge.  The interest rate swap became effective on January 15, 2020 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.4975%, the counterparty pays us, and if the one-month LIBOR is less than 1.4975%, we pay the counterparty, the difference between the fixed rate of 1.4975% and one-month LIBOR.  

During the third quarter of 2019, we entered into an interest rate swap agreement on a total notional amount of $50 million with a fixed interest rate of 1.144% that we designated as a cash flow hedge. The interest rate swap became effective on September 16, 2019 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.144%, the counterparty pays us, and if the one-month LIBOR is less than 1.144%, we pay the counterparty, the difference between the fixed rate of 1.144% and one-month LIBOR.

We measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from third parties.  We consider those inputs to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. At March 31, 2021, the fair value of our interest rate swaps was a net liability of $467,000 which is included in accrued expenses and other liabilities on the accompanying condensed consolidated balance sheet. During the first quarter of 2021, we paid or accrued approximately $305,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps.  From inception of the swap agreements through March 31, 2021 we paid or accrued approximately $931,000 in net payments made to the counterparty by us pursuant to the terms of the swap (consisting of approximately $199,000 in payments or accruals made to us by the counterparty, offset by approximately $1.1 million of payments due to the counterparty from us).  Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or a liability, with a corresponding amount recorded in accumulated other

comprehensive income (“AOCI”) within shareholders’ equity.  Amounts are classified from AOCI to the income statement in the period or periods the hedged transaction affects earnings.

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Segment Reporting

(9) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  No individual property meets the requirements necessary to be considered its own segment.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Recent Accounting Pronouncements (Policies)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Recent Accounting Pronouncements

 

Accounting for Lease Concessions Granted in Connection with the COVID-19 Pandemic

On April 8, 2020, the Financial Accounting Standards Board ("FASB") held a public meeting and shortly afterwards issued a question-and-answer ("Q&A") document which was intended to provide accounting relief for lease concessions related to the COVID-19 pandemic. The accounting relief permits an entity to choose to forgo the evaluation of the enforceable rights and obligations of a lease contract, which is a requirement of Accounting Standards Codification Topic 842, Leases, which we adopted on January 1, 2019, as long as the total rent payments after the lease concessions are substantially the same, or less than, the total payments previously required by the lease. An entity may account for COVID-19 related lease concessions either (i) as if they were part of the enforceable rights and obligations of the parties under the existing lease contract; or (ii) as a lease modification. To the extent that a rent concession is granted as a deferral of payments, but the total lease payments are substantially the same, lessors are allowed to account for the concession as if no change had been made to the original lease contract.

      

Based on the Q&A, an entity is not required to account for all lease concessions related to the effects of the COVID-19 pandemic under one elected option, however, the entity is required to apply the elected option consistently to leases with similar characteristics and in similar circumstances. The COVID-19 pandemic did not start to adversely impact the economic conditions in the United States until late March 2020 and did not have a material effect on our operations or financial results during the three months ended March 31, 2021 or the year ended December 31, 2020.

Reference Rate Reform

In March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, “Reference Rate Reform.” The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. We will evaluate the impact of the guidance and may apply elections as applicable as additional changes in the market occur.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2026

 

 

5

 

(a.)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b.)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(b.)

 

(a.)

UHS has one 5-year renewal option at the existing lease rate (through 2031).  

(b.)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Summarized Financial Information of Equity Affiliates (Tables)
3 Months Ended
Mar. 31, 2021
Equity Method Investments And Joint Ventures [Abstract]  
Limited Liability Companies Accounted for Under Equity Method

The following property table represents the five LLCs/LPs in which we own a non-controlling interest and were accounted for under the equity method as of March 31, 2021:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)(e.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)(f.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

Grayson Properties II (d.)(f.)

 

 

95

%

 

Texoma Medical Plaza II

 

(a.)

This LLC has a third-party term loan of $9.2 million, which is non-recourse to us, outstanding as of March 31, 2021.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan of $13.3 million, which is non-recourse to us, outstanding as of March 31, 2021.

(c.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.4 million has been funded as of March 31, 2021. During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

(d.)

Construction on this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, none of which has been funded as of March 31, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $12.4 million as of March 31, 2021.

(e.)

The LLC is the lessee with a third-party lessor under a ground lease for land.

(f.)

These LPs are the lessees with UHS-related parties for the land related to these properties.

Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method Below are the condensed combined statements of income (unaudited) for the four LLCs/LPs accounted for under the equity method at March 31, 2021 and 2020.    

 

 

 

Three Months Ended

March 31,

 

 

 

2021

 

 

2020

 

 

 

(amounts in thousands)

 

Revenues

 

$

2,788

 

 

$

2,516

 

Operating expenses

 

 

1,107

 

 

 

1,028

 

Depreciation and amortization

 

 

521

 

 

 

442

 

Interest, net

 

 

431

 

 

 

318

 

Net income

 

$

729

 

 

$

728

 

Our share of net income

 

$

471

 

 

$

435

 

   

Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method

Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs/LPs that were accounted for under the equity method as of March 31, 2021 and December 31, 2020:

 

 

 

March 31,

2021

 

 

December 31,

2020

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

41,822

 

 

$

42,374

 

Other assets (a.)

 

 

8,817

 

 

 

8,818

 

Total assets

 

$

50,639

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Other liabilities (a.)

 

$

8,543

 

 

$

9,402

 

Mortgage notes payable, non-recourse to us

 

 

34,896

 

 

 

39,735

 

Advances payable to us (b.)

 

 

3,500

 

 

 

-

 

Equity

 

 

3,700

 

 

 

2,055

 

Total liabilities and equity

 

$

50,639

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Investments in LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

9,087

 

 

$

4,278

 

   Amounts included in accrued expenses and other liabilities

 

 

(2,700

)

 

 

(3,020

)

Our share of equity in LLCs, net

 

$

6,387

 

 

$

1,258

 

 

 

(a.)

Other assets and other liabilities as of both March 31, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.

 

(b.)

Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.  

 

Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

3/31/2021

 

 

12/31/2020

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan) (b.)

 

$

-

 

 

$

4,777

 

 

Repaid in Feb., 2021

Grayson Properties (5.034% fixed rate mortgage loan) (c.)

 

 

13,295

 

 

 

13,372

 

 

September, 2021

Brunswick Associates (3.64% fixed rate mortgage loan)

 

 

9,185

 

 

 

9,250

 

 

December, 2024

Grayson Properties II (3.70% fixed rate construction loan) (d.)

 

 

12,416

 

 

 

12,336

 

 

June, 2025

 

 

$

34,896

 

 

$

39,735

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

 

(b.)

Upon maturity in February, 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

 

(c.)

This loan is scheduled to mature within the next twelve months, at which time the entity intends to refinance pursuant to a new mortgage loan.

 

(d.)

This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Lease Accounting (Tables)
3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions

The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three month periods ended March 31, 2021 and 2020 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the lease term. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.

 

 

Three Months Ended

 

 

March 31,

 

 

2021

 

 

2020

 

UHS facilities:

 

 

 

 

 

 

 

Base rents

$

5,146

 

 

$

4,244

 

Bonus rents

 

1,695

 

 

 

1,380

 

Tenant reimbursements

 

291

 

 

 

257

 

Lease revenue - UHS facilities

$

7,132

 

 

$

5,881

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-related parties:

 

 

 

 

 

 

 

Base rents

 

10,505

 

 

 

10,378

 

Tenant reimbursements

 

2,587

 

 

 

2,464

 

Lease revenue - Non-related parties

$

13,092

 

 

$

12,842

 

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Debt and Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

March 31,

2021

 

December 31,

2020

 

Tangible net worth

 

> =$125,000

 

$

147,654

 

$

147,263

 

Total leverage

 

< 60%

 

 

45.3

%

 

44.8

%

Secured leverage

 

< 30%

 

 

8.5

%

 

8.6

%

Unencumbered leverage

 

< 60%

 

 

43.3

%

 

41.4

%

Fixed charge coverage

 

> 1.50x

 

4.8x

 

4.7x

 

 

Outstanding Mortgages, Excluding Net Debt Premium

As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2021 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

$

5,381

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

5,449

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,474

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,538

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

12,984

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

2,789

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

8,656

 

 

 

3.95

%

 

January, 2030

Rosenberg Children's Medical Plaza fixed rate mortgage loan

 

 

12,450

 

 

 

4.42

%

 

September, 2033

Total, excluding net debt premium and net financing fees

 

 

58,721

 

 

 

 

 

 

 

     Less net financing fees

 

 

(447

)

 

 

 

 

 

 

     Plus net debt premium

 

 

129

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

58,403

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. 

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.1
General - Additional Information (Detail)
Mar. 31, 2021
Property
4 Unconsolidated Limited Liability Companies / Limited Partner | Minimum  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Non-controlling equity interest, ownership percentage 33.00%
4 Unconsolidated Limited Liability Companies / Limited Partner | Maximum  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Non-controlling equity interest, ownership percentage 95.00%
Limited Liability Companies  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Number of real estate investments 5
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail)
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2019
Jul. 31, 2019
USD ($)
Time
Mar. 31, 2021
USD ($)
Property
Time
Lease
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Related Party Transaction [Line Items]          
Annual advisory fee as percentage of average invested real estate assets     0.70% 0.70%  
Grayson Properties Two L P | Denison Texas          
Related Party Transaction [Line Items]          
Non-controlling equity interest, ownership percentage 95.00%        
Universal Health Services, Inc          
Related Party Transaction [Line Items]          
Number of term renewal options | Time     6    
Additional renewal terms     5 years    
Number of medical office buildings and free standing emergency departments | Property     18    
Option to renew lease, notice period prior to termination date of current term     90 days    
Period to purchase respective leased facilities at same price after lease terms     180 days    
Renewal period of respective leased facilities at same price after lease terms     180 days    
Number of renewal options at existing lease rate | Time     3    
Lease revenue [1]     $ 7,132,000 $ 5,881,000  
Master flex lease term 10 years        
Percentage of rentable square feet 50.00%        
Number of ground leases | Lease     12    
Aggregate lease payments for 2021     $ 508,000    
Aggregate lease payments for 2022     508,000    
Aggregate lease payments for 2023     508,000    
Aggregate lease payments for 2024     508,000    
Aggregate lease payments for 2025     508,000    
Aggregate lease payments for thereafter     $ 29,000,000.0    
Percentage ownership of outstanding shares     5.70%   5.70%
Universal Health Services, Inc | Southwest Healthcare System, Inland Valley Campus          
Related Party Transaction [Line Items]          
Lease expiration date     Dec. 31, 2021    
Lease revenue     $ 1,100,000   $ 4,400,000
Universal Health Services, Inc | Base Rents          
Related Party Transaction [Line Items]          
Lease revenue     5,146,000 4,244,000  
Universal Health Services, Inc | Base Rents | Southwest Healthcare System, Inland Valley Campus          
Related Party Transaction [Line Items]          
Lease revenue     662,000   2,600,000
Universal Health Services, Inc | Bonus Rents          
Related Party Transaction [Line Items]          
Lease revenue     1,695,000 $ 1,380,000  
Universal Health Services, Inc | Bonus Rents | Southwest Healthcare System, Inland Valley Campus          
Related Party Transaction [Line Items]          
Lease revenue     $ 454,000   $ 1,800,000
Universal Health Services, Inc | Customer Concentration Risk | Revenues          
Related Party Transaction [Line Items]          
Percentage of revenues generated from leases and tenants     22.00% 22.00%  
Universal Health Services, Inc | Customer Concentration Risk | Revenues | Tenants          
Related Party Transaction [Line Items]          
Percentage of revenues generated from leases and tenants     36.00% 32.00%  
Universal Health Services, Inc | Hospital Facilities Leased          
Related Party Transaction [Line Items]          
Number of hospital facilities leased | Property     3    
Universal Health Services, Inc | Minimum          
Related Party Transaction [Line Items]          
Initial lease terms     13 years    
Remaining lease terms on ground leases     28 years    
Universal Health Services, Inc | Maximum          
Related Party Transaction [Line Items]          
Initial lease terms     15 years    
Remaining lease terms on ground leases     78 years    
Universal Health Services Inc And Catholic Health Initiatives          
Related Party Transaction [Line Items]          
Number of term renewal options | Time   5      
Option to renew lease, notice period prior to termination date of current term   270 days      
Renewal period of respective leased facilities at same price after lease terms   270 days      
Triple net lease agreement period   20 years      
Renewal option term   10 years      
Project manager's aggregate fee   $ 750,000      
Change in control of trust notice, description   upon 30 days’ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the JV decline to exercise its purchase right)      
Universal Health Services of Delaware Inc          
Related Party Transaction [Line Items]          
Advisory fee     $ 1,100,000 $ 1,000,000.0  
Cost, Product and Service [Extensible List]     Management Service Management Service  
Average invested real estate assets     $ 607,000,000 $ 581,000,000  
[1] Includes bonus rental on UHS hospital facilities of $1,695 and $1,380 for the three-month periods ended March 31, 2021 and 2020, respectively.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) - Universal Health Services, Inc
3 Months Ended
Mar. 31, 2021
USD ($)
McAllen Medical Center  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 5,485,000
End of Lease Term 2026-12
Renewal Term (years) 5 years [1]
Wellington Regional Medical Center  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 3,030,000
End of Lease Term 2021-12
Renewal Term (years) 10 years [2]
Southwest Healthcare System, Inland Valley Campus  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 2,648,000
End of Lease Term 2021-12
Renewal Term (years) 10 years [2]
[1] UHS has one 5-year renewal option at the existing lease rate (through 2031).  
[2] UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) - Universal Health Services, Inc
3 Months Ended
Mar. 31, 2021
Time
RenewalOption
Operating Leased Assets [Line Items]  
Number of renewal option at existing lease rate 3
McAllen Medical Center  
Operating Leased Assets [Line Items]  
Number of renewal option at existing lease rate 1
Renewal option term at existing lease rate 5 years
Renewal option at existing lease rate expiration year 2031
Wellington Regional Medical Center And Southwest Healthcare System  
Operating Leased Assets [Line Items]  
Number of renewal options at fair market value lease rates | RenewalOption 2
Renewal options term at fair market value lease rates 5 years
Wellington Regional Medical Center And Southwest Healthcare System | Minimum  
Operating Leased Assets [Line Items]  
Renewal options at fair market value lease rates expiration year 2022
Wellington Regional Medical Center And Southwest Healthcare System | Maximum  
Operating Leased Assets [Line Items]  
Renewal options at fair market value lease rates expiration year 2031
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Dividends and Equity Issuance Program - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Dividends and Equity Issuance [Line Items]      
Dividends declared and paid $ 9,564   $ 9,424
Declared and paid dividends, per share $ 0.695   $ 0.685
At-The-Market Equity Issuance Program (ATM)      
Dividends and Equity Issuance [Line Items]      
Aggregate sales of threshold amount   $ 100,000  
Issued (in shares) 0 2,704  
Average sale price per share   $ 101.30  
Net cash proceeds from stock issued   $ 270,000  
Payment of stock issuance cost   $ 4,000  
At-The-Market Equity Issuance Program (ATM) | Other Expenses      
Dividends and Equity Issuance [Line Items]      
Payments for stock issuance $ 507,000    
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Acquisitions and Dispositions - Additional Information (Detail)
3 Months Ended
Mar. 31, 2021
Acquisition
Disposition
Mar. 31, 2020
Acquisition
Disposition
Business Combinations [Abstract]    
Number of acquisitions | Acquisition 0 0
Number of dispositions | Disposition 0 0
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Summarized Financial Information of Equity Affiliates - Additional Information (Detail)
3 Months Ended
Mar. 31, 2021
Property
Limited Liability Companies | Medical office buildings  
Schedule Of Equity Method Investments [Line Items]  
Number of real estate investments 5
Minimum  
Schedule Of Equity Method Investments [Line Items]  
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member 60 days
Maximum  
Schedule Of Equity Method Investments [Line Items]  
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member 90 days
4 Unconsolidated Limited Liability Companies / Limited Partner | Minimum  
Schedule Of Equity Method Investments [Line Items]  
Non-controlling equity interest, ownership percentage 33.00%
4 Unconsolidated Limited Liability Companies / Limited Partner | Maximum  
Schedule Of Equity Method Investments [Line Items]  
Non-controlling equity interest, ownership percentage 95.00%
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Limited Liability Companies Accounted for Under Equity Method (Detail) - Equity Method Investments
3 Months Ended
Mar. 31, 2021
Suburban Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 33.00%
Property Owned by LLC/LP St. Matthews Medical Plaza II
Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Ownership 74.00% [1],[2]
Property Owned by LLC/LP Mid Coast Hospital MOB [1],[2]
Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [3],[4]
Property Owned by LLC/LP Texoma Medical Plaza [3],[4]
FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [5]
Property Owned by LLC/LP Forney Medical Plaza II [5]
Grayson Properties II LP  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [3],[6]
Property Owned by LLC/LP Texoma Medical Plaza II [3],[6]
[1] The LLC is the lessee with a third-party lessor under a ground lease for land.
[2] This LLC has a third-party term loan of $9.2 million, which is non-recourse to us, outstanding as of March 31, 2021.
[3] These LPs are the lessees with UHS-related parties for the land related to these properties.
[4] This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan of $13.3 million, which is non-recourse to us, outstanding as of March 31, 2021.
[5] We have committed to invest up to $2.5 million in equity and debt financing, of which $2.4 million has been funded as of March 31, 2021. During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.
[6] Construction on this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, none of which has been funded as of March 31, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $12.4 million as of March 31, 2021.
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail)
3 Months Ended
Mar. 31, 2021
USD ($)
Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan $ 9,200,000
FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Committed investment in equity and debt financing, funded 2,400,000
Member loan used to repay mortgage loan 3,500,000
Repayment of loan 4,700,000
FTX MOB Phase II limited partnership | Maximum  
Schedule Of Equity Method Investments [Line Items]  
Commitment to investment 2,500,000
Grayson Properties II LP  
Schedule Of Equity Method Investments [Line Items]  
Construction loan 13,100,000
Construction loan outstanding balance 12,400,000
Grayson Properties II LP | Maximum | Denison Texas  
Schedule Of Equity Method Investments [Line Items]  
Commitment to investment 4,800,000
Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan $ 13,300,000
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Schedule Of Equity Method Investments [Line Items]    
Revenues $ 20,699 $ 19,207
Net income 5,586 4,554
Our share of net income 471 435
Equity Method Investment, Nonconsolidated Investee or Group of Investees    
Schedule Of Equity Method Investments [Line Items]    
Revenues 2,788 2,516
Operating expenses 1,107 1,028
Depreciation and amortization 521 442
Interest, net 431 318
Net income 729 728
Our share of net income $ 471 $ 435
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2020
Dec. 31, 2019
Schedule Of Equity Method Investments [Line Items]        
Total Assets $ 495,794 $ 494,009    
Equity 158,667 159,005 $ 172,440 $ 181,734
Total Liabilities and Equity 495,794 494,009    
Investments in LLCs before amounts included in accrued expenses and other liabilities 9,087 4,278    
Equity Method Investment, Nonconsolidated Investee or Group of Investees        
Schedule Of Equity Method Investments [Line Items]        
Net property, including construction in progress 41,822 42,374    
Other assets [1] 8,817 8,818    
Total Assets 50,639 51,192    
Other liabilities [1] 8,543 9,402    
Mortgage notes payable, non-recourse to us 34,896 39,735    
Advances payable to us [2] 3,500      
Equity 3,700 2,055    
Total Liabilities and Equity 50,639 51,192    
Investments in LLCs before amounts included in accrued expenses and other liabilities 9,087 4,278    
Amounts included in accrued expenses and other liabilities (2,700) (3,020)    
Our share of equity in LLCs, net $ 6,387 $ 1,258    
[1] Other assets and other liabilities as of both March 31, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.
[2] Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Schedule Of Equity Method Investments [Line Items]    
Right-of-use land assets $ 8,907 $ 8,914
Right-of-use land liabilities 8,907 8,914
Limited Liability Companies    
Schedule Of Equity Method Investments [Line Items]    
Right-of-use land assets 4,300 4,300
Right-of-use land liabilities $ 4,300 $ 4,300
FTX MOB Phase II limited partnership    
Schedule Of Equity Method Investments [Line Items]    
Debt Instrument Maturity Date 2023-03  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) - Equity Method Investments - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 34,896 $ 39,735
FTX MOB Phase II    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1],[2]   4,777
Debt Instrument Maturity Date [2] 2021-02  
Grayson Properties    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1],[3] $ 13,295 13,372
Debt Instrument Maturity Date [3] 2021-09  
Brunswick Associates    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 9,185 9,250
Debt Instrument Maturity Date 2024-12  
Grayson Properties Two L P    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1],[4] $ 12,416 $ 12,336
Debt Instrument Maturity Date [4] 2025-06  
[1] All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity
[2] Upon maturity in February, 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.
[3]

This loan is scheduled to mature within the next twelve months, at which time the entity intends to refinance pursuant to a new mortgage loan.

[4] This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail)
$ in Millions
Mar. 31, 2021
USD ($)
Grayson Properties Two L P  
Schedule Of Equity Method Investments [Line Items]  
Construction loan $ 13.1
FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Member loan used to repay mortgage loan $ 3.5
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Non-Related Parties    
Leases Disclosure [Line Items]    
Lease revenue $ 13,092 $ 12,842
Non-Related Parties | Base Rents    
Leases Disclosure [Line Items]    
Lease revenue 10,505 10,378
Non-Related Parties | Tenant Reimbursements    
Leases Disclosure [Line Items]    
Lease revenue 2,587 2,464
Universal Health Services, Inc    
Leases Disclosure [Line Items]    
Lease revenue [1] 7,132 5,881
Universal Health Services, Inc | Base Rents    
Leases Disclosure [Line Items]    
Lease revenue 5,146 4,244
Universal Health Services, Inc | Bonus Rents    
Leases Disclosure [Line Items]    
Lease revenue 1,695 1,380
Universal Health Services, Inc | Tenant Reimbursements    
Leases Disclosure [Line Items]    
Lease revenue $ 291 $ 257
[1] Includes bonus rental on UHS hospital facilities of $1,695 and $1,380 for the three-month periods ended March 31, 2021 and 2020, respectively.
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Lease Accounting - Additional Information (Detail)
3 Months Ended 12 Months Ended
Mar. 31, 2021
USD ($)
Bed
Land
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Leases Disclosure [Line Items]      
Lessee in connection with ground leases for land | Land 14    
Right-of-use land assets $ 8,907,000   $ 8,914,000
Ground lease liabilities $ 8,907,000   8,914,000
Kindred Chicago Central Hospital Central Chicago, Illinois      
Leases Disclosure [Line Items]      
Lease expiration date Dec. 31, 2021    
Lease revenue $ 390,000   1,600,000
Number of beds in specialty hospital | Bed 95    
Evansville Rehabilitation Hospital Evansville, Indiana      
Leases Disclosure [Line Items]      
Lease expiration date May 31, 2019    
Corpus Christi Corpus Christi Texas      
Leases Disclosure [Line Items]      
Lease expiration date Jun. 01, 2019    
Universal Health Services, Inc      
Leases Disclosure [Line Items]      
Lease revenue [1] $ 7,132,000 $ 5,881,000  
Universal Health Services, Inc | Southwest Healthcare System, Inland Valley Campus      
Leases Disclosure [Line Items]      
Lease expiration date Dec. 31, 2021    
Lease revenue $ 1,100,000   4,400,000
Universal Health Services, Inc | Base Rents      
Leases Disclosure [Line Items]      
Lease revenue 5,146,000 4,244,000  
Universal Health Services, Inc | Base Rents | Southwest Healthcare System, Inland Valley Campus      
Leases Disclosure [Line Items]      
Lease revenue 662,000   2,600,000
Universal Health Services, Inc | Bonus Rents      
Leases Disclosure [Line Items]      
Lease revenue 1,695,000 $ 1,380,000  
Universal Health Services, Inc | Bonus Rents | Southwest Healthcare System, Inland Valley Campus      
Leases Disclosure [Line Items]      
Lease revenue $ 454,000   $ 1,800,000
[1] Includes bonus rental on UHS hospital facilities of $1,695 and $1,380 for the three-month periods ended March 31, 2021 and 2020, respectively.
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Debt and Financial Instruments - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 27, 2018
USD ($)
Option
Mar. 31, 2020
USD ($)
Derivative
Jan. 31, 2020
USD ($)
Derivative
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Derivative
Sep. 30, 2019
USD ($)
Derivative
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Debt Instrument [Line Items]                
Proceeds from lines of credit       $ 11,450,000 $ 6,250,000      
Outstanding borrowings under revolving credit agreement       247,650,000       $ 236,200,000
Letters of credit outstanding       5,600        
Available borrowing capacity       96,700,000       108,200,000
Compensating balance       0        
Interest Rate Swap | Cash Flow Hedge                
Debt Instrument [Line Items]                
Number of interest rate cap agreements | Derivative   1 1   1 1    
Derivative instruments, fixed rate   0.565% 1.4975%   0.565% 1.144%    
Notional amount   $ 55,000,000 $ 35,000,000   $ 55,000,000 $ 50,000,000    
Expiration date of interest rate   Mar. 25, 2027 Sep. 16, 2024     Sep. 16, 2024    
Level 2                
Debt Instrument [Line Items]                
Mortgage loan fair value       61,600,000       62,000,000.0
Mortgage debt               $ 59,200,000
Derivative interest rate cap, net payment received or accrued from counterparties       931,000        
Derivative interest rate cap, payment received or accrued from counterparties       199,000        
Derivative interest rate cap, offset due to counterparties       1,100,000        
Level 2 | Interest Rate Swap                
Debt Instrument [Line Items]                
Liability derivatives, fair value       467,000,000,000        
Derivative interest rate cap, net payment received or accrued from counterparties       305,000        
Credit Agreement                
Debt Instrument [Line Items]                
Outstanding borrowing       $ 350,000,000        
Credit Agreement                
Debt Instrument [Line Items]                
Outstanding borrowing $ 350,000,000              
Unsecured revolving amended credit agreement terminated date 2022-03              
Number of additional six month extension options | Option 2              
Credit Agreement | Swingline/Short-Term Loans                
Debt Instrument [Line Items]                
Outstanding borrowing $ 30,000,000              
Credit Agreement | Letters of Credit                
Debt Instrument [Line Items]                
Outstanding borrowing $ 40,000,000              
Revolving B Facility                
Debt Instrument [Line Items]                
Outstanding borrowing             $ 300,000,000  
Proceeds from lines of credit             50,000,000  
Increase in borrowing capacity             $ 350,000,000  
Credit facility, Interest Rate Terms       one, two, three, or six months LIBOR plus an applicable margin ranging from 1.85% to 2.10% or at the Base Rate plus an applicable margin ranging from 0.85% to 1.10%.        
Base rate description       the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%.        
Facility fee payable on commitment       0.20%        
Revolving B Facility | LIBOR                
Debt Instrument [Line Items]                
Margin points added to the reference rate 1.95%     1.95%        
Revolving B Facility | Base Rate                
Debt Instrument [Line Items]                
Margin points added to the reference rate 0.95%     0.95%        
Revolving B Facility | Minimum                
Debt Instrument [Line Items]                
Facility fee payable on commitment 0.15%              
Revolving B Facility | Minimum | LIBOR                
Debt Instrument [Line Items]                
Margin points added to the reference rate 1.85%              
Margin points added to the base rate 1.00%              
Revolving B Facility | Minimum | Base Rate                
Debt Instrument [Line Items]                
Margin points added to the reference rate 0.85%              
Revolving B Facility | Minimum | Federal Funds Effective Rate                
Debt Instrument [Line Items]                
Margin points added to the base rate 0.50%              
Revolving B Facility | Maximum                
Debt Instrument [Line Items]                
Facility fee payable on commitment 0.35%              
Revolving B Facility | Maximum | LIBOR                
Debt Instrument [Line Items]                
Margin points added to the reference rate 2.10%              
Revolving B Facility | Maximum | Base Rate                
Debt Instrument [Line Items]                
Margin points added to the reference rate 1.10%              
Revolving A Facility                
Debt Instrument [Line Items]                
Credit facility, Interest Rate Terms       one, two, three, or six-month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%.        
Base rate description       the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.        
Facility fee payable on commitment       0.20%        
Revolving A Facility | LIBOR                
Debt Instrument [Line Items]                
Margin points added to the reference rate       1.20%        
Revolving A Facility | Base Rate                
Debt Instrument [Line Items]                
Margin points added to the reference rate       0.20%        
Revolving A Facility | Minimum                
Debt Instrument [Line Items]                
Facility fee payable on commitment 0.15%              
Revolving A Facility | Minimum | LIBOR                
Debt Instrument [Line Items]                
Margin points added to the reference rate 1.10%              
Margin points added to the base rate 1.00%              
Revolving A Facility | Minimum | Base Rate                
Debt Instrument [Line Items]                
Margin points added to the reference rate 0.10%              
Revolving A Facility | Minimum | Federal Funds Effective Rate                
Debt Instrument [Line Items]                
Margin points added to the base rate 0.50%              
Revolving A Facility | Maximum                
Debt Instrument [Line Items]                
Facility fee payable on commitment 0.35%              
Revolving A Facility | Maximum | LIBOR                
Debt Instrument [Line Items]                
Margin points added to the reference rate 1.35%              
Revolving A Facility | Maximum | Base Rate                
Debt Instrument [Line Items]                
Margin points added to the reference rate 0.35%              
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Covenant, Tangible net worth $ 125,000  
Tangible net worth $ 147,654 $ 147,263
Total leverage 45.30% 44.80%
Secured leverage 8.50% 8.60%
Unencumbered leverage 43.30% 41.40%
Fixed charge coverage 4.80% 4.70%
Maximum    
Debt Instrument [Line Items]    
Covenant, Total leverage 60.00%  
Covenant, Secured leverage 30.00%  
Covenant, Unencumbered leverage 60.00%  
Minimum    
Debt Instrument [Line Items]    
Covenant, Fixed charge coverage 1.50%  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 58,721  
Less net financing fees [1] (447)  
Plus net debt premium [1] 129  
Total mortgages notes payable, non-recourse to us, net 58,403 [1] $ 58,895
700 Shadow Lane and Goldring MOBs Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 5,381  
Debt Instrument Interest Rate Stated Percentage 4.54%  
Debt Instrument Maturity Date 2022-06  
BRB Medical Office Building Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 5,449  
Debt Instrument Interest Rate Stated Percentage 4.27%  
Debt Instrument Maturity Date 2022-12  
Desert Valley Medical Center Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 4,474  
Debt Instrument Interest Rate Stated Percentage 3.62%  
Debt Instrument Maturity Date 2023-01  
2704 North Tenaya Way Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 6,538  
Debt Instrument Interest Rate Stated Percentage 4.95%  
Debt Instrument Maturity Date 2023-11  
Summerlin Hospital Medical Office Building III Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 12,984  
Debt Instrument Interest Rate Stated Percentage 4.03%  
Debt Instrument Maturity Date 2024-04  
Tuscan Professional Building Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 2,789  
Debt Instrument Interest Rate Stated Percentage 5.56%  
Debt Instrument Maturity Date 2025-06  
Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 8,656  
Debt Instrument Interest Rate Stated Percentage 3.95%  
Debt Instrument Maturity Date 2030-01  
Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 12,450  
Debt Instrument Interest Rate Stated Percentage 4.42%  
Debt Instrument Maturity Date 2033-09  
[1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting - Additional Information (Detail)
3 Months Ended
Mar. 31, 2021
Segment
Segment Reporting [Abstract]  
Number of reportable segments 1
EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 189 312 1 true 68 0 false 15 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Statements of Income Sheet http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Statements of Income (Parenthetical) Sheet http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical Condensed Consolidated Statements of Income (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Changes in Equity Sheet http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity Condensed Consolidated Statements of Changes in Equity Statements 7 false false R8.htm 100070 - Statement - Condensed Consolidated Statements of Changes in Equity (Parenthetical) Sheet http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityParenthetical Condensed Consolidated Statements of Changes in Equity (Parenthetical) Statements 8 false false R9.htm 100080 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 9 false false R10.htm 100090 - Disclosure - General Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneral General Notes 10 false false R11.htm 100100 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Notes 11 false false R12.htm 100110 - Disclosure - Dividends and Equity Issuance Program Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram Dividends and Equity Issuance Program Notes 12 false false R13.htm 100120 - Disclosure - Acquisitions and Dispositions Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureAcquisitionsAndDispositions Acquisitions and Dispositions Notes 13 false false R14.htm 100130 - Disclosure - Summarized Financial Information of Equity Affiliates Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates Summarized Financial Information of Equity Affiliates Notes 14 false false R15.htm 100140 - Disclosure - Recent Accounting Pronouncements Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 15 false false R16.htm 100150 - Disclosure - Lease Accounting Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccounting Lease Accounting Notes 16 false false R17.htm 100160 - Disclosure - Debt and Financial Instruments Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstruments Debt and Financial Instruments Notes 17 false false R18.htm 100170 - Disclosure - Segment Reporting Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureSegmentReporting Segment Reporting Notes 18 false false R19.htm 100180 - Disclosure - Recent Accounting Pronouncements (Policies) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureRecentAccountingPronouncementsPolicies Recent Accounting Pronouncements (Policies) Policies http://www.uhrit.com/20210331/taxonomy/role/DisclosureRecentAccountingPronouncements 19 false false R20.htm 100190 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Tables http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions 20 false false R21.htm 100200 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables Summarized Financial Information of Equity Affiliates (Tables) Tables http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates 21 false false R22.htm 100210 - Disclosure - Lease Accounting (Tables) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingTables Lease Accounting (Tables) Tables http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccounting 22 false false R23.htm 100220 - Disclosure - Debt and Financial Instruments (Tables) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables Debt and Financial Instruments (Tables) Tables http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstruments 23 false false R24.htm 100230 - Disclosure - General - Additional Information (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail General - Additional Information (Detail) Details 24 false false R25.htm 100240 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Details http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables 25 false false R26.htm 100250 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Details 26 false false R27.htm 100260 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Details 27 false false R28.htm 100270 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail Dividends and Equity Issuance Program - Additional Information (Detail) Details 28 false false R29.htm 100280 - Disclosure - Acquisitions and Dispositions - Additional Information (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureAcquisitionsAndDispositionsAdditionalInformationDetail Acquisitions and Dispositions - Additional Information (Detail) Details 29 false false R30.htm 100290 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Details 30 false false R31.htm 100300 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail Limited Liability Companies Accounted for Under Equity Method (Detail) Details 31 false false R32.htm 100310 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Details 32 false false R33.htm 100320 - Disclosure - Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail) Details 33 false false R34.htm 100330 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail) Details 34 false false R35.htm 100340 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) Details 35 false false R36.htm 100350 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) Notes http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) Details 36 false false R37.htm 100360 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail) Notes http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail) Details 37 false false R38.htm 100370 - Disclosure - Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) Details 38 false false R39.htm 100380 - Disclosure - Lease Accounting - Additional Information (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail Lease Accounting - Additional Information (Detail) Details 39 false false R40.htm 100390 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail Debt and Financial Instruments - Additional Information (Detail) Details 40 false false R41.htm 100400 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Details 41 false false R42.htm 100410 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Details 42 false false R43.htm 100420 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://www.uhrit.com/20210331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail Segment Reporting - Additional Information (Detail) Details 43 false false All Reports Book All Reports uht-10q_20210331.htm uht-20210331.xsd uht-20210331_cal.xml uht-20210331_def.xml uht-20210331_lab.xml uht-20210331_pre.xml uht-ex311_8.htm uht-ex312_6.htm uht-ex321_9.htm uht-ex322_7.htm http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 61 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "uht-10q_20210331.htm": { "axisCustom": 0, "axisStandard": 27, "contextCount": 189, "dts": { "calculationLink": { "local": [ "uht-20210331_cal.xml" ] }, "definitionLink": { "local": [ "uht-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "uht-10q_20210331.htm" ] }, "labelLink": { "local": [ "uht-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "uht-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml" ] }, "schema": { "local": [ "uht-20210331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 410, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 13, "http://www.uhrit.com/20210331": 16, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 33 }, "keyCustom": 82, "keyStandard": 230, "memberCustom": 41, "memberStandard": 21, "nsprefix": "uht", "nsuri": "http://www.uhrit.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - General", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneral", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions", "shortName": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Dividends and Equity Issuance Program", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram", "shortName": "Dividends and Equity Issuance Program", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Acquisitions and Dispositions", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAcquisitionsAndDispositions", "shortName": "Acquisitions and Dispositions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Summarized Financial Information of Equity Affiliates", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates", "shortName": "Summarized Financial Information of Equity Affiliates", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Recent Accounting Pronouncements", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRecentAccountingPronouncements", "shortName": "Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "uht:DisclosuresOfLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Lease Accounting", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccounting", "shortName": "Lease Accounting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "uht:DisclosuresOfLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Debt and Financial Instruments", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstruments", "shortName": "Debt and Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Segment Reporting", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Recent Accounting Pronouncements (Policies)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRecentAccountingPronouncementsPolicies", "shortName": "Recent Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Statements of Income", "role": "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome", "shortName": "Condensed Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions (Tables)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables", "shortName": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables", "shortName": "Summarized Financial Information of Equity Affiliates (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "uht:ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Lease Accounting (Tables)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingTables", "shortName": "Lease Accounting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "uht:ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "uht:ScheduleOfFinancialCovenantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Debt and Financial Instruments (Tables)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables", "shortName": "Debt and Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "uht:ScheduleOfFinancialCovenantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_srtRangeAxis_srtMinimumMember_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_uhtUnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - General - Additional Information (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "shortName": "General - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtLimitedLiabilityCompanyOrLimitedPartnerMember_20210331", "decimals": "INF", "lang": null, "name": "uht:NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction", "reportCount": 1, "unique": true, "unitRef": "U_uhtProperty", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "4", "first": true, "lang": null, "name": "uht:AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions - Additional Information (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "4", "first": true, "lang": null, "name": "uht:AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapMajorPropertyClassAxis_uhtMcAllenMedicalCenterMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesIncMember_20210331", "decimals": "0", "first": true, "lang": null, "name": "uht:OperatingLeasesAnnualFutureMinimumPaymentsReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "shortName": "Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapMajorPropertyClassAxis_uhtMcAllenMedicalCenterMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesIncMember_20210331", "decimals": "0", "first": true, "lang": null, "name": "uht:OperatingLeasesAnnualFutureMinimumPaymentsReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapMajorPropertyClassAxis_uhtMcAllenMedicalCenterMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesIncMember_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "uht:OperatingLeasesRenewalOptionsTermAtExistingLeaseRate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "shortName": "Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapMajorPropertyClassAxis_uhtMcAllenMedicalCenterMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesIncMember_20210101_20210331", "decimals": null, "first": true, "lang": "en-US", "name": "uht:OperatingLeasesRenewalOptionsTermAtExistingLeaseRate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfDividends", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail", "shortName": "Dividends and Equity Issuance Program - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfBusinessesAcquired", "reportCount": 1, "unique": true, "unitRef": "U_uhtAcquisition", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Acquisitions and Dispositions - Additional Information (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAcquisitionsAndDispositionsAdditionalInformationDetail", "shortName": "Acquisitions and Dispositions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfBusinessesAcquired", "reportCount": 1, "unique": true, "unitRef": "U_uhtAcquisition", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesHospitalIncMember_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "uht:BonusRentalIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Statements of Income (Parenthetical)", "role": "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical", "shortName": "Condensed Consolidated Statements of Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesHospitalIncMember_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "uht:BonusRentalIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapRealEstatePropertiesAxis_uhtMedicalOfficeBuildingsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtLimitedLiabilityCompanyOrLimitedPartnerMember_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "U_uhtProperty", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "shortName": "Summarized Financial Information of Equity Affiliates - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapRealEstatePropertiesAxis_uhtMedicalOfficeBuildingsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtLimitedLiabilityCompanyOrLimitedPartnerMember_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "U_uhtProperty", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_uhtSuburbanPropertiesMember_us-gaapFairValueByAssetClassAxis_us-gaapEquityMethodInvestmentsMember_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "shortName": "Limited Liability Companies Accounted for Under Equity Method (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_uhtSuburbanPropertiesMember_us-gaapFairValueByAssetClassAxis_us-gaapEquityMethodInvestmentsMember_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapRealEstatePropertiesAxis_uhtBrunswickAssociatesMember_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermLoansPayable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "shortName": "Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapRealEstatePropertiesAxis_uhtBrunswickAssociatesMember_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermLoansPayable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "shortName": "Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "shortName": "Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "uht:EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20210331", "decimals": "-3", "lang": null, "name": "uht:EquityMethodInvestmentSummarizedFinancialInformationAssetsPropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "shortName": "Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "span", "p", "td", "tr", "table", "div", "uht:EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtLimitedLiabilityCompanyOrLimitedPartnerMember_20210331", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapFairValueByAssetClassAxis_us-gaapEquityMethodInvestmentsMember_20210331", "decimals": "-3", "first": true, "lang": null, "name": "uht:EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "shortName": "Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapFairValueByAssetClassAxis_us-gaapEquityMethodInvestmentsMember_20210331", "decimals": "-3", "first": true, "lang": null, "name": "uht:EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapRealEstatePropertiesAxis_uhtGraysonPropertiesTwoLPMember_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConstructionLoan", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "shortName": "Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_srtCounterpartyNameAxis_uhtNonRelatedPartyMember_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Lease Accounting - Components of the \"Lease Revenue - UHS facilities\" and \"Lease Revenue - Non-related Parties\" Captions (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "shortName": "Lease Accounting - Components of the \"Lease Revenue - UHS facilities\" and \"Lease Revenue - Non-related Parties\" Captions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "uht:ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_srtCounterpartyNameAxis_uhtNonRelatedPartyMember_us-gaapLeaseContractualTermAxis_uhtBaseRentsMember_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "uht:NumberOfGroundLeasesForLand", "reportCount": 1, "unique": true, "unitRef": "U_uhtLand", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Lease Accounting - Additional Information (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "shortName": "Lease Accounting - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "uht:NumberOfGroundLeasesForLand", "reportCount": 1, "unique": true, "unitRef": "U_uhtLand", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLinesOfCredit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Debt and Financial Instruments - Additional Information (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "shortName": "Debt and Financial Instruments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-2", "lang": null, "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "uht:ScheduleOfFinancialCovenantsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-3", "first": true, "lang": null, "name": "uht:TangibleNetWorth", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail", "shortName": "Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "uht:ScheduleOfFinancialCovenantsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-3", "first": true, "lang": null, "name": "uht:TangibleNetWorth", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NonRecourseDebt", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "shortName": "Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NonRecourseDebt", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_uhtSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Segment Reporting - Additional Information (Detail)", "role": "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail", "shortName": "Segment Reporting - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_uhtSegment", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Changes in Equity", "role": "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "shortName": "Condensed Consolidated Statements of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "uht:DividendsPerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Changes in Equity (Parenthetical)", "role": "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityParenthetical", "shortName": "Condensed Consolidated Statements of Changes in Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "INF", "first": true, "lang": null, "name": "uht:DividendsPerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210331.htm", "contextRef": "C_0000798783_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } } }, "segmentCount": 68, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "verboseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "verboseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block]", "terseLabel": "Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r28", "r78", "r404" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of investment, including named security. Excludes consolidated entity.", "label": "Equity Method Investee Name [Domain]", "terseLabel": "Investment, Name" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r142", "r181", "r184", "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r199", "r200", "r280", "r281", "r282", "r283", "r284", "r285", "r305", "r350", "r354" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r199", "r200", "r280", "r281", "r282", "r283", "r284", "r285", "r305", "r350", "r354" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateLoanTypeAxis": { "auth_ref": [ "r382", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by type of loan for investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.", "label": "Mortgage Loans On Real Estate Loan Type [Axis]", "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type" } } }, "localname": "MortgageLoansOnRealEstateLoanTypeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateLoanTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of loan within investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.", "label": "Mortgage Loans On Real Estate Loan Type [Domain]", "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type" } } }, "localname": "MortgageLoansOnRealEstateLoanTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r142", "r181", "r184", "r353" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r138", "r181", "r182", "r306", "r349", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r138", "r181", "r182", "r306", "r349", "r351" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r189", "r199", "r200", "r280", "r281", "r282", "r283", "r284", "r285", "r305", "r350", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r189", "r199", "r200", "r280", "r281", "r282", "r283", "r284", "r285", "r305", "r350", "r354" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Information by name of investment, including named security. Excludes consolidated entity.", "label": "Schedule Of Equity Method Investment Equity Method Investee Name [Axis]", "terseLabel": "Investment, Name" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r139", "r140", "r181", "r183", "r352", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r139", "r140", "r181", "r183", "r352", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r401", "r403" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_AggregateSalesOfThresholdAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate sales of threshold amount.", "label": "Aggregate Sales Of Threshold Amount", "terseLabel": "Aggregate sales of threshold amount" } } }, "localname": "AggregateSalesOfThresholdAmount", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual advisory fees as percentage of average invested real estate assets.", "label": "Annual Advisory Fees As Percentage Of Average Invested Real Estate Assets", "terseLabel": "Annual advisory fee as percentage of average invested real estate assets" } } }, "localname": "AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "uht_AtMarketATMProgramsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shelf registration.", "label": "At Market A T M Programs [Member]", "terseLabel": "At-The-Market Equity Issuance Program (ATM)" } } }, "localname": "AtMarketATMProgramsMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_AverageInvestedRealEstateAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Average invested real estate assets.", "label": "Average Invested Real Estate Assets", "terseLabel": "Average invested real estate assets" } } }, "localname": "AverageInvestedRealEstateAssets", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_BRBMedicalOfficeBuildingFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BRB medical office building fixed rate mortgage loan.", "label": "B R B Medical Office Building Fixed Rate Mortgage Loan [Member]", "terseLabel": "BRB Medical Office Building Fixed Rate Mortgage Loan" } } }, "localname": "BRBMedicalOfficeBuildingFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_BaseRentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Base rents.", "label": "Base Rents [Member]", "terseLabel": "Base Rents" } } }, "localname": "BaseRentsMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_BonusRentalIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Bonus rental income.", "label": "Bonus Rental Income", "terseLabel": "Bonus rental" } } }, "localname": "BonusRentalIncome", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "uht_BonusRentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonus rents.", "label": "Bonus Rents [Member]", "terseLabel": "Bonus Rents" } } }, "localname": "BonusRentsMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_BrunswickAssociatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest", "label": "Brunswick Associates [Member]", "terseLabel": "Brunswick Associates" } } }, "localname": "BrunswickAssociatesMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "domainItemType" }, "uht_ChangeInControlOfTrustNoticePeriodDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in control of trust notice period, description.", "label": "Change In Control Of Trust Notice Period Description", "terseLabel": "Change in control of trust notice, description" } } }, "localname": "ChangeInControlOfTrustNoticePeriodDescription", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Components of lessor lease revenue with UHS facilities and non-related parties.", "label": "Components Of Lessor Lease Revenue With U H S Facilities And Non Related Parties Table [Text Block]", "terseLabel": "Components of the \"Lease Revenue - UHS facilities\" and \"Lease Revenue - Non-related Parties\" Captions" } } }, "localname": "ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingTables" ], "xbrltype": "textBlockItemType" }, "uht_ConstructionLoanOutstandingBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Construction loan outstanding balance.", "label": "Construction Loan Outstanding Balance", "terseLabel": "Construction loan outstanding balance" } } }, "localname": "ConstructionLoanOutstandingBalance", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "uht_CorpusChristiCorpusChristiTexasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corpus Christi Corpus Christi, Texas.", "label": "Corpus Christi Corpus Christi Texas [Member]", "terseLabel": "Corpus Christi Corpus Christi Texas" } } }, "localname": "CorpusChristiCorpusChristiTexasMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_CumulativeDividendsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative dividends.", "label": "Cumulative Dividends [Member]", "terseLabel": "Common stock" } } }, "localname": "CumulativeDividendsMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "uht_DebtAndFinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt and financial instruments disclosure.", "label": "Debt And Financial Instruments Disclosure [Text Block]", "terseLabel": "Debt and Financial Instruments" } } }, "localname": "DebtAndFinancialInstrumentsDisclosureTextBlock", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "uht_DebtInstrumentCovenantComplianceSecuredLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant compliance secured leverage ratio.", "label": "Debt Instrument Covenant Compliance Secured Leverage Ratio", "terseLabel": "Covenant, Secured leverage" } } }, "localname": "DebtInstrumentCovenantComplianceSecuredLeverageRatio", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_DebtInstrumentCovenantFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant fixed charge coverage ratio.", "label": "Debt Instrument Covenant Fixed Charge Coverage Ratio", "terseLabel": "Covenant, Fixed charge coverage" } } }, "localname": "DebtInstrumentCovenantFixedChargeCoverageRatio", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_DebtInstrumentCovenantLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant leverage ratio.", "label": "Debt Instrument Covenant Leverage Ratio", "terseLabel": "Covenant, Total leverage" } } }, "localname": "DebtInstrumentCovenantLeverageRatio", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_DebtInstrumentCovenantTangibleNetWorth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant tangible net worth.", "label": "Debt Instrument Covenant Tangible Net Worth", "terseLabel": "Covenant, Tangible net worth" } } }, "localname": "DebtInstrumentCovenantTangibleNetWorth", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "monetaryItemType" }, "uht_DebtInstrumentCovenantUnencumberedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant unencumbered leverage ratio.", "label": "Debt Instrument Covenant Unencumbered Leverage Ratio", "terseLabel": "Covenant, Unencumbered leverage" } } }, "localname": "DebtInstrumentCovenantUnencumberedLeverageRatio", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_DebtInstrumentMaturityMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, maturity, month and year.", "label": "Debt Instrument Maturity Month And Year", "terseLabel": "Debt Instrument Maturity Date" } } }, "localname": "DebtInstrumentMaturityMonthAndYear", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "gYearMonthItemType" }, "uht_DenisonTexasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denison, Texas.", "label": "Denison Texas [Member]", "terseLabel": "Denison Texas" } } }, "localname": "DenisonTexasMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_DerivativeInterestRateCapNetPaymentReceivedOrAccruedFromCounterParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative interest rate cap, net payment received or accrued from counter parties.", "label": "Derivative Interest Rate Cap Net Payment Received Or Accrued From Counter Parties", "terseLabel": "Derivative interest rate cap, net payment received or accrued from counterparties" } } }, "localname": "DerivativeInterestRateCapNetPaymentReceivedOrAccruedFromCounterParties", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_DerivativeInterestRateCapPaymentOffsetDueToCounterParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative interest rate cap payment offset due to counter parties.", "label": "Derivative Interest Rate Cap Payment Offset Due To Counter Parties", "terseLabel": "Derivative interest rate cap, offset due to counterparties" } } }, "localname": "DerivativeInterestRateCapPaymentOffsetDueToCounterParties", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_DerivativeInterestRateCapPaymentReceivedOrAccruedFromCounterParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative interest rate cap payment received or accrued from counter parties.", "label": "Derivative Interest Rate Cap Payment Received Or Accrued From Counter Parties", "terseLabel": "Derivative interest rate cap, payment received or accrued from counterparties" } } }, "localname": "DerivativeInterestRateCapPaymentReceivedOrAccruedFromCounterParties", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_DesertValleyMedicalCenterFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Desert valley medical center fixed rate mortgage loan.", "label": "Desert Valley Medical Center Fixed Rate Mortgage Loan [Member]", "terseLabel": "Desert Valley Medical Center Fixed Rate Mortgage Loan" } } }, "localname": "DesertValleyMedicalCenterFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_DisclosuresOfLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosures of leases.", "label": "Disclosures Of Leases [Text Block]", "terseLabel": "Lease Accounting" } } }, "localname": "DisclosuresOfLeasesTextBlock", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccounting" ], "xbrltype": "textBlockItemType" }, "uht_DividendsAndEquityIssuanceLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends and equity issuance.", "label": "Dividends And Equity Issuance [Line Items]", "terseLabel": "Dividends and Equity Issuance [Line Items]" } } }, "localname": "DividendsAndEquityIssuanceLineItems", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_DividendsAndEquityIssuanceTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends and equity issuance.", "label": "Dividends And Equity Issuance [Table]", "terseLabel": "Dividends And Equity Issuance [Table]" } } }, "localname": "DividendsAndEquityIssuanceTable", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_DividendsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends, per share.", "label": "Dividends Per Share", "terseLabel": "Dividend, per share" } } }, "localname": "DividendsPerShare", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "perShareItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationAdvancePaymentToLoansToRelatedParty": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10050.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial information advance payment to loans to related party.", "label": "Equity Method Investment Summarized Financial Information Advance Payment To Loans To Related Party", "terseLabel": "Advances payable to us" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationAdvancePaymentToLoansToRelatedParty", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationAssetsPropertyPlantAndEquipmentNet": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10070.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial information assets property plant and equipment net.", "label": "Equity Method Investment Summarized Financial Information Assets Property Plant And Equipment Net", "terseLabel": "Net property, including construction in progress" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationAssetsPropertyPlantAndEquipmentNet", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10030.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial information depreciation and amortization.", "label": "Equity Method Investment Summarized Financial Information Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationDepreciationAndAmortization", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationInterestExpense": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10040.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial information interest expense.", "label": "Equity Method Investment Summarized Financial Information Interest Expense", "terseLabel": "Interest, net" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationInterestExpense", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10040.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment Summarized Financial Information Mortgage Notes Payable", "label": "Equity Method Investment Summarized Financial Information Mortgage Notes Payable", "terseLabel": "Mortgage Loan Balance", "verboseLabel": "Mortgage notes payable, non-recourse to us" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10020.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment, summarized financial information, operating expenses.", "label": "Equity Method Investment Summarized Financial Information Operating Expenses", "terseLabel": "Operating expenses" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10080.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial information other assets.", "label": "Equity Method Investment Summarized Financial Information Other Assets", "terseLabel": "Other assets" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationOtherAssets", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment Summarized Financial Information Other Liabilities", "label": "Equity Method Investment Summarized Financial Information Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentsAccruedExpensesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10020.0, "parentTag": "us-gaap_EquityMethodInvestments", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity method investments accrued expenses and other liabilities.", "label": "Equity Method Investments Accrued Expenses And Other Liabilities", "negatedLabel": "Amounts included in accrued expenses and other liabilities" } } }, "localname": "EquityMethodInvestmentsAccruedExpensesAndOtherLiabilities", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investments Summarized Combined Balance Sheet Information.", "label": "Equity Method Investments Summarized Combined Balance Sheet Information Table [Text Block]", "terseLabel": "Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method" } } }, "localname": "EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "xbrltype": "textBlockItemType" }, "uht_EquityMethodInvestmentsSummarizedIncomeStatementInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investments Summarized Income Statement Information.", "label": "Equity Method Investments Summarized Income Statement Information Table [Text Block]", "terseLabel": "Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method" } } }, "localname": "EquityMethodInvestmentsSummarizedIncomeStatementInformationTableTextBlock", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "xbrltype": "textBlockItemType" }, "uht_EvansvilleRehabilitationHospitalEvansvilleIndianaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Evansville Rehabilitation Hospital Evansville, Indiana.", "label": "Evansville Rehabilitation Hospital Evansville Indiana [Member]", "terseLabel": "Evansville Rehabilitation Hospital Evansville, Indiana" } } }, "localname": "EvansvilleRehabilitationHospitalEvansvilleIndianaMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_FTXMobPhaseTwoLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest", "label": "F T X Mob Phase Two L P [Member]", "terseLabel": "FTX MOB Phase II limited partnership" } } }, "localname": "FTXMobPhaseTwoLPMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "domainItemType" }, "uht_FTXMobPhaseTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest", "label": "F T X Mob Phase Two [Member]", "terseLabel": "FTX MOB Phase II" } } }, "localname": "FTXMobPhaseTwoMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "uht_FederalFundsEffectiveRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal funds effective rate.", "label": "Federal Funds Effective Rate [Member]", "terseLabel": "Federal Funds Effective Rate" } } }, "localname": "FederalFundsEffectiveRateMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_FinancingFeesNet": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail": { "order": 11100.0, "parentTag": "us-gaap_SecuredDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing fees net.", "label": "Financing Fees Net", "negatedLabel": "Less net financing fees" } } }, "localname": "FinancingFeesNet", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "monetaryItemType" }, "uht_FixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed charge coverage ratio.", "label": "Fixed Charge Coverage Ratio", "terseLabel": "Fixed charge coverage" } } }, "localname": "FixedChargeCoverageRatio", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_FundedInvestmentCommitments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Funded investment commitments.", "label": "Funded Investment Commitments", "positiveLabel": "Committed investment in equity and debt financing, funded" } } }, "localname": "FundedInvestmentCommitments", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "uht_GraysonPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest", "label": "Grayson Properties [Member]", "terseLabel": "Grayson Properties" } } }, "localname": "GraysonPropertiesMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "domainItemType" }, "uht_GraysonPropertiesTwoLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grayson properties two LP.", "label": "Grayson Properties Two L P [Member]", "terseLabel": "Grayson Properties Two L P", "verboseLabel": "Grayson Properties II LP" } } }, "localname": "GraysonPropertiesTwoLPMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_IncreaseDecreaseInLeasingCosts": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in leasing costs.", "label": "Increase Decrease In Leasing Costs", "negatedLabel": "Leasing costs paid" } } }, "localname": "IncreaseDecreaseInLeasingCosts", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "uht_IncreaseDecreaseInTenantReservesDepositsDeferredAndPrepaidRents": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in tenant reserves, deposits, deferred and prepaid rents.", "label": "Increase Decrease In Tenant Reserves Deposits Deferred And Prepaid Rents", "terseLabel": "Tenant reserves, deposits and deferred and prepaid rents" } } }, "localname": "IncreaseDecreaseInTenantReservesDepositsDeferredAndPrepaidRents", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "uht_InitialLeaseExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial lease expiration period.", "label": "Initial Lease Expiration Period", "terseLabel": "Initial lease terms" } } }, "localname": "InitialLeaseExpirationPeriod", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_InvestmentCommitments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Commitments to invest.", "label": "Investment Commitments", "terseLabel": "Commitment to investment" } } }, "localname": "InvestmentCommitments", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "uht_KindredChicagoCentralHospitalCentralChicagoIllinoisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kindred Chicago Central Hospital Central Chicago, Illinois.", "label": "Kindred Chicago Central Hospital Central Chicago Illinois [Member]", "terseLabel": "Kindred Chicago Central Hospital Central Chicago, Illinois" } } }, "localname": "KindredChicagoCentralHospitalCentralChicagoIllinoisMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_LeaseAndOtherReceivables": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease and other receivables.", "label": "Lease And Other Receivables", "terseLabel": "Lease and other receivables from UHS" } } }, "localname": "LeaseAndOtherReceivables", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "uht_LeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease expiration, month and year.", "label": "Lease Expiration Month And Year", "verboseLabel": "End of Lease Term" } } }, "localname": "LeaseExpirationMonthAndYear", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "xbrltype": "gYearMonthItemType" }, "uht_LeaseReceivableOther": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease receivable, other.", "label": "Lease Receivable Other", "terseLabel": "Lease receivable - other" } } }, "localname": "LeaseReceivableOther", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "uht_LeaseRenewalNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease renewal, notice period.", "label": "Lease Renewal Notice Period", "terseLabel": "Option to renew lease, notice period prior to termination date of current term" } } }, "localname": "LeaseRenewalNoticePeriod", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_LeasesDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases Disclosure [Line Items]", "label": "Leases Disclosure [Line Items]", "terseLabel": "Leases Disclosure [Line Items]" } } }, "localname": "LeasesDisclosureLineItems", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail" ], "xbrltype": "stringItemType" }, "uht_LeasesDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases Disclosure [Table]", "label": "Leases Disclosure [Table]", "terseLabel": "Leases Disclosure [Table]" } } }, "localname": "LeasesDisclosureTable", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail" ], "xbrltype": "stringItemType" }, "uht_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "verboseLabel": "Aggregate lease payments for thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_LeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leverage ratio.", "label": "Leverage Ratio", "terseLabel": "Total leverage" } } }, "localname": "LeverageRatio", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_LimitedLiabilityCompanyOrLimitedPartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Limited liability company or limited partner.", "label": "Limited Liability Company Or Limited Partner [Member]", "terseLabel": "Limited Liability Companies" } } }, "localname": "LimitedLiabilityCompanyOrLimitedPartnerMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_LineOfCreditFacilityExpirationYearAndMonth": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility expiration year and month.", "label": "Line Of Credit Facility Expiration Year And Month", "terseLabel": "Unsecured revolving amended credit agreement terminated date" } } }, "localname": "LineOfCreditFacilityExpirationYearAndMonth", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "uht_LineOfCreditIncreaseInBorrowingCapacity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Line of credit increase in borrowing capacity.", "label": "Line Of Credit Increase In Borrowing Capacity", "terseLabel": "Increase in borrowing capacity" } } }, "localname": "LineOfCreditIncreaseInBorrowingCapacity", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_MarginOnBaseRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Margin on base rate.", "label": "Margin On Base Rate", "terseLabel": "Margin points added to the base rate" } } }, "localname": "MarginOnBaseRate", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "uht_MasterFlexLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master flex lease term.", "label": "Master Flex Lease Term", "terseLabel": "Master flex lease term" } } }, "localname": "MasterFlexLeaseTerm", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_McAllenMedicalCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UHS-related hospital facility.", "label": "Mc Allen Medical Center [Member]", "terseLabel": "McAllen Medical Center" } } }, "localname": "McAllenMedicalCenterMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "domainItemType" }, "uht_MedicalOfficeBuildingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical office buildings.", "label": "Medical Office Buildings [Member]", "terseLabel": "Medical office buildings" } } }, "localname": "MedicalOfficeBuildingsMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_MemberLoanUsedToRepayMortgageLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Member loan used to repay mortgage loan.", "label": "Member Loan Used To Repay Mortgage Loan", "terseLabel": "Member loan used to repay mortgage loan" } } }, "localname": "MemberLoanUsedToRepayMortgageLoan", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "uht_MortgageDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Mortgage debt.", "label": "Mortgage Debt", "terseLabel": "Mortgage debt" } } }, "localname": "MortgageDebt", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_NonRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non related party.", "label": "Non Related Party [Member]", "terseLabel": "Non-Related Parties" } } }, "localname": "NonRelatedPartyMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "uht_NumberOfBedInSpecialtyHospital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of bed in specialty hospital.", "label": "Number Of Bed In Specialty Hospital", "terseLabel": "Number of beds in specialty hospital" } } }, "localname": "NumberOfBedInSpecialtyHospital", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfBusinessesDisposed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of businesses disposed.", "label": "Number Of Businesses Disposed", "verboseLabel": "Number of dispositions" } } }, "localname": "NumberOfBusinessesDisposed", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of extension options.", "label": "Number Of Extension Options", "terseLabel": "Number of additional six month extension options" } } }, "localname": "NumberOfExtensionOptions", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfGroundLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ground leases.", "label": "Number Of Ground Leases", "terseLabel": "Number of ground leases" } } }, "localname": "NumberOfGroundLeases", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfGroundLeasesForLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ground leases for land.", "label": "Number Of Ground Leases For Land", "terseLabel": "Lessee in connection with ground leases for land" } } }, "localname": "NumberOfGroundLeasesForLand", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfLeasedPropertiesForMedicalOfficeBuildingsAndFreeStandingEmergencyDepartments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of leased properties for medical office buildings and free standing emergency departments.", "label": "Number Of Leased Properties For Medical Office Buildings And Free Standing Emergency Departments", "terseLabel": "Number of medical office buildings and free standing emergency departments" } } }, "localname": "NumberOfLeasedPropertiesForMedicalOfficeBuildingsAndFreeStandingEmergencyDepartments", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of real estate properties including property under construction.", "label": "Number Of Real Estate Properties Including Property Under Construction", "terseLabel": "Number of real estate investments" } } }, "localname": "NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of renewal options.", "label": "Number Of Renewal Options", "terseLabel": "Number of term renewal options" } } }, "localname": "NumberOfRenewalOptions", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfTradingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading period.", "label": "Number Of Trading Period", "terseLabel": "Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member" } } }, "localname": "NumberOfTradingPeriod", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_OperatingLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease remaining lease term.", "label": "Operating Lease Remaining Lease Term", "terseLabel": "Remaining lease terms on ground leases" } } }, "localname": "OperatingLeaseRemainingLeaseTerm", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_OperatingLeasesAnnualFutureMinimumPaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating leases, annual future minimum payments receivable.", "label": "Operating Leases Annual Future Minimum Payments Receivable", "terseLabel": "Annual Minimum Rent" } } }, "localname": "OperatingLeasesAnnualFutureMinimumPaymentsReceivable", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "xbrltype": "monetaryItemType" }, "uht_OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, number of renewal options at existing lease rates.", "label": "Operating Leases Number Of Renewal Options At Existing Lease Rates", "terseLabel": "Number of renewal options at existing lease rate", "verboseLabel": "Number of renewal option at existing lease rate" } } }, "localname": "OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "positiveIntegerItemType" }, "uht_OperatingLeasesNumberOfRenewalOptionsAtFairMarketValueLeaseRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, number of renewal options at fair market value lease rates.", "label": "Operating Leases Number Of Renewal Options At Fair Market Value Lease Rates", "terseLabel": "Number of renewal options at fair market value lease rates" } } }, "localname": "OperatingLeasesNumberOfRenewalOptionsAtFairMarketValueLeaseRates", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "positiveIntegerItemType" }, "uht_OperatingLeasesRenewalOptionsAtExistingLeaseRateExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, renewal options at existing lease rate, expiration year.", "label": "Operating Leases Renewal Options At Existing Lease Rate Expiration Year", "terseLabel": "Renewal option at existing lease rate expiration year" } } }, "localname": "OperatingLeasesRenewalOptionsAtExistingLeaseRateExpirationYear", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "gYearItemType" }, "uht_OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, renewal options at fair market value lease rates, expiration year.", "label": "Operating Leases Renewal Options At Fair Market Value Lease Rates Expiration Year", "terseLabel": "Renewal options at fair market value lease rates expiration year" } } }, "localname": "OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "gYearItemType" }, "uht_OperatingLeasesRenewalOptionsTermAtExistingLeaseRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, renewal options term at existing lease rate.", "label": "Operating Leases Renewal Options Term At Existing Lease Rate", "terseLabel": "Renewal option term at existing lease rate" } } }, "localname": "OperatingLeasesRenewalOptionsTermAtExistingLeaseRate", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "durationItemType" }, "uht_OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, renewal options term at fair market value lease rates.", "label": "Operating Leases Renewal Options Term At Fair Market Value Lease Rates", "terseLabel": "Renewal options term at fair market value lease rates" } } }, "localname": "OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "durationItemType" }, "uht_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_PaymentsForStockIssuanceOtherFeesAndExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for stock issuance other fees and expenses.", "label": "Payments For Stock Issuance Other Fees And Expenses", "terseLabel": "Payments for stock issuance" } } }, "localname": "PaymentsForStockIssuanceOtherFeesAndExpenses", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_PercentageOfOwnershipInterestRelatedParties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership interest related parties.", "label": "Percentage Of Ownership Interest Related Parties", "terseLabel": "Percentage ownership of outstanding shares" } } }, "localname": "PercentageOfOwnershipInterestRelatedParties", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "uht_PercentageOfRentableSquareFeet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of rentable square feet.", "label": "Percentage Of Rentable Square Feet", "terseLabel": "Percentage of rentable square feet" } } }, "localname": "PercentageOfRentableSquareFeet", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "uht_PeriodToPurchaseRespectiveLeasedFacilitiesAfterLeaseTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period to purchase respective leased facilities after lease terms.", "label": "Period To Purchase Respective Leased Facilities After Lease Terms", "terseLabel": "Period to purchase respective leased facilities at same price after lease terms" } } }, "localname": "PeriodToPurchaseRespectiveLeasedFacilitiesAfterLeaseTerms", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phoenix children's east valley care center fixed rate mortgage loan.", "label": "Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan [Member]", "terseLabel": "Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan" } } }, "localname": "PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_PropertyOwnedByLimitedLiabilityOrLimitedPartnerCompany": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property owned by limited liability or limited partner company.", "label": "Property Owned By Limited Liability Or Limited Partner Company", "terseLabel": "Property Owned by LLC/LP" } } }, "localname": "PropertyOwnedByLimitedLiabilityOrLimitedPartnerCompany", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "xbrltype": "stringItemType" }, "uht_RenewalOptionTermsAdditionalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renewal option terms additional period.", "label": "Renewal Option Terms Additional Period", "terseLabel": "Additional renewal terms" } } }, "localname": "RenewalOptionTermsAdditionalPeriod", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_RenewalOptionTermsMaximumAdditionalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renewal option terms maximum additional period.", "label": "Renewal Option Terms Maximum Additional Period", "terseLabel": "Renewal period of respective leased facilities at same price after lease terms" } } }, "localname": "RenewalOptionTermsMaximumAdditionalPeriod", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_RenewalOptionsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renewal options term.", "label": "Renewal Options Term", "terseLabel": "Renewal option term" } } }, "localname": "RenewalOptionsTerm", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_RepaymentOfLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of loan.", "label": "Repayment Of Loan", "terseLabel": "Repayment of loan" } } }, "localname": "RepaymentOfLoan", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "uht_RevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue.", "label": "Revenue [Member]", "terseLabel": "Revenues" } } }, "localname": "RevenueMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_RevolvingAFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving A facility.", "label": "Revolving A Facility [Member]", "terseLabel": "Revolving A Facility" } } }, "localname": "RevolvingAFacilityMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_RevolvingBFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving B facility.", "label": "Revolving B Facility [Member]", "terseLabel": "Revolving B Facility" } } }, "localname": "RevolvingBFacilityMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_RevolvingCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving credit agreement.", "label": "Revolving Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "RevolvingCreditAgreementMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rosenberg children's medical plaza fixed rate mortgage loan.", "label": "Rosenberg Children Medical Plaza Fixed Rate Mortgage Loan [Member]", "terseLabel": "Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan" } } }, "localname": "RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_ScheduleOfFinancialCovenantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Financial Covenants.", "label": "Schedule Of Financial Covenants Table [Text Block]", "terseLabel": "Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement" } } }, "localname": "ScheduleOfFinancialCovenantsTableTextBlock", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "uht_SecuredLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured leverage ratio.", "label": "Secured Leverage Ratio", "terseLabel": "Secured leverage" } } }, "localname": "SecuredLeverageRatio", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seven hundred shadow lane and goldring medical office building fixed rate mortgage loan.", "label": "Seven Hundred Shadow Lane And Goldring Medical Office Building Fixed Rate Mortgage Loan [Member]", "terseLabel": "700 Shadow Lane and Goldring MOBs Fixed Rate Mortgage Loan" } } }, "localname": "SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_SharesIssuedAveragePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued average price per share.", "label": "Shares Issued Average Price Per Share", "terseLabel": "Average sale price per share" } } }, "localname": "SharesIssuedAveragePricePerShare", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "uht_SharesOfBeneficialInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of beneficial interest.", "label": "Shares Of Beneficial Interest [Abstract]", "terseLabel": "Shares of Beneficial Interest:" } } }, "localname": "SharesOfBeneficialInterestAbstract", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "uht_SouthwestHealthcareSystemInlandValleyCampusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UHS-related hospital facility.", "label": "Southwest Healthcare System Inland Valley Campus [Member]", "terseLabel": "Southwest Healthcare System, Inland Valley Campus" } } }, "localname": "SouthwestHealthcareSystemInlandValleyCampusMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_SuburbanPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest", "label": "Suburban Properties [Member]", "terseLabel": "Suburban Properties" } } }, "localname": "SuburbanPropertiesMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "uht_SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summerlin hospital medical office building three fixed rate mortgage loan.", "label": "Summerlin Hospital Medical Office Building Three Fixed Rate Mortgage Loan [Member]", "terseLabel": "Summerlin Hospital Medical Office Building III Fixed Rate Mortgage Loan" } } }, "localname": "SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_TangibleNetWorth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tangible net worth.", "label": "Tangible Net Worth", "terseLabel": "Tangible net worth" } } }, "localname": "TangibleNetWorth", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "monetaryItemType" }, "uht_TenantReimbursementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tenant reimbursements.", "label": "Tenant Reimbursements [Member]", "terseLabel": "Tenant Reimbursements" } } }, "localname": "TenantReimbursementsMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail" ], "xbrltype": "domainItemType" }, "uht_TenantReservesDepositsAndDeferredAndPrepaidRents": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount at the balance sheet date that has been received by the entity that represents collections of cash or other assets related to real estate operations revenue for which revenue has not yet been recognized and money paid in advance to protect the provider of a product or services, such as a lessor, against damage or non-payment by the tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property and other contractual breaches.", "label": "Tenant Reserves Deposits And Deferred And Prepaid Rents", "terseLabel": "Tenant reserves, deposits and deferred and prepaid rents" } } }, "localname": "TenantReservesDepositsAndDeferredAndPrepaidRents", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "uht_TenantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tenants.", "label": "Tenants [Member]", "terseLabel": "Tenants" } } }, "localname": "TenantsMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_TripleNetLeaseAgreementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Triple net lease agreement period.", "label": "Triple Net Lease Agreement Period", "terseLabel": "Triple net lease agreement period" } } }, "localname": "TripleNetLeaseAgreementPeriod", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_TuscanyProfessionalBuildingFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument 100% consolidated", "label": "Tuscany Professional Building Fixed Rate Mortgage Loan [Member]", "terseLabel": "Tuscan Professional Building Fixed Rate Mortgage Loan" } } }, "localname": "TuscanyProfessionalBuildingFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two seven zero four north Tenaya way fixed rate mortgage loan.", "label": "Two Seven Zero Four North Tenaya Way Fixed Rate Mortgage Loan [Member]", "terseLabel": "2704 North Tenaya Way Fixed Rate Mortgage Loan" } } }, "localname": "TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unconsolidated limited liabilities or limited partner.", "label": "Unconsolidated Limited Liabilities Or Limited Partner [Member]", "terseLabel": "4 Unconsolidated Limited Liability Companies / Limited Partner" } } }, "localname": "UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_UnencumberedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unencumbered leverage ratio.", "label": "Unencumbered Leverage Ratio", "terseLabel": "Unencumbered leverage" } } }, "localname": "UnencumberedLeverageRatio", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_UniversalHealthServicesHospitalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Universal health services hospital Inc.", "label": "Universal Health Services Hospital Inc [Member]", "terseLabel": "UHS Hospital Facilities" } } }, "localname": "UniversalHealthServicesHospitalIncMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "domainItemType" }, "uht_UniversalHealthServicesIncAndCatholicHealthInitiativesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Universal Health Services, Inc and Catholic Health Initiatives.", "label": "Universal Health Services Inc And Catholic Health Initiatives [Member]", "terseLabel": "Universal Health Services Inc And Catholic Health Initiatives" } } }, "localname": "UniversalHealthServicesIncAndCatholicHealthInitiativesMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_UniversalHealthServicesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related-party principal tenant.", "label": "Universal Health Services Inc [Member]", "terseLabel": "Universal Health Services, Inc", "verboseLabel": "UHS Facilities" } } }, "localname": "UniversalHealthServicesIncMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "uht_UniversalHealthServicesOfDelawareIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wholly-owned subsidiary of Universal Health Services, Inc.; Advisor to UHT", "label": "Universal Health Services Of Delaware Inc [Member]", "terseLabel": "Universal Health Services of Delaware Inc" } } }, "localname": "UniversalHealthServicesOfDelawareIncMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UHS-related hospital facility.", "label": "Wellington Regional Medical Center And Southwest Healthcare System [Member]", "terseLabel": "Wellington Regional Medical Center And Southwest Healthcare System" } } }, "localname": "WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "domainItemType" }, "uht_WellingtonRegionalMedicalCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UHS-related hospital facility.", "label": "Wellington Regional Medical Center [Member]", "terseLabel": "Wellington Regional Medical Center" } } }, "localname": "WellingtonRegionalMedicalCenterMember", "nsuri": "http://www.uhrit.com/20210331", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities And Other Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r12", "r32", "r33", "r34", "r338", "r359", "r362" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive (loss)/income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r31", "r34", "r35", "r81", "r82", "r83", "r221", "r355", "r356" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated other comprehensive income/(loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r10" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Capital in excess of par value" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r81", "r82", "r83", "r201", "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Common stock" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition", "terseLabel": "Restricted stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfAboveAndBelowMarketLeases": { "auth_ref": [ "r67" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of non-cash amortization of intangible asset (liability) for above and below market leases.", "label": "Amortization Of Above And Below Market Leases", "terseLabel": "Amortization related to above/below market leases, net" } } }, "localname": "AmortizationOfAboveAndBelowMarketLeases", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r52", "r67", "r253" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization Of Debt Discount Premium", "terseLabel": "Amortization of debt premium" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r48", "r67", "r255" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization Of Financing Costs", "terseLabel": "Amortization of deferred financing costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r76", "r123", "r128", "r134", "r151", "r216", "r222", "r245", "r322", "r336" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsLeasedToOthersMember": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable property, plant or equipment held for lease to others under contractual agreements meeting the criteria for operating lease classification.", "label": "Assets Leased To Others [Member]", "terseLabel": "Hospital Facilities Leased" } } }, "localname": "AssetsLeasedToOthersMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r16", "r69" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r63", "r69", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r63", "r246" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Increase/(decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedge" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock Dividends Per Share Cash Paid", "terseLabel": "Declared and paid dividends, per share" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common shares, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common shares, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r173" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r9" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2021 - 13,772,095; 2020 - 13,771,287" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensatingBalanceAmount": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.", "label": "Compensating Balance Amount", "terseLabel": "Compensating balance" } } }, "localname": "CompensatingBalanceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r38", "r40", "r41", "r46", "r329", "r347" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Total comprehensive income/(loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r38", "r40", "r45", "r214", "r226", "r328", "r346" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest", "totalLabel": "Subtotal - comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest [Abstract]", "terseLabel": "Comprehensive income:" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r113", "r114", "r142", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r113", "r114", "r142", "r243", "r244", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r113", "r114", "r142", "r243", "r244", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r113", "r114", "r142", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "verboseLabel": "Percentage of revenues generated from leases and tenants" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r113", "r114", "r142", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r71", "r72", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for construction in progress expenditures that have occurred.", "label": "Construction In Progress Expenditures Incurred But Not Yet Paid", "terseLabel": "Invoices accrued for construction and improvements" } } }, "localname": "ConstructionInProgressExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionLoan": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans.", "label": "Construction Loan", "terseLabel": "Construction loan" } } }, "localname": "ConstructionLoan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r50", "r306" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10070.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost Of Goods And Services Sold", "positiveTerseLabel": "Advisory fee", "terseLabel": "Advisory fees to UHS" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r49" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10050.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs And Expenses", "totalLabel": "Costs and Expenses, Total" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs And Expenses [Abstract]", "terseLabel": "Expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeDividends": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative cash dividends distributed to shareholders.", "label": "Cumulative Dividends", "negatedLabel": "Cumulative dividends" } } }, "localname": "CumulativeDividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r112", "r142" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Margin points added to the reference rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.", "label": "Debt Instrument Description Of Variable Rate Basis", "terseLabel": "Base rate description" } } }, "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Debt Instrument Interest Rate Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt Instrument Interest Rate Terms", "terseLabel": "Credit facility, Interest Rate Terms" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r25", "r79", "r174", "r175", "r176", "r177", "r253", "r254", "r256", "r334" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedPremium": { "auth_ref": [ "r253", "r256" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail": { "order": 11110.0, "parentTag": "us-gaap_SecuredDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt premium.", "label": "Debt Instrument Unamortized Premium", "verboseLabel": "Plus net debt premium" } } }, "localname": "DebtInstrumentUnamortizedPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost assets and assets classified as other.", "label": "Deferred Costs And Other Assets", "terseLabel": "Deferred charges and other assets, net" } } }, "localname": "DeferredCostsAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r67", "r169" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10060.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r67", "r121" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract Type [Domain]", "terseLabel": "Derivative Contract" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r27", "r29", "r233", "r287" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Fair Value Of Derivative Liability", "terseLabel": "Liability derivatives, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative Fixed Interest Rate", "terseLabel": "Derivative instruments, fixed rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r232", "r234", "r235", "r238" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument Risk [Axis]", "terseLabel": "Derivative Instrument" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r231", "r232", "r235" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Derivative Instruments Gain Loss By Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeMaturityDates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the derivative contract matures, in CCYY-MM-DD format.", "label": "Derivative Maturity Dates", "terseLabel": "Expiration date of interest rate" } } }, "localname": "DerivativeMaturityDates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "auth_ref": [ "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "The number of derivative instruments of a particular group held by the entity.", "label": "Derivative Number Of Instruments Held", "terseLabel": "Number of interest rate cap agreements" } } }, "localname": "DerivativeNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r178", "r333" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r47", "r90", "r91", "r92", "r93", "r94", "r101", "r103", "r105", "r106", "r107", "r108", "r109", "r330", "r348" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "terseLabel": "Basic earnings per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r47", "r90", "r91", "r92", "r93", "r94", "r103", "r105", "r106", "r107", "r108", "r109", "r330", "r348" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Diluted earnings per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r81", "r82", "r83", "r87", "r95", "r97", "r111", "r154", "r173", "r178", "r201", "r202", "r203", "r206", "r207", "r247", "r248", "r249", "r250", "r251", "r252", "r355", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r0", "r76", "r151", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment Nonconsolidated Investee [Axis]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r0", "r76", "r151", "r245" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment Nonconsolidated Investee [Domain]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "auth_ref": [ "r0", "r76", "r151", "r245" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment Nonconsolidated Investee Or Group Of Investees [Member]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage", "positiveLabel": "Ownership", "terseLabel": "Non-controlling equity interest, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r17", "r124", "r148" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "totalLabel": "Our share of equity in LLCs, net" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments And Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments Disclosure [Text Block]", "terseLabel": "Summarized Financial Information of Equity Affiliates" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsMember": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.", "label": "Equity Method Investments [Member]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Text Block]", "terseLabel": "Limited Liability Companies Accounted for Under Equity Method" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r239", "r242" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r198", "r240", "r277", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r190", "r191", "r196", "r198", "r240", "r278" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r198", "r277", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r145", "r146", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Accumulated Amortization", "terseLabel": "Intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r43", "r67", "r122", "r148", "r326", "r344" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income Loss From Equity Method Investments", "terseLabel": "Equity in income of unconsolidated LLCs", "verboseLabel": "Our share of net income" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r66" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase Decrease In Accrued Interest Receivable Net", "negatedLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r66" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInLeasingReceivables": { "auth_ref": [ "r66" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements.", "label": "Increase Decrease In Leasing Receivables", "negatedLabel": "Lease receivable" } } }, "localname": "IncreaseDecreaseInLeasingReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r66" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase Decrease In Other Operating Capital Net", "negatedLabel": "Other, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r166", "r167" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets Net Excluding Goodwill", "terseLabel": "Intangible assets (net of accumulated amortization of $19.0 million and $19.5 million, respectively)" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r331" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income Expense Net", "terseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r61", "r64", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r325", "r343" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable Current And Noncurrent", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r378", "r379", "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r378", "r379", "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesAtFairValue": { "auth_ref": [ "r375", "r376", "r377" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10010.0, "parentTag": "us-gaap_EquityMethodInvestments", "weight": 1.0 }, "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Investments In And Advances To Affiliates At Fair Value", "terseLabel": "Investments in limited liability companies (\"LLCs\")", "verboseLabel": "Investments in LLCs before amounts included in accrued expenses and other liabilities" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r4", "r18" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_RealEstateInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.", "label": "Lease Expiration Date1", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "verboseLabel": "Aggregate lease payments for 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "verboseLabel": "Aggregate lease payments for 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "verboseLabel": "Aggregate lease payments for 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "verboseLabel": "Aggregate lease payments for 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year", "verboseLabel": "Aggregate lease payments for 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeaseRenewalTerm": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor Operating Lease Renewal Term", "terseLabel": "Renewal Term (years)" } } }, "localname": "LessorOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter Of Credit [Member]", "terseLabel": "Letters of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters Of Credit Outstanding Amount", "terseLabel": "Letters of credit outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r76", "r129", "r151", "r217", "r222", "r223", "r245" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r76", "r151", "r245", "r324", "r340" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r7", "r323", "r335" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line Of Credit", "terseLabel": "Line of credit borrowings", "verboseLabel": "Outstanding borrowings under revolving credit agreement" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line Of Credit Facility Commitment Fee Percentage", "terseLabel": "Facility fee payable on commitment" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r21" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line Of Credit Facility Maximum Borrowing Capacity", "terseLabel": "Outstanding borrowing" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r21" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line Of Credit Facility Remaining Borrowing Capacity", "terseLabel": "Available borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate L I B O R [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long Term Debt Fair Value", "terseLabel": "Mortgage loan fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Long Term Loans Payable", "terseLabel": "Third-party term loan" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MajorPropertyClassAxis": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Amount of property owned but leased or available for lease to third parties, by major property class.", "label": "Major Property Class [Axis]", "terseLabel": "Major Property Class" } } }, "localname": "MajorPropertyClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MajorPropertyClassDomain": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The major classes of assets leased or available for lease to third parties under operating lease agreements as of the balance sheet date.", "label": "Major Property Class [Domain]", "terseLabel": "Major Property Class" } } }, "localname": "MajorPropertyClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ManagementServiceMember": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Contractually stipulated right to receive compensation for operating and managing business.", "label": "Management Service [Member]", "terseLabel": "Management Service" } } }, "localname": "ManagementServiceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r1", "r211" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers Acquisitions And Dispositions Disclosures [Text Block]", "terseLabel": "Acquisitions and Dispositions" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAcquisitionsAndDispositions" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by/(used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r63", "r65", "r68" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r36", "r39", "r44", "r68", "r76", "r86", "r90", "r91", "r92", "r93", "r96", "r97", "r104", "r123", "r127", "r130", "r133", "r136", "r151", "r245", "r327", "r345" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r84", "r85", "r88", "r89", "r98", "r99", "r100", "r155", "r156", "r185", "r186", "r187", "r188", "r204", "r208", "r209", "r210", "r307", "r308", "r309", "r358", "r359", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "New Accounting Pronouncements And Changes In Accounting Principles [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonRecourseDebt": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail": { "order": 11090.0, "parentTag": "us-gaap_SecuredDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt for which creditor does not have general recourse to the debtor but rather has recourse only to the property used for collateral in the transaction or other specific property.", "label": "Non Recourse Debt", "verboseLabel": "Outstanding Balance" } } }, "localname": "NonRecourseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number Of Businesses Acquired", "terseLabel": "Number of acquisitions" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAcquisitionsAndDispositionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number Of Real Estate Properties", "terseLabel": "Number of real estate investments", "verboseLabel": "Number of hospital facilities leased" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r123", "r127", "r130", "r133", "r136" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Income before equity in income of unconsolidated limited liability companies (\"LLCs\"), interest expense and gains on sales" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r110", "r262", "r265" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10090.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease Lease Income", "terseLabel": "Lease revenue" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r259" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "positiveLabel": "Ground lease liabilities", "terseLabel": "Ground lease liabilities, net", "verboseLabel": "Right-of-use land liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r258" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right-of-use land assets, net", "verboseLabel": "Right-of-use land assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "General" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneral" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets [Abstract]", "terseLabel": "Other Assets:" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r30", "r32" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 10030.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax", "terseLabel": "Unrealized derivative gains/(losses) on cash flow hedges", "verboseLabel": "Unrealized net gain(loss) on cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r37", "r40", "r214", "r215", "r220" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent", "totalLabel": "Total other comprehensive gain/(loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]", "terseLabel": "Other comprehensive gain/(loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r51" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10080.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost And Expense Operating", "terseLabel": "Other operating expenses" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other Expenses" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "Payment Of Financing And Stock Issuance Costs", "terseLabel": "Payment of stock issuance cost" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForDepositsOnRealEstateAcquisitions": { "auth_ref": [ "r54" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow related to amounts given in advance to show or confirm an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.", "label": "Payments For Deposits On Real Estate Acquisitions", "negatedLabel": "Deposit on real estate assets" } } }, "localname": "PaymentsForDepositsOnRealEstateAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r58" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments Of Dividends", "negatedLabel": "Dividends paid", "terseLabel": "Dividends declared and paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r60" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments Of Financing Costs", "negatedLabel": "Financing costs paid" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r55" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments To Acquire Investments", "negatedLabel": "Investments in LLCs" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": { "auth_ref": [ "r53", "r268" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.", "label": "Payments To Fund Longterm Loans To Related Parties", "negatedLabel": "Advance made to LLC" } } }, "localname": "PaymentsToFundLongtermLoansToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred shares of beneficial interest, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred shares of beneficial interest, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred shares of beneficial interest, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred shares of beneficial interest, outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r8" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Net cash proceeds from stock issued" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r56" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds From Issuance Or Sale Of Equity", "terseLabel": "Issuance of shares of beneficial interest, net" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r57", "r80" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds From Lines Of Credit", "positiveTerseLabel": "Proceeds from lines of credit", "terseLabel": "Net borrowings on line of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product And Service Other [Member]", "terseLabel": "Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r36", "r39", "r62", "r76", "r86", "r96", "r97", "r123", "r127", "r130", "r133", "r136", "r151", "r214", "r218", "r219", "r225", "r226", "r245", "r332" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyManagementFeeRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of revenue derived from managing real estate properties.", "label": "Property Management Fee Revenue", "terseLabel": "Project manager's aggregate fee" } } }, "localname": "PropertyManagementFeeRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r19", "r171" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r5", "r170" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r341" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10260.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property Accumulated Depreciation", "negatedLabel": "Accumulated depreciation" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r342" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10250.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property At Cost", "terseLabel": "Buildings and improvements and construction in progress" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r342" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_RealEstateInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property Net", "totalLabel": "Real Estate Investment Property, Net, Total" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestments": { "auth_ref": [ "r342" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investments, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; (7) other real estate investments; (8) real estate joint ventures; and (9) unconsolidated real estate and other joint ventures not separately presented.", "label": "Real Estate Investments", "totalLabel": "Net Real Estate Investments" } } }, "localname": "RealEstateInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Real Estate Investments [Abstract]", "terseLabel": "Real Estate Investments:" } } }, "localname": "RealEstateInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePeriodIncreaseDecrease": { "auth_ref": [ "r393" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) before accumulated depreciation of real estate investments for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "Real Estate Period Increase Decrease", "terseLabel": "Additions to real estate investments, net" } } }, "localname": "RealEstatePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstatePropertiesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by ownership of the property.", "label": "Real Estate Properties [Axis]", "terseLabel": "Real Estate Property Ownership" } } }, "localname": "RealEstatePropertiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePropertiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents categories of ownership of real estate properties.", "label": "Real Estate Properties [Domain]", "terseLabel": "Real Estate Properties" } } }, "localname": "RealEstatePropertiesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r197", "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r197", "r268", "r271", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r266", "r267", "r269", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r59" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments Of Secured Debt", "negatedLabel": "Repayments of mortgage notes payable" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r11", "r178", "r205", "r339", "r358", "r362" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Cumulative net income" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r81", "r82", "r83", "r87", "r95", "r97", "r154", "r201", "r202", "r203", "r206", "r207", "r355", "r357" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Cumulative net income" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r119", "r120", "r126", "r131", "r132", "r138", "r139", "r142", "r180", "r181", "r306" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10110.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue From Contract With Customer Including Assessed Tax", "terseLabel": "Other revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r42", "r76", "r119", "r120", "r126", "r131", "r132", "r138", "r139", "r142", "r151", "r245", "r332" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10010.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10040.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Revenues, Total" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r25", "r79", "r174", "r175", "r176", "r177", "r253", "r254", "r256", "r334" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule Of Debt Instruments [Text Block]", "terseLabel": "Outstanding Mortgages, Excluding Net Debt Premium" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Equity Method Investments [Line Items]", "terseLabel": "Schedule Of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r0", "r76", "r150", "r151", "r245" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule Of Equity Method Investments [Table]", "terseLabel": "Schedule Of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule Of Operating Leased Assets [Table]", "terseLabel": "Schedule Of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessor's property under leasing agreements and property available for lease (not currently under lease) by property class, the gross amount, accumulated depreciation and net amount of as of the balance sheet date.", "label": "Schedule Of Property Subject To Or Available For Operating Lease [Text Block]", "terseLabel": "Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities" } } }, "localname": "ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r77", "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r7", "r323", "r337" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt", "terseLabel": "Mortgage notes payable, non-recourse to us, net", "totalLabel": "Total mortgages notes payable, non-recourse to us, net" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r115", "r117", "r118", "r123", "r125", "r130", "r134", "r135", "r136", "r137", "r138", "r141", "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureSegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r66" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.", "label": "Short Term Debt [Member]", "terseLabel": "Swingline/Short-Term Loans" } } }, "localname": "ShortTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short Term Debt Type [Axis]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short Term Debt Type [Domain]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r26", "r81", "r82", "r83", "r87", "r95", "r97", "r111", "r154", "r173", "r178", "r201", "r202", "r203", "r206", "r207", "r247", "r248", "r249", "r250", "r251", "r252", "r355", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Common stock" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r81", "r82", "r83", "r111", "r306" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r8", "r9", "r173", "r178" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r8", "r9", "r173", "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r9", "r13", "r14", "r76", "r144", "r151", "r245" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "totalLabel": "Total Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r76", "r81", "r82", "r83", "r87", "r95", "r151", "r154", "r178", "r201", "r202", "r203", "r206", "r207", "r212", "r213", "r224", "r245", "r247", "r248", "r252", "r356", "r357" ], "calculation": { "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10060.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "January 1, 2021", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r75", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Dividends and Equity Issuance Program" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r145", "r146", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Type Of Cost Good Or Service Extensible List", "terseLabel": "Cost, Product and Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r102", "r107" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Weighted average number of shares outstanding - Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r101", "r107" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Weighted average number of shares outstanding - Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.uhrit.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 15 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=75018788&loc=d3e30768-111565" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121578510&loc=d3e41551-112718" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919311-209978" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919398-209981" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 3))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r394": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r395": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r396": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r397": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r398": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r399": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r400": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r401": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r402": { "Footnote": "3", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r403": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r404": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" } }, "version": "2.1" } ZIP 62 0001564590-21-025570-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-025570-xbrl.zip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